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Bladder cancer is the most common malignancy of the urinary tract in humans 
with a high incidence and rate of recurrence. Poor prognoses are associated 
with disease progression including the development of resistance to 
chemotherapy. Epithelial-to-mesenchymal transition (EMT) and high insulin-
like growth factor (IGF)-activity have been reported to facilitate tumour 
development in many cancer types including bladder. Insulin-like growth 
factor binding protein 2 (IGFBP-2), a member of the IGF system as well as the 
second most abundant IGFBP in human serum, can exert effects that either 
promote or suppress cancer progression in an IGF-dependent and/or -
independent way. In this thesis, the levels of IGFBP-2, its regulation, role and 
the mechanisms underlying its actions were investigated in bladder cancer cell 
lines.  The relationship between IGF/IGFBP-2-activity and their involvement 
in EMT was also assessed.  
We observed that the epithelial-like RT4 cells had abundant levels of IGFBP-2 
whereas the mesenchymal-like T24 and TCCSUP bladder cancer cells lines 
were null for IGFBP-2. We determined that IGFBP-2 was epigenetically 
silenced in the mesenchymal cell lines via DNA methylation, suggesting a 
reduction in IGFBP-2 was associated with more aggressive disease.  
 To investigate this further, we found that silencing IGFBP-2 in epithelial-like 
RT4 cells led to increased cell proliferation, cell invasion, as well as colony 
formation: along this was associated with a decrease in the levels of E-cadherin 
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(an epithelial marker) and the nuclear translocation of the β-catenin. Adding 
exogenous IGFBP-2 to mesenchymal-like T24 and TCCSUP cells had the 
opposite effects on all cell phenotypes that were associated with an increase 
in the levels of N-cadherin (a mesenchymal marker). The cell lines with higher 
levels of endogenous IGFBP-2 were also found to be more sensitive to cisplatin.  
As the data suggested that IGFBP-2 could act in both an IGF-dependent and 
independent manner, we also examined the actions of IGF-I and found that 
IGF-I induced an increase in cell proliferation, invasion, migration, colony 
formation and EMT-related cancer progression in both RT4 and T24 bladder 
cancer cell lines that appeared to involve the IGF-IR/PI3K/Akt signalling 
pathway. 
IGFBP-2 appears to play an inhibitory role in the progression of bladder cancer 
by decreasing proliferation, invasion, migration, colony-formation and by 
modifying markers of EMT. We also observed that IGFBP-2 may represent a 
biomarker for chemo-sensitivity. IGFBP-2 achieves its effects on cell actions in 
both IGF-dependent and independent ways and as anticipated the addition of 
IGF-I alone had a stimulatory effect in all cell lines, on all cell phenotypes to 
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1.1 Bladder Cancer 
As the most common malignancy of the urinary tract, bladder cancer is a major 
clinical problem with its high incidence and recurrence, poor prognosis after 
progression, and great costs to both patients and the society. 
1.1.1 Epidemiology 
Based on GLOBOCAN estimates, 429,800 new cases of bladder cancer and 
165,100 deaths occurred worldwide in 2012, making this disease the ninth 
most common cancer for both sexes combined (Ferlay, Soerjomataram et al. 
2015, Siegel, Miller et al. 2015, Torre, Bray et al. 2015). In the UK, bladder 
cancer is also the ninth most common cancer, for both sexes combined, with 
28 cases diagnosed every day (2013), and it is the fourth most common cancer 
in males, while the fourteenth most common cancer in females (2013) (Cancer 
Research UK 2016).  
Bladder cancer is relatively common in more developed regions with a 10-fold 
variation in incidence rates internationally with the highest rates in Europe, 
Northern America, Western Asia, and Northern Africa, and lowest in Eastern, 
Middle and Western Africa (see Figure 1). In recent years, a slight decline or 
stability in both incidence and mortality rates, in general, have been observed 
in most western countries, whilst the opposite has been seen in some eastern 
European and developing countries. These patterns might partly reflect 
differences in the stage and extent of the tobacco epidemic, changes in coding 
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practices, schistosomiasis prevalence (Africa) and occupational exposure 
(Chavan, Bray et al. 2014, Torre, Bray et al. 2015).  
 
Figure 1: bladder cancer incidence rates by sex and world area (adapted from 
(Torre, Bray et al. 2015)) 
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1.1.2 Risk factors 
Cigarette smoking is the most well-established and the leading known risk 
factor for bladder cancer. It was reported that the risk among smokers is 
approximately 2- to 6-fold higher than among non-smokers, and smoking is 
estimated to be the cause of about 31% of bladder cancer deaths among males 
and 14% among females worldwide (Parkin 2008).  
Workplace exposures such as industrial chemicals including aromatic amines 
(like benzidine which is used in the dye industry) and certain organic 
chemicals are reported to be another cause of bladder cancer if exposure is not 
limited by good workplace safety practices. Workplace exposures can act 
together with cigarette smoking to further increase the risk of developing 
bladder cancer (American Cancer Society 2016).  
In less developed regions, especially Africa and Western Asia, another well-
studied risk factor for bladder cancer is chronic infection with Schistosoma 
hematobium, which is a parasitic worm that causes urinary schistosomiasis, 
that accounts for nearly 50% of bladder cancers in some parts of Africa and 
around 3% of cases worldwide (Parkin 2006, Jemal, Bray et al. 2011, Oh and 
Weiderpass 2014).  
During the past decade, emerging evidence has accumulated indicating a 
potential role of oncogenic viruses, including BK virus, Kaposi’s sarcoma-
associated herpesvirus (KSHV) and human papillomavirus (HPV), as possible 
cofactors in the development and progression of vesical neoplasm (Griffiths 
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and Mellon 2000, Cancer Genome Atlas Research 2014, Paradzik, Bucevic-
Popovic et al. 2014, Alexander, Wang et al. 2015, Lee, Jeon et al. 2015, Yin, Lee 
et al. 2015). 
Bladder cancer incidence is strongly age-related with highest incidence rates 
being in the elderly. For both sexes combined, more than half (54%) of bladder 
cancer cases in the UK each year are diagnosed in people aged 75 and over 
(Cancer Research UK 2016), and about 90% are older than 55 (American 
Cancer Society 2016). Studies of young patients, initially diagnosed at 40 years 
old or younger, have shown that the disease is mostly low grade and stage, and 
has a favourable prognosis; however, a small subset of patients with high-stage 
and high-grade tumours share similar clinical behaviours with the elderly 
group and have poor outcomes (Stanton, Xiao et al. 2013, Gunlusoy, Ceylan et 
al. 2015, Wang, Ji et al. 2016). 
There is also a gender difference in bladder cancer incidence: males are three 
to four times more likely than females to develop bladder cancer (Ferlay, 
Soerjomataram et al. 2015, American Cancer Society 2016). However, it has 
been shown that women are generally diagnosed with the more advanced 
disease at presentation and have a worse prognosis (Henning, Wehrberger et 
al. 2013, Dobruch, Daneshmand et al. 2016). Differences in risk exposure, 
including smoking status, are independent of the difference in incidence 
between the sexes, and molecular mechanisms such as metabolism of 
carcinogens by hepatic enzymes and the activity of the sex steroid hormone 
pathways between the two sexes are suggested to be potential explanations 
(Lucca, Klatte et al. 2015, Dobruch, Daneshmand et al. 2016). 
Chapter 1 - General Introduction 
Page | 6  
 
Obesity is associated with a linear increase in the risk of bladder cancer 
according to findings from a dose-response meta-analysis of fifteen cohort 
studies with 38,072 bladder cancer cases among 14,201,500 participants 
included (Sun, Zhao et al. 2015).  
There is no strong epidemiological evidence for a hereditary cause of most 
cases of bladder cancer, although familial clusters of bladder cancer have been 
reported. The increased familial risk was indicated to be primarily in relatives 
who smoked (Tanaka, Miyazawa et al. 2011). 
1.1.3 Classification 
Bladder cancer can be classified into several different types according to 
different criteria. 
1.1.3.1 Normal bladder 
The bladder is a hollow organ located in the pelvis, and its main function is to 
store urine. Urine is generated by the kidneys and then carried to the bladder 
through ureters (see Figure 2). With flexible, muscular walls, an average adult 
bladder is able to hold approximately 300-400ml of urine without a significant 
rise in internal pressure, and the muscle contraction of bladder walls aids the 
process of urination in which urine is disposed of through the urethra (Lukacz, 
Sampselle et al. 2011). 
 
 
Chapter 1 - General Introduction 
Page | 7  
 
The bladder wall consists of four main layers (see Figure 2). 
 The innermost layer which lines the bladder wall is called the 
urothelium or transitional epithelium and is made up of cells called 
urothelial or transitional cells. 
 The thin layer beneath the urothelium is called the lamina propria that 
comprises connective tissue, blood vessels and nerves. 
 The third layer is a thick layer of muscles called the muscularis propria. 
 The outermost layer is a layer of fatty connective tissue that separates 
the bladder from other nearby organs. 
 
Figure 2: diagram of bladder location and bladder wall structure (adapted from 
(American Cancer Society 2016)) 
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1.1.3.2 Bladder cancer of different histological types 
Based on cellular characterisation, bladder cancers can be divided into several 
histological types. A very rare type is called sarcoma, where the cancer cells 
originate in the muscle cells of the bladder wall. There is another rare type, 
with an incidence of less than 1% in the US (American Cancer Society 2016), 
which starts in neuroendocrine cells, called small cell carcinoma that is also 
reported to develop in the urothelium (Zhao and Flynn 2012). 
Greater than 90% of bladder cancers are of urothelial origin. Among those 
urothelial carcinomas, transitional cell carcinoma of bladder (TCCB) is by 
far the most prevalent (about 90%) histological type (Cancer Research UK 
2016). About 8% of bladder cancer cases in the UK (Cancer Research UK 2016) 
and 1-2% in the US (American Cancer Society 2016) are squamous cell 
carcinoma (SCC) that originates in the flat cells. Approximately 1-2% of 
bladder cancers are adenocarcinoma which develop from cells that produce 
mucus (American Cancer Society 2016, Cancer Research UK 2016).  
It has been indicated that squamous cell carcinoma (SCC) of the bladder is 
usually caused by schistosomiasis, and TCCB is associated with cigarette 
smoking (Torre, Bray et al. 2015). 
Based on the growing pattern, TCCB can also be divided into two subtypes, 
papillary and flat. Papillary carcinomas grow toward the hollow centre of the 
bladder in a finger-like shape, and flat carcinomas, which are also called 
carcinoma in situ (CIS), are stemless tumours growing only in the urothelium 
(American Cancer Society 2016). CIS is often multifocal occurring not only in 
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the bladder but also in the upper urinary tract, prostatic ducts and prostatic 
urethra, and it can be missed at cystoscopy when not biopsied (Babjuk, Bohle 
et al. 2017). 
At the molecular level, urothelial carcinomas of the bladder were classified 
into three major subtypes including the urobasal, the squamous cell cancer-
like (SCCL) and the genomically unstable subtype according to the whole 
genome gene expression by the Lund group in 2013. The SCCL bladder cancer 
subtype was reported uniformly expressing keratin 5 (KRT 5), P-cadherin, 
keratin 14 (KRT 14), epidermal growth factor receptor (EGFR) and cell cycle 
genes through the tumour parenchyma, and it was associated with the worst 
disease-specific survival among the three defined subtypes (Sjodahl, Lovgren 
et al. 2013). In 2014, the Cancer Genome Atlas Research Network described a 
“basal/squamous-like” cluster of bladder cancers which is similar to that of 
basal-like breast cancers, as well as squamous cell cancers of the head and 
neck and lung (Cancer Genome Atlas Research 2014). And the KRT 5-
expressing urothelial basal cells were demonstrated to be the likely 
progenitors of carcinoma in situ (CIS), squamous cell carcinoma (SCC) and 
muscle-invasive bladder cancers (Van Batavia, Yamany et al. 2014). 
1.1.3.3 Bladder cancer of different clinical behaviours 
Bladder cancers of urothelial origin are the most intensively studied, and they 
are divided into non-invasive and invasive cancers according to whether 
cancer cells have invaded into the lamina propria.  The majority of bladder 
cancers (70%) are non-invasive tumours that do not penetrate the urothelium 
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and nearly all squamous cell carcinoma and adenocarcinoma are invasive 
(Genua, Xu et al. 2012, Stanton, Xiao et al. 2013, American Cancer Society 
2016). 
Based on the criterion of whether tumours have invaded the muscularis 
propria of the bladder wall, bladder cancers are also divided into non-muscle 
invasive (NMIBC) and muscle invasive (MIBC) cancers. Non-muscle invasive 
bladder cancers (NMIBC) include both non-invasive tumours and any invasive 
tumours that have not grown into the muscle layer of the bladder (American 
Cancer Society 2016). Among muscle-invasive bladder cancers, tumours 
which have spread to nearby organs are also called advanced bladder cancers 
(Cancer Research UK 2016). 
1.1.3.4 Bladder cancer grade and stage 
Tumour grade and stage are the most important factors for predicting disease 
behaviour and prognosis. 
Tumours are graded according to cellular characteristics, and there are two 
bladder cancer classification systems currently in use. The widely used 
traditional World Health Organization (WHO) 1973 classification divides 
bladder cancers into three grades (G1-3) based on cell anaplasia and lesions 
with higher grade (poorly differentiated tumours) that are at a greater risk of 
recurrence and progression (World Health Organization 1973). A new 
histologic classification system was developed by WHO in 2004 introducing 
the terms urothelial neoplasm of low malignant potential (UNLMP) and 
papillary carcinoma of low and high grade (Eble 2004). The new system 
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expands the description of the categories of NMIBC aiming to improve 
standardised interpretation of pathological samples for better disease 
behaviour characterisation. For example, a tumour with particularly good 
prognosis (papillary urothelial neoplasm of low malignant potential) no longer 
carries the label of “cancer”, and the use of ambiguous grading such as grade 
1/2 or 2/3 (as done in the WHO 1973 classification) is avoided (Montironi and 
Lopez-Beltran 2005). However, a multicentre study in 328 bladder tumours 
showed that reproducibility of both the WHO 1973 and the WHO 2004 
classifications are poor with the scoring of individual criteria poorly 
reproducible, indicating the descriptions of the criteria for grade are not 
specific, and the prognostic value of both classification differ per pathologist 
(Bosschieter, Hentschel et al. 2018). 
The universal staging system of bladder cancer is the TNM classification (see 
Table 1) according to the depth of invasion (T) (see Figure 3), involvement of 
regional lymph nodes (N) and the presence or absence of distant metastases 
(M) (Turo, Cross et al. 2012, Knowles and Hurst 2015). 
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Tis: transitional carcinoma in situ 
Ta: non-invasive papillary carcinoma 
T1: invasive papillary carcinoma into the lamina propria 
T2: invasive papillary carcinoma into the muscularis propria  
(T2a into the superficial layer, and T2b into the deeper layer) 
T3: invasive papillary carcinoma out of the muscularis propria 
without contiguous organs affected 
T4: invasive papillary carcinoma out of the muscularis propria 
with contiguous organs affected 
[* Tis – T1 are included in non-muscle invasive bladder cancers 
(NMIBC),  
also called superficial bladder cancers;  
 T2 – T4 are included in muscle-invasive bladder cancers (MIBC), and  




NX: Regional lymph nodes cannot be assessed 
N0: No regional lymph node metastases 
N1: Metastasis to a single lymph node, ≤2cm in greatest 
dimension 
N2: Metastasis in a single lymph node, >2cm and ≤5cm in 
greatest 
dimension; 
Or multiple lymph nodes, none >5cm in greatest 
dimension 




MX: Distant metastasis cannot be assessed 
M0: No distant metastasis 
M1: Distant metastasis 
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Figure 3: grading and staging of bladder cancer (adapted from (Turo, Cross et 
al. 2012)) 
 
TCCB is characterised by polychronotropism that is a tendency for a tumour 
to recur over time and in new locations in the urothelial tract, with a variable 
rate of progression (Turo, Cross et al. 2012). On average, about 70% of patients 
present with NMIBC at diagnosis, with CIS being 10%, Ta being 70% and T1 
being 20%. For patients with Ta tumours, high recurrence (up to 80%) is the 
main clinical issue. However, for the other 30% with CIS/T1 tumours, 
progression is the main concern, occurring in up to 45%. Progression to, or 
presentation with, muscle-invasive disease (T2 - T4) indicates the critical step 
in the disease course of bladder cancer, necessitating more radical and 
aggressive therapies, and carrying a 5-year survival rate of only 27-50% 
(Wallace, Bryan et al. 2002, Kirkali, Chan et al. 2005, van Rhijn, Burger et al. 
2009). 
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And updated guidenlines on non-muscle-invaisve bladder cancer (NMIBC) 
were released by the European Association of Urology (EAU) in 2016 
stratifying patients into low-, intermediate- and high-risk groups in aid of the 
decisions about adjuvant intravesical instillations (Babjuk, Bohle et al. 2017). 
Notably, although tumours classified as stage CIS (Tis) and T1 are grouped as 
NMIBC, highly malignant potential has been demonstrated by molecular 
biology techniques and clinical experience (Babjuk, Bohle et al. 2017). 
1.1.4 Clinical information 
1.1.4.1 Symptoms 
The most common presenting symptom of bladder cancer is painless 
haematuria with approximately 80-85% of patients diagnosed with either 
visible or non-visible haematuria. Other urinary tract symptoms contribute to 
15-20% of patients, especially those with CIS, are the same as that of bladder 
irritability which includes increased frequency of urination, urgency and 
dysuria (Amling 2001, Zhang, Han et al. 2015). For advanced bladder cancers 
which have grown large enough or have even spread to other parts of the body, 
urinary retention and weight loss are commonly observed (American Cancer 
Society 2016).  
1.1.4.2 Diagnosis & Surveillance 
In diagnosing bladder cancer, cystoscopy and urine cytology are two gold 
standard assays that are also applied in the follow-up surveillance. Cystoscopy 
is an endoscopy of the bladder via the urethra and is capable of identifying 
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most bladder tumours, but there are still false negative results due to operator 
errors or difficulty in detection of flat carcinoma in situ (CIS) presenting the 
sensitivity and specificity of white light cystoscopy range from 62-84% and 
43-98%, respectively (Cauberg Evelyne, de la Rosette et al. 2011). It is a costly 
and quite traumatic procedure accompanied by significant discomfort and 
anxiety and constitutes a large part of the lifetime painful experiences of 
patients (Amling 2001, Tanaka, Miyazawa et al. 2011, Zhang, Han et al. 2015, 
Cancer Research UK 2016). Urine cytology, the examination of cellular changes 
from a urine specimen under a microscope, is successful in the diagnosis of 
most high-grade tumours in both non-muscle invasive and muscle invasive 
types, but has a major limitation with its low sensitivity in the detection of low-
grade tumours, at about 4-31% (Zhang, Han et al. 2015). 
Since bladder cancer can recur and progress, it requires lifelong surveillance 
after diagnosis and patients are mainly subjected to regular endoscopic check-
ups which are not only painful but also costly. Although the incidence of the 
disease appears to have stabilised in most western countries over the past 
decades, it still poses a heavy economic burden to the society as a result of 
population ageing as well as growth worldwide. Therefore, more accurate 
markers for timely diagnosis are in urgent need. A few such markers have been 
approved for clinical use following clinical trials, but most still need more 
investigation.  
With the advantage of being easily accessible in a rapid and non-invasive 
manner, urinary markers aid diagnosis by acting as predictive indicators of 
bladder cancer recurrence and survival in patients presenting with 
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haematuria. Most of the markers are still at the pre-clinical stage, and the 
prime tests approved by the Food and Drug Administration (FDA) are bladder 
tumour antigen (BTA) stat and BTA TRAK test, which provide semi- and 
complete quantitative detection of both complement factor H and complement 
factor H-related proteins, respectively, with relatively high sensitivity and 
specificity. Molecular markers including specific gene mutations and 
methylations, chromosome aberrations, and transcribed, non-protein-coding 
microRNA molecules, which play a key role in transcriptional regulation of 
gene expression, have also been studied in recent years in order to achieve 
better and earlier detection of bladder cancer (Tanaka, Miyazawa et al. 2011, 
Zhang, Han et al. 2015, Motawi, Rizk et al. 2016, Rodrigues, Jeronimo et al. 
2016). 
1.1.4.3 Treatments 
1.1.4.3.1 Treatment for NMIBC 
The primary treatment for NMIBC is transurethral endoscopic resection to 
remove the cancer. Perioperative intravesical therapy, chemotherapy or 
bacillus Calmette-Guérin (BCG) treatment into the bladder will be given to 
patients to reduce the risk of recurrence (Turo, Cross et al. 2012, Cancer 
Research UK 2016). 
1.1.4.3.2 Treatment for MIBC 
Partial or radical cystectomy to remove part of or the whole bladder as well as 
contiguous organs according to the area that the cancer cells have affected can 
be applied to treat invasive disease.  
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Compared with surgery, radiotherapy that uses high-energy rays to kill cancer 
cells has the advantage of keeping the bladder. However, it can cause side 
effects such as diarrhoea or inflammation of the bladder during treatment, and 
surgery would be highly recommended if cancer recurs. 
With a response rate of 50-70% to frontline treatments, bladder cancer is 
considered to be a chemosensitive malignancy. Chemotherapy, especially 
those cisplatin-based combination therapies that represent the standard first-
line therapy, is commonly used to destroy bladder cancer cells via the drugs’ 
cytotoxic effects (von der Maase, Sengelov et al. 2005). It can be applied before 
surgery or radiotherapy to shrink the tumour size to improve the efficacy of 
subsequent treatments. Also, it can be used during radiotherapy 
(chemoradiation, with both therapies combined) to achieve better effects. 
When used after surgery, it may stop cancer recurrence. Side effects may 
happen depending on the dose of the drugs and the patient's’ individual 
reaction (Cancer Research UK 2016). 
1.1.4.3.3 Treatment for advanced bladder cancer 
Advanced bladder cancer indicates MIBC has spread out of the bladder. For 
local spread (to nearby areas such as ureters, urethra, prostate or vagina) of 
advanced bladder cancer, surgery to remove cancer or radiotherapy are 
mainly used; for distant spread (to the lymph nodes in the pelvis, abdomen or 
neck, or to the lungs, the liver or the bones) disease, intensive chemotherapy 
and radiotherapy, or minor surgery to control  as well as reduce symptoms are 
considered (Cancer Research UK 2016). 
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1.1.4.3.4 Targeted therapies 
In recent years, bladder cancer has been recognized as a disease with several 
dysregulated cellular processes, and novel targeted therapies have been 
undergoing investigation. Molecules involved are of great interest to 
researchers to develop accurate biomarkers for better diagnosis, as mentioned 
in 1.1.4.2, as well as for more reliable prognostic tests to predict individual 
tumour behaviour (Nagata, Muto et al. 2016). Also, potential targeted 
therapies specific to the tumours will reduce treatment side effects as well as 
morbidity, and therefore bring notable impact to future cancer management 
(Mitra and Cote 2009, Turo, Cross et al. 2012). 
Clinical trials in NMIBC are mainly assessing the role of immunotherapy and 
agents targeting molecules such as vascular endothelial growth factor (VEGF) 
and fibroblast growth factor receptor-3 (FGFR-3) which could be efficiently 
inhibited, leading to reduced tumour growth (Ghosh, Brancato et al. 2014, van 
Kessel, Zuiverloon et al. 2015).  NMIBC with high recurrence is related to 
activation of the Ras-MAPK (mitogen-activated protein kinase) pathway, and 
the less common but more aggressive MIBC is linked to alterations in the p53 
and retinoblastoma pathways (Mitra and Cote 2009, Tanaka, Miyazawa et al. 
2011, Knowles and Hurst 2015). However, at present, none of the approved 
targeted agents for cancer therapy have been approved for the treatment of 
bladder cancer, and limited success was shown by the few clinical trials, due 
to a lack of efficacy and toxic effects (van Kessel, Zuiverloon et al. 2015).  
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1.1.4.4 Prevention 
There are three major types of prevention defined for cancer, including 
bladder cancer. Primary prevention focuses on avoiding the development of 
cancer in the general healthy public. Secondary prevention concentrates on 
preventing premalignant lesions progressing to cancers. Moreover, tertiary 
prevention emphasises stopping cancer progression in patients who have 
already received treatment after being diagnosed with early cancer (Tanaka, 
Miyazawa et al. 2011). 
Specifically for bladder cancer, it is highly recommended to avoid smoking and 
limit exposure to certain chemicals in the workplace to prevent the contact of 
certain carcinogenic chemicals with the urothelium. Drinking plenty of liquid, 
mainly water, and eating lots of fruit and vegetables are also advised. No 
routine screening is in place for the general public, however people at very 
high risk (certain birth defects of the bladder or those with a lot of work-
related exposure to certain chemicals) are sent for screening (Tanaka, 
Miyazawa et al. 2011, American Cancer Society 2016). 
1.2 Insulin-like Growth Factor (IGF) System 
The insulin-like growth factor (IGF) family consists of two polypeptide ligands 
(IGF-I and IGF-II), two types of cell-surface receptors (IGFRs including IGF-I 
receptor and IGF-II receptor, with abbreviation of IGF-IR and IGF-IIR 
respectively) and six specific high-affinity binding proteins (IGFBP-1 to IGFBP-
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6), as well as a large group of IGFBP proteases which cleave IGFBPs leading to 
the release of bound  IGFs (Zha and Lackner 2010). 
1.2.1 IGFs 
An insulin-like factor which could not be removed by anti-insulin antibodies 
was discovered during the 1960s (Froesch, Buergi et al. 1963), and following 
sequencing, two peptides were identified (Rinderknecht and Humbel 1976) 
that were named insulin-like growth factor (IGF) I and II because of their 
structural and functional homology with insulin  (Livingstone 2013). 
IGF-I and IGF-II are both single-chain polypeptides mainly synthesized in the 
liver but they are also secreted locally by most tissues where they can act in an 
autocrine or paracrine manner (Le Roith 1997, Livingstone 2013). IGF-I is a 
basic protein of 70 amino acids with a molecular weight of 7.65 KDa, while IGF-
II is a slightly acidic peptide of 67 residues with a molecular weight of 7.47 KDa 
(Stewart and Rotwein 1996). They have about 62% homology in their amino 
acid sequences and share high similarity of structure with proinsulin (Yu and 
Rohan 2000, Dung V. Nguyen 2013). 
The location of the IGF-I and IGF-II genes are on chromosomes 12 and 11, 
respectively, with the IGF-II gene being 1.4 kilobases downstream from the 
insulin gene. The IGF-I gene has two promoter sites while the IGF-II gene has 
four, and it has been identified that both IGFs have multiple transcripts (Yu 
and Rohan 2000).  While the expression of IGF-I gene is highly regulated by 
growth hormone (GH), IGF-II expression is much less GH-dependent but 
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mainly regulated by genetic factors such as genomic imprinting (Yu and Rohan 
2000, Livingstone 2013). Expressions of both IGFs are also affected by other 
factors such as hormones (e.g. estrogens) as well as growth factors such as 
fibroblast growth factors (FGFs) (Yu and Rohan 2000). 
Levels of IGFs in the blood present little difference between sexes but vary 
considerably with age. Serum IGF-I, which is required for maximal postnatal 
growth, are low at birth and increase progressively until puberty reaching a 
sharp upsurge, after which the concentration declines gradually with age. 
Different from IGF-I, serum IGF-II levels rise from birth until puberty, but then 
remain stable. IGF-II is considered to be the primary growth factor essential 
for embryonic and foetal growth (Stewart and Rotwein 1996, Yu and Rohan 
2000). Nutritional status and dietary energy intake are critical regulators of 
IGF-I levels and nutrition is linked to growth via the IGF axis (Thissen, 
Ketelslegers et al. 1994). 
Both IGF-I and IGF-II act as mitogens and can also inhibit apoptosis, thereby 
playing an important role not only in regulating normal cell proliferation and 
differentiation, but also in key aspects of neoplasia such as transformation and 
anti-apoptotic signalling (Yu and Rohan 2000, Zha and Lackner 2010). 
1.2.2 IGFRs and cell signalling 
The IGF-IR and the IGF-IIR are both located on the cell membrane and are both 
glycoproteins. However, they are completely different regarding structure as 
well as function. The IGF-IR is a tetramer consisting of two identical α subunits 
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and β subunits respectively, while the IGF-IIR is a monomer called the IGF-
II/mannose 6-phosphate  (M6P) receptor because it has three ligand-binding 
regions in its extracellular domain that can bind both IGF-II and M6P-
containing molecules (Yu and Rohan 2000). 
The IGF-IR is structurally and functionally homologous to the insulin receptor 
(IR). Insulin signals through the IR that exists in two isoforms (IR-A and IR-B) 
formed by the absence or presence of exon 11, respectively. It has been 
demonstrated that the expression of IR-A occurs in foetal cells as well as many 
tumour cells, and that signalling through IR-A leads to a more mitogenic effect 
compared with than that of signalling via IR-B. Hybrid receptors (see Figure 4) 
are composed of an α and β subunit of an IR (IR-A or IR-B) bound to the α and 
β subunit of the IGF-IR (Gallagher and LeRoith 2010). 
IGFs and insulin can bind to each other’s receptors, though the binding affinity 
is much weaker than that for the preferred ligand (Zha and Lackner 2010). IGF-
I can bind to its specific IGF-IR as well as either type of the hybrid receptors, 
while IGF-II is able to bind to the IGF-IR, IGF-IIR as well as IR-A but only to the 
IGF-IR/IR-A hybrid. As for insulin, having negligible affinity for either IGF-IR 
containing hybrid, it can only bind to the IR as well as its specific IR-A/IR-B 
hybrids (see Figure 4) (Gallagher and LeRoith 2010). 
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Figure 4: IGF-IR, IR, and hybrid receptors (adapted from (Gallagher and LeRoith 
2010)) 
 
Compared with IGF-II, IGF-I has a higher affinity for the IGF-IR (Yu and Rohan 
2000). The IGF-IR shares high structural similarity with the IR (60% 
homology). It is one of the cognate receptor tyrosine kinase (RTK) for the PI3K 
(phosphoinositide-3 kinase)/Akt (a serine/threonine kinase, also known as 
protein kinase B, or PKB)  pathway and binding of IGFs to the IGF-IR can induce 
IGF-IR clustering and auto-phosphorylation resulting in activation of 
downstream signalling (Baselga 2011). In contrast, instead of mediating 
signalling, the main role of the IGF-IIR is to regulate extracellular IGF-II levels 
through receptor-mediated endocytosis followed by IGF-II degradation in 
lysosomes (Zha and Lackner 2010). 
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There are two main signal transduction pathways including the PI3K/Akt 
pathway and the mitogen-activated protein kinase (MAPK) pathway which 
have been well characterised for the IGF-IR (see Figure 5) (Zha and Lackner 
2010). 
 




Chapter 1 - General Introduction 
Page | 25  
 
IGFs are both capable of binding to and stimulating the catalytic activity of the 
IGF-IR. Upon activation, phosphorylated IGF-IR stimulates the two signalling 
pathways by recruiting and activating their adaptor proteins, insulin receptor 
substrate 1/2 (IRS-1/IRS-2) and Src homology 2 domain containing proteins 
(Shc) respectively. 
In the MAPK pathway, the stimulation of Shc initiates cascades that result in 
the activation of target nuclear genes such as ETS domain containing protein 
(ELK1) leading to an enhancement of cell proliferation (Zha and Lackner 2010, 
Baselga 2011). The PI3K/Akt signalling pathway is switched on by IRS-1 
phosphorylation resulting from activation of the IGF-IR. Phosphorylated IRS-
1 binds to p85, the regulatory subunit of PI3K, which results in the removal of 
the inhibitory effect of p85 on p110, the catalytic subunit of PI3K, and thus 
leads to full activation of PI3K. Activated PI3K catalyses the phosphorylation 
of phosphatidylinositol bisphosphate (PIP2) into phosphatidylinositol 
triphosphate (PIP3) which provides Akt with a docking site to move to the cell 
membrane to play a critical role as the central mediator of the PI3K/Akt 
pathway. Once localized, Akt is phosphorylated and activated by 3-
phosphoinositide-dependent protein kinase 1 (PDK1) and mammalian target 
of rapamycin complex 2 (mTORC2) complex and then mediates a series of cell 
signalling events including increased cell survival and proliferation through 
activation or inhibition of key effectors such as B-cell lymphoma 2 (BCL-2), 
BCL-2-associated death promoter (BAD), Forkhead box proteins (Foxo, e.g. 
Foxo3a)  transcription factors and p27, increased protein synthesis and cell 
growth by disinhibition of mammalian target of rapamycin complex 1 
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(mTORC1), and increased glycogen conversion from glucose after the 
inhibition of Glycogen synthase kinase 3-β (GSK-3β). Beside the stimulatory 
components, there are also some molecules acting in an intrinsic inhibitory 
way in the pathway, such as phosphatase and tensin homologue deleted on 
chromosome ten (PTEN) that converts PIP3 back into PIP2. PTEN is 
considered to be a tumour suppressor which modulates cell growth and 
apoptosis (Yamada and Araki 2001) and PTEN loss due to mutations also plays 
a role in activating this pathway (Zha and Lackner 2010, Sfakianos, Lin Gellert 
et al. 2014). 
1.2.3 IGFBPs 
Six IGFBPs (IGFBP-1 to 6) with specific binding affinities for IGFs have been 
identified through cloning and sequencing (Yu and Rohan 2000, Sandhu, 
Gibson et al. 2004). They are secreted proteins that are also found 
intracellularly, with evidence for nuclear translocation of some IGFBPs such as 
IGFBP-2 (Ahmad, Morton et al. 2011, Baxter 2014). All six IGFBPs are 
structurally similar consisting of three distinct domains, including N-terminal, 
linker, and C-terminal, and they have similar IGF binding determinants located 
in both the N- and C-domains. There are also other functional motifs, such as 
Arg-Gly-Asp (RGD) integrin-binding motif and nuclear localization signal (NLS) 
motif, which enable IGFBPs to engage in various interactions with ligands 
other than IGFs (Fukushima and Kataoka 2007, Forbes, McCarthy et al. 2012). 
Basic characteristics of IGFBPs are summarised in Table 2. 
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Table 2: summary of IGFBPs characteristics (adapted from (Fukushima and 
Kataoka 2007)) 
 IGFBP-1 IGFBP-2 IGFBP-3 IGFBP-4 IGFBP-5 IGFBP-6 
Gene 
location 7p13-p12 2q33-q34 7p13-p12 
17q12-
q21.1 2q33-q36 12q13 
Gene size 
(kbp) 5.3 31.0 9.0 14.0 23.0 4.7 
mRNA size 




protein) 25 31 43-45 24 29 28-30 
Amino acids 
(mature 
protein) 234, 216 289 274 237 252 213 
Serum 
concentration 
(nM) 2-15 2-15 100 2-15 2-15 2-15 
RGD sequence √ √     
NLS   √  √ √ 
 
Levels of most of the IGFBPs are stable in the circulation except for IGFBP-1, 
which is closely related to levels of insulin with a negative correlation (Yu and 
Rohan 2000). Like IGFs, levels of IGFBPs in blood show little variation between 
sexes but change significantly with age. Concentrations of IGFBP-1 and IGFBP-
2 in blood are high at birth and then decline with age until puberty to reach a 
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nadir, after which the levels stay relatively constant or increase slightly. 
IGFBP-3 shows a similar age-specific distribution to that of IGF-1. There is 
limited data indicating that levels of IGFBP-5 decline with age, but strong 
evidence to show that concentrations of IGFBP-4 and IGFBP-6 increase with 
age (Yu and Rohan 2000). 
Compared with the IGFRs, IGFBPs have a higher binding affinity for the IGFs. 
In the pool of circulating IGF-I and IGF-II, less than 1% are free in serum, while 
more than 99% are bound and restricted to IGFBPs. IGFBP-bound IGFs are 
more stable, whilst unbound/free IGFs have a circulating half-life of only a few 
minutes due to degradation (Yu and Rohan 2000). The predominant 
circulating form of IGFs in serum is a ternary complex consisting of IGF, IGFBP-
3 (and, to a lower degree, IGFBP-5), as well as the acid-labile subunit (ALS) 
which is a glycoprotein staying in the circulation. The remaining bound IGFs 
are thought to be carried by IGFBPs of the smaller molecular weight in binary 
complexes without the involvement of ALS that can be carried out of the 
circulation (Baxter 2014). 
IGFBPs can modulate cell function in both IGF-dependent and IGF-
independent ways (Yu and Rohan 2000, Baxter 2014). In respect of IGF-
dependent actions, IGFBPs regulate the availability of IGFs to their receptors 
by first binding and then either transporting or sequestering IGFs, resulting in 
either stimulation (Uzoh, Holly et al. 2011) or suppression of cell proliferation. 
In IGF-independent model, direct interaction of IGFBPs with cell surface 
molecules, such as integrin recptors and some have reported the existence of 
IGFBP receptors (IGFBPRs)  and intracellular IGFBPs interactions with nuclear 
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hormone receptors (Beattie, Phillips et al. 2008, Perks and Holly 2008). Some 
preclinical studies have shown the paradoxical role of IGFBPs, such as IGFBP-
2, both in tumour suppression (Hoflich, Lahm et al. 1998) and promotion 
(Foulstone, Zeng et al. 2013) in various cancers in different contexts. 
1.2.4 IGF axis and bladder cancer 
The IGF axis is a critical regulator of many physiological processes, including 
cell proliferation, differentiation, apoptosis and metabolism of glucose and is 
often found to be dysregulated in a number of different cancers and as such 
has been intensively investigated as a potential target to inhibit cancer 
progression. 
Multiple components of the IGF axis haven been reported to be dysregulated 
in cancer. 
High levels of circulating IGF-I are associated with an increased risk of certain 
types of cancers, including prostate (Roddam, Allen et al. 2008), colorectal 
(Rinaldi, Cleveland et al. 2010), and breast cancers (both pre- and post-
menopausal women) (Endogenous, Breast Cancer Collaborative et al. 2010). 
Upregulated levels of IGF-II have been associated with Ewing’s sarcoma 
(Manara, Landuzzi et al. 2007), a paediatric tumour type, as well as a worse 
prognosis in a variety of adult malignancies (Singer, Mogg et al. 2004, Lu, 
Katsaros et al. 2006). IGFs are suggested to influence tumour progression and 
metastases by promoting cancer cell proliferation, angiogenesis, survival and 
motility, as well as synergising with other molecules and growth factors 
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(Clayton, Banerjee et al. 2011). However, a pilot study demonstrated that 
levels of free IGF-I either in urine or serum are not helpful in predicting tumour 
development in patients with bladder cancer (Serel, Turan et al. 2003). 
Overexpression of the IGF-IR has been reported in several cancers (Bergmann, 
Funatomi et al. 1995, Pandini, Vigneri et al. 1999, Hellawell, Turner et al. 2002, 
Weber, Fottner et al. 2002, Fottner, Minnemann et al. 2006). Hyper-activation 
of the IGF-IR pathway is considered to lead to promotion and progression of 
many cancer types including bladder cancer (Metalli, Lovat et al. 2010), and 
repressing IGF-IR signalling using microRNA-143 has been indicated to 
enhance cell chemo-sensitivity and reduce cell proliferation in bladder cancer 
(Wang, Li et al. 2017). With the development of research into novel agents 
targeting pathways, emerging studies have identified the IGF-IR as a 
therapeutic target (Sachdev and Yee 2007, Heidegger, Massoner et al. 2015). 
Levels of IGFBP-1 and -2 can be suppressed by insulin, and low concentrations 
of both IGFBPs in obese people due to hyperinsulinemia have been suggested 
to elevate the potential mitogenicity of the IGFs, which leads to an increased 
risk of cancer in obese individuals (Renehan, Frystyk et al. 2006).  
Conflicting data have been reported on IGFBP-2 expression levels in different 
disease settings and its role in cancers. It is considered to be an oncogenic 
protein with elevated expression observed in many cancers such as glioma 
(Moore, Holmes et al. 2009) and prostate (Karantanos, Corn et al. 2013), with 
inhibition of IGFBP-2 reported to improve cell sensitivity to cisplatin in 
bladder cancer (Zhu H 2015). In our laboratory, investigations have been 
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making in the field of how IGFs and related factors may mediate the effects of 
nutrition on chronic illness and major epithelial caners, and works focused on 
IGFBP-2 suggest its promoting role in the development of various cancers such 
as breast (Perks, Vernon et al. 2007, Foulstone, Zeng et al. 2013) and prostate 
(Uzoh, Holly et al. 2011). However, high levels of IGFBP-2 are observed in 
rapidly growing non-invasive brain tumours, whereas low/undetectable 
levels are found in invasive malignant tumours (Shelton, Mukherjee et al. 
2010). 
IGFBP-3, the most abundant IGFBP, is purported to play a protective role in 
cancer development as consequence of sequestering IGFs and decreasing the 
IGF-dependent signalling via the IGF-IR, thus causing cell cycle arrest and 
apoptotic signals upregulation (Jogie-Brahim, Feldman et al. 2009). It can also 
act in an IGF-independent manner exerting both positive and negative effects 
on cell functions (McCaig, Perks et al. 2002, Perks, Burrows et al. 2011). 
1.3 Epithelial-to-Mesenchymal Transition (EMT) 
1.3.1 Definition 
Epithelial-to-mesenchymal transition (EMT) is defined as a series of events 
during which epithelial cells lose their epithelial characteristics like 
intercellular adhesion and cell polarity, and gain an enhancement of 
mesenchymal properties like cell motility (Guarino, Rubino et al. 2007, Gos, 
Miloszewska et al. 2009). 
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The EMT phenomenon was first observed during embryonic development 
(Savagner, Boyer et al. 1994) and described as “epithelial-mesenchymal 
transformation” using a model of chick primitive streak formation (Hay 1995). 
The term “transformation” has been changed to “transition” over time based 
on the difference of it between neoplastic transformation (Kalluri and Neilson 
2003) and the nature of reversibility during this process (Chen, Han et al. 2012, 
Martyn-Hemphill, Mak et al. 2013). 
Conversely, mesenchymal-to-epithelial transition (MET) describes the reverse 
process of EMT in which cells are switched from a mesenchymal-like to an 
epithelial-like phenotype by regaining key epithelial features like homotypic 
adhesion: this frequently occurs during early embryogenesis as well as the 
wound healing process (McConkey, Choi et al. 2009, Chen, Han et al. 2012). 
1.3.2 Subtypes 
EMT is categorised into three distinct types that are involved in different 
functional settings.  
Type 1 EMT, which is also called developmental EMT, is associated with 
implantation, embryo formation as well as organ development, and generates 
diverse cell types which share common mesenchymal phenotypes in an 
organised manner (Kalluri and Weinberg 2009).  
Type 2 EMT links to organ fibrosis and inflammation. In the situation of 
inflammation, as can be seen during wound healing and tissue regeneration, 
EMT ceases once inflammation is attenuated (Kalluri and Weinberg 2009).  
Chapter 1 - General Introduction 
Page | 33  
 
Type 3 EMT is also called oncogenic EMT, and it occurs in neoplastic cells 
which have undergone genetic and epigenetic alterations previously, 
specifically in genes which favour clonal outgrowth and the development of 
localised tumours (Kalluri and Weinberg 2009, Yun and Kim 2013). 
1.3.3 EMT and cancer 
Invasion, as the mark of malignancy, encompasses the translocation of tumour 
cells from the original neoplastic focus into adjacent host tissues, and distant 
metastases take place when these invasive cells enter the circulation after 
intravasation through lymph or blood vessels (Guarino, Rubino et al. 2007, Son 
and Moon 2010). 
EMT enables cells to change from an adherent epithelial-like into a highly 
motile mesenchymal-like phenotype, which allows cells to gain the ability to 
migrate and invade after being released from the parent epithelial tissue site, 
and thereby facilitates metastatic progression of cancer (Guarino, Rubino et al. 
2007, Gos, Miloszewska et al. 2009, Tiwari, Gheldof et al. 2012, Smith and 
Bhowmick 2016). 
In addition, MET, the reverse process of EMT plays a part in the establishment 
and stabilisation of distant metastases by allowing invasive cancerous cells to 
regain epithelial features and integrate into the secondary foci (Guarino, 
Rubino et al. 2007, Yang and Weinberg 2008). 
So far, there is growing evidence supporting EMT with cancer progression, and 
it has become the most accepted explanation of distant metastases of epithelial 
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cancers including TCCB (Guarino, Rubino et al. 2007, De Wever, Pauwels et al. 
2008, Acloque, Adams et al. 2009, McConkey, Choi et al. 2009, van der Horst, 
Bos et al. 2012, Zhu, Pan et al. 2012, Murai, Yamada et al. 2014, Wu, Sarkissyan 
et al. 2016). 
1.3.4 Molecular mechanisms of EMT 
The process of EMT comprises a form of epithelial plasticity that is categorised 
by changes in epithelial cells not only morphologically but also molecularly 
(Abba, Patil et al. 2016). Although the molecular basis has not been fully 
elucidated, some key molecules and transduction pathways that are 
potentially involved have been reported. 
Typically, EMT is characterised by down-regulation of epithelial cell adhesion 
proteins, E-cadherin and cytokeratins and associated with up-regulation of 
mesenchymal proteins such as N-cadherin and vimentin (Ko, Yanai et al. 2009, 
Yao, Li et al. 2013, Wu, Sarkissyan et al. 2016). Transcription factors like Snail, 
Slug, Twist, and zinc finger E-box-binding homeobox (ZEB1 and ZEB2) are 
categorised as EMT inducers (Wu, Sarkissyan et al. 2016). Understanding the 
molecular mechanisms responsible for EMT-mediated tumour progression 
will be of great importance to disease management. 
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1.3.4.1 Cadherin switching 
Cadherins are prime mediators of intercellular adhesion and are expressed 
ubiquitously in all tissues. By forming homodimers, they bind to their 
counterparts on adjacent cells at adherens junctions (AJs) and play key roles 
in embryonic development as well as in the maintenance of normal tissue 
architecture (Ko, Yanai et al. 2009, Mitra and Cote 2009). 
Among classical cadherin family members, E-cadherin is expressed by most 
normal epithelial cells and plays a central role in facilitating the barrier 
functions of epithelial tissues by connecting epithelial cells through its 
interaction with β-catenin and the actin cytoskeleton (see Figure 6) 
(McConkey, Choi et al. 2009). N-cadherin is expressed by neural, endothelial 
and muscle cells and not normally by epithelial cells (Bryan 2015). 
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Figure 6: cell-cell adhesion in epithelial tissues (adapted from (McConkey, Choi 
et al. 2009)) 
Molecular structure of adherens junction showing the relationship between E-cadherin 
molecules and neighbouring cells, and among E-cadherin, catenins, and cytoskeleton. 
 
The change of cadherins that occurs during the process of EMT is named 
“Cadherin Switching (CS)” indicating the switching in the expression of 
cadherins from one subclass to another, or the termination of expression of a 
certain cadherin subclass in a tissue (Bryan and Tselepis 2010). 
In the context of epithelial malignancies including bladder cancer, CS is 
typically observed where normal expression of E-cadherin is replaced by the 
abnormal expression of N-cadherin, or N-cadherin expression is increased 
while E-cadherin levels do not change significantly. This switch may mediate 
the migration of cells into tissues with a similar cadherin expression profile 
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(e.g. vascular endothelium) and away from the epithelial compartment and it 
may also change intracellular signalling to enhance cell growth and invasion 
(Bryan 2015). 
P-cadherin has also been demonstrated playing a very important role in TCCB 
with increased expression associated with higher grade and stage of tumours 
as well as worse prognosis, and similar findings were noted in breast cancers 
(Bryan, Atherfold et al. 2008). And an alternative switch from E-cadherin to P-
cadherin instead of N-cadherin has been observed in cancers such as bladder, 
gastric and breast, although the role of P-cadherin in CS is less clear than that 
of N-cadherin (Bryan and Tselepis 2010). In addition, P-cadherin has also been 
shown to inhibit invasion and promote an epithelial instead of a mesenchymal 
phenotype in some malignancies such as malignant melanoma and oral 
squamous cell carcinoma (Bryan and Tselepis 2010). 
1.3.4.2 Wnt/β-catenin signalling pathway 
The Wnt/β-catenin signalling pathway is one of several signalling pathways 
that have been strongly implicated in inducing EMT in epithelial cells including 
bladder cancer urothelial cells, and its aberrations have been linked to many 
cancers (Loh, Hedditch et al. 2013, Gheidari, Bakhshandeh et al. 2014, Li, Ma 
et al. 2014). β-catenin interacts with E-cadherin directly and is confined by it 
to the cell adhesion complex as shown in Figure 6, and nuclear translocation 
of β-catenin presents a key step involved in Wnt/β-catenin signalling pathway 
(see Figure 7). 
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Figure 7: the Wnt/β-catenin pathway and the nuclear translocation of β-catenin 
(adapted from (Jin, George Fantus et al. 2008)). 
 
In the absence of Wnt signalling, cytoplasmic β-catenin is phosphorylated and 
degraded by a multi-protein scaffolding complex consisting of adenomatous 
polyposis coli (APC), casein kinase 1 (CK1), GSK-3β, and axin. When the 
pathway is activated, by the binding of a Wnt ligand to its frizzled 
transmembrane receptor, GSK-3β is inactivated by phosphorylation of its 
serine and then the degradation of β-catenin is blocked. Thus β-catenin 
accumulates, translocates into the nucleus where it binds to Transcription 
factor (TCF)/Lymphoid enhancer-binding factor (LEF) members and 
transcriptionally regulates Wnt target genes including cyclin D1 and c-myc, 
resulting in promotion of cancer development (Jin, George Fantus et al. 2008, 
Ahmad, Morton et al. 2011). 
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As shown in Figure 5 in section 1.2.2, the inhibition of GSK-3β also occurs in 
PI3K/Akt pathway in IGF-signalling system, and accumulating evidence 
indicates that accumulation of Snail, a GSK-3 substrate, resulting from GSK-
3β’s inhibition leads to the downregulation of E-cadherin since Snail is a 
transcriptional repressor of E-cadherin (Bachelder, Yoon et al. 2005, Doble 
and Woodgett 2007). And a reduction of E-cadherin, as mentioned above in 
1.3.4.1, is an important event in the EMT process. 
1.3.5 EMT and IGF axis in cancer 
In recent years, emerging evidence indicates a role of the IGF axis in EMT.  
By upregulating certain molecules including transcription factors, such as 
ZEB-1, which lead to changes of EMT molecules, IGF-I/IGF-IR signalling, 
especially the PI3K/Akt pathway, has been implicated in inducing EMT in 
many types of cancer, including the breast (Walsh and Damjanovski 2011, Al 
Moustafa 2013, Liao, Wang et al. 2014, Taliaferro-Smith, Oberlick et al. 2015, 
Zielinska, Bahl et al. 2015),  prostate (Graham, Zhau et al. 2008), gastric (Li, Li 
et al. 2015, Li, Xu et al. 2015), colorectal (Yao, Su et al. 2016), and non-small 
cell lung cancer (Nurwidya, Takahashi et al. 2014). Attenuation of IGF-IR 
signalling inhibits or even reverses EMT in cancers including breast 
(Lorenzatti, Huang et al. 2011), pancreatic (Subramani, Lopez-Valdez et al. 
2014) and non-small cell lung cancer (Nurwidya, Takahashi et al. 2014, Zhou, 
Wang et al. 2015). Emerging evidence supports the significant correlation 
between decreased E-cadherin expression and tumour development, and it 
has been identified as an epithelial marker, with its downregulation 
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considered to be a critical event in EMT in association with increased risk of 
tumour recurrence and progression, as well as with shorter survival in bladder 
cancer patients (Bringuier, Umbas et al. 1993, Byrne, Shariat et al. 2001, 
Mahnken, Kausch et al. 2005, Mhawech-Fauceglia, Fischer et al. 2006). 
It has also been reported that IGF-II, acting via the IGF-IR, promotes EMT by 
relocating E-cadherin from the membrane to the cytoplasm with increased 
degradation of E-cadherin (Morali, Delmas et al. 2001). A reduction of 
membrane E-cadherin can also release β-catenin into the cytoplasm, which can 
lead to its stabilization as well as translocation into nucleus activating Wnt 
signalling when it over-loads its degradation pathway, thereby stimulating 
tumour migration (see Figure 7) (Morali, Delmas et al. 2001, Ahmad, Morton 
et al. 2011). This, however, can only occur when the normal β-catenin 
degradation pathway is impaired which can be caused by inactivation of GSK-
3β via its phosphorylation by Akt, which itself is activated by the PI3K/Akt 
signalling pathway. Also, the IGF-IR has been found to be within the same 
membrane complex as E-cadherin/β-catenin (Morali, Delmas et al. 2001). 
IGFBPs have also been reported to promote EMT: IGFBP-3 promotes EMT as 
well as invasion in transformed human oesophageal epithelial cells, by acting 
in an IGF-independent manner through TGF-β (transforming growth factor β) 
signalling, another critical EMT-mediating signalling pathway (Natsuizaka, 
Ohashi et al. 2010) and IGFBP-4 is reported to promote EMT in glioblastoma 
cells (Praveen Kumar, Sehgal et al. 2014). 
The link between IGF-IR/PI3K and E-cadherin/β-catenin pathways and 
bladder cancer formation as well as progression was also supported by a 
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clinical study that reported the correlations between high levels of β-
catenin/pAkt (activated Akt) and low levels of PTEN which blocks cell 
proliferation (Ahmad, Morton et al. 2011).  
A further interaction between the IGF-IR/PI3K and E-cadherin/-catenin 
pathways was realised when it became clear that -catenin was able to bind in 
a complex with forkhead box O (FOXO) transcription factors in the nucleus. 
FOXO proteins mainly mediate ageing and stress signalling that promote cell 
cycle arrest, stress resistance, and apoptosis. Nuclear FOXO proteins compete 
with TCF transcription factors for binding to -catenin and this competition 
determines the resultant transcriptional targets affected by -catenin.  
Insulin/IGF induced activation of Akt results in phosphorylation of FOXO 
proteins leading to their binding to 14-3-3 proteins that then retains the FOXO 
proteins in the cytoplasm and thus promotes cell survival by reducing the 
nuclear actions of FOXO proteins (Jin, George Fantus et al. 2008).  
However, a recent study in colon cancer showed opposite results that -
catenin binding to FOXO3a proteins diverts the affected target genes away 
from inducing genes associated with apoptosis to instead of genes associated 
with cell scattering and metastasis (Tenbaum, Ordonez-Moran et al. 2012). 
Consistent with this effect on metastasis, high levels of both -catenin and 
FOXO3a in colorectal cancers are associated with reduced patient survival 
(Tenbaum, Ordonez-Moran et al. 2012). 
In contrast with bladder cancer, low levels of FOXO3a have been associated 
with reduced patient survival, and knockdown of FOXO3a in bladder cancer 
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cells increased cell motility and reduced E-cadherin levels (Shiota, Song et al. 
2010). Similarly, low levels of FOXA1 have been associated with high-grade 
bladder cancer, and knockdown of FOXA1 in bladder cancer cells decreased E-
cadherin expression and increased cell proliferation (DeGraff, Clark et al. 
2012). 
These reports indicate that there are functional interactions between FOXO 
proteins and E-cadherin/-catenin in bladder cancers but with different 
consequences to that reported in colon cancer cells. The interactions between 
FOXO proteins and -catenin/TCF proteins in the nucleus and the 




The term epigenetics was first introduced in the early 1940s, and its widely 
accepted definition is “the study of changes in gene function that are 
mitotically and/or meiotically heritable and that do not entail a change in DNA 
sequence” (Dupont, Armant et al. 2009). 
Epigenetic regulation plays an important part in different stages of normal 
development, through which they gain the ability to develop cell- and tissue- 
type specific gene expressions, although most of their cells contain the same 
genome (Waterland and Michels 2007, Nickel and Stadler 2015). 
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1.4.2 Epigenetics and cancer 
So far, epigenetic alterations described in the literature consist of DNA 
methylation, histone modifications, nucleosome remodelling, and non-coding 
RNAs (ncRNAs) (Dupont, Armant et al. 2009, Han, Wolff et al. 2012, Nickel and 
Stadler 2015). 
In recent decades, epigenetic abnormalities have been widely studied and are 
considered to play a critical role in cancer initiation as well as progression 
(Han, Wolff et al. 2012). Abnormal epigenetic modifications which lead to gene 
aberrant expression and malfunction have been reported in many types of 
cancer, including liver (El Tayebi and Abdelaziz 2016), lung (Hwang, Kim et al. 
2013), lymphoma (Hassler, Klisaroska et al. 2012), colorectal (Williams, Zhang 
et al. 2011), breast (Liu, Liu et al. 2014, Nickel and Stadler 2015) as well as 
bladder (Han, Wolff et al. 2012, Tahara, Shibata et al. 2014, Wu, Cao et al. 2015). 
Dysregulation of members of the IGF family resulting from epigenetic 
modifications have also been demonstrated in many studies, among which 
genes of IGFBP family have consistently been reported to exhibit aberrant DNA 
methylations in tumours. Methylation is characterised as the predominant 
modification in mammalian DNA. Aberrant DNA methylation refers to a 
process by which methyl group are added to DNA bases catalysed by 
methyltransferases (DNMT 1-3), and it happens exclusively at cytosine and 
guanine nucleotides with the intervening phosphate group (CpG) 
dinucleotides in mammals (Dupont, Armant et al. 2009). For example, gene 
promoter hypermethylation of IGFBP-2 in hepatomas (Chiba, Yokosuka et al. 
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2005), and of the IGFBP-3 promoter in several types of cancer, such as renal 
(Morris, Gentle et al. 2008), ovarian (Wiley, Katsaros et al. 2006), breast (Zeng, 
Jarrett et al. 2013), and bladder (Christoph, Weikert et al. 2006). In a study of 
hepatocellular carcinoma, IGFBP-3 was considered to be a tumour suppressor 
with proof of cell growth inhibition after its reactivation (Baxter 2014), and 
DNA methylation of IGFBP-3 is proposed as a potential marker of disease stage 
as well as tumour aggressiveness (Perks and Holly 2015). Of the other IGFBP 
genes, IGFBP-4 was found hypermethylated in about 42% of lung 
adenocarcinomas, and IGFBP-6 in approximately 23% of gastric carcinomas 
(Baxter 2014). 
Likewise, associations of EMT with aberrant epigenetic regulations, especially 
DNA methylations, have been suggested in cancers, for instance bladder (Han, 
Wolff et al. 2012, Tahara, Shibata et al. 2014, Varol, Konac et al. 2014, Wu, Cao 
et al. 2015) and breast (Liu, Liu et al. 2014, Nickel and Stadler 2015). For 
example, loss of expression of Discs large homolog 5 (Dlg5) has been reported 
to involve in the prostate cancer cell migration and invasion (Tomiyama, 
Sezaki et al. 2015), and hypermethylation of Dlg5 gene was found associated 
with silencing of Klg5 expression in bladder cancer cell lines and in bladder 
cancer tumours, especially in muscle-invasive tumours (Zhou, Guo et al. 2015). 
Moreover, some studies have elucidated underlying abnormal modulations of 
EMT-inducing transcription factors caused by epigenetic modifications 
(Huangyang and Shang 2013, Malouf, Taube et al. 2013, Bedi, Mishra et al. 
2014, Carmona, Davalos et al. 2014, Diaz-Lopez, Diaz-Martin et al. 2015). 
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While most studies place emphasis on the research of tumours induced by 
silenced tumour suppressor genes due to abnormal hypermethylation of the 
promoters, global hypomethylation (losses of DNA methylation) has also been 
indicated in the development and progression of cancer (Chen and Wu 2016). 
A genome-wide analysis of DNA methylation patterns in urothelial tumours 
showed distinct methylation patterns, with hypo- only in non-invasive 
tumours and widespread hyper- in invasive ones, implying different 
underlying epigenetic pathways (Wolff, Chihara et al. 2010). 
Based on the nature of reversibility of epigenetic alterations, compared with 
genetic mutations, the accumulating findings of epigenetically regulated genes, 
as well as potentially involved transduction signalling pathways, provide the 
possibility of treating some tumour subtypes by reversing their phenotypes 
(Knowles and Hurst 2015), and all this information has shed light on possible 
epigenetic target cancer therapies. For example, drugs such as decitabine (5-
aza-dCyd), and gemcitabine, which is a pillar in the treatment of MIBC (Kaneko, 
Kikuchi et al. 2011), could hypothetically be used as effective anticancer agent 
targeting the reversal of methylation-mediated silencing of critical genes in 
certain cancers (Ghoshal and Bai 2007, Gray, Baird et al. 2012). 
1.5 Project Aims 
With the background of emerging evidence indicating the potential 
involvement of the IGF axis and EMT in many cancers that has led to promising 
diagnostic/prognostic biomarkers and/or therapeutic treatments, it is 
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frustrating that there is limited literature regarding this for bladder cancer. 
Particularly as this is one of the most expensive malignancies due to its high 
recurrence in early stage tumours and high morbidity in advanced disease. 
Therefore, the principle objective of this project was to determine the role of 
the IGF axis in relation to EMT and progression of bladder cancer. 
1.5.1 Project hypothesis 
An increase of IGF-activity results in decreased levels of E-cadherin, induction 
of N-cadherin, and an increase in nuclear localisation of β-catenin, which 
promotes EMT and the progression of bladder cancer. IGFBP-2 acts as a 
protective factor in bladder cancer development, and so is suppressed in 
aggressive disease via gene promoter hypermethylation. 
1.5.2 Project aims: 
 To assess the levels and role of IGFBP-2 in bladder cancer. 
 To explore the association of IGFBP-2 with cell sensitivity to cisplatin in 
bladder cancer. 
 To investigate the regulatory and working mechanisms of IGFBP-2 in 
bladder cancer. 
 To assess the effect of IGF-I on bladder cancer cells. 
 To look into the relationship of EMT and IGFBP-2/IGF-I in bladder cancer. 
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2.1 Cell Culture 
2.1.1 Equipment 
Incubator (SANYO MCO-18AIC, Panasonic Biomedical, Leicestershire, 
UK) 
Hood (BIOMAT Class II, Medical Air Technology, Manchester, UK) 
Cell Culture Plastics (Greiner Bio-one, Gloucester, UK) 
Pasteur Pipettes (Fisher Scientific, Loughborough, UK) 
Centrifuge (Centaur2, MSE, London, UK) 
Syringe/Needles (Terumo, Leuven, Belgium) 
Hemocytometer (Fisher Scientific, Leicestershire, UK) 
Cryogenic vials (NUNC, Roskilde, Denmark) 
Filters 0.2µm (Appleton Woods, Birmingham, UK) 
2.1.2 Cell Lines 
Four human urinary bladder cancer cell lines and one primary human bladder 
smooth muscle cell line (BdSMC), were used in this study, and their 
characteristics are listed below (see Table 3). 
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Table 3: Cell line characteristic 
Cell line Source info. Obtainment info. 
RT4 
Organism: Homo sapiens (human) 
Tissue: urinary bladder 
Disease: transitional cell papilloma 




Growth properties: adherent 
Purchased from ATCC 
Catalogue No.: HTB-2 
Lot No.: 59817519 
UMUC3 
Organism: Homo sapiens (human) 
Tissue: urinary bladder 





Growth properties: adherent 
Purchased from ATCC 
Catalogue No.: CRL-1749 
T24 
Organism: Homo sapiens (human) 
Tissue: urinary bladder 





Growth properties: adherent 
A kind gift from Professor 
Margaret Knowles 
(University of Leeds) 
TCCSUP 
Organism: Homo sapiens (human) 
Tissue: urinary bladder 
Disease: grade IV, transitional cell carcinoma 




Growth properties: adherent  
Purchased from ATCC 
Catalogue No.: HTB-5 
BdSMC 
Organism: Homo sapiens (human) 
Tissue: urinary bladder 





Growth properties: adherent 
Purchased from Lonza 
Product code: CC-
25533T25 
Lot No.: 0000450859 
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2.1.3 Cell Culture Solutions 
2.1.3.1 Growth Media (GM) 
Five different GM were used for the cell lines respectively as shown below (see 
Table 4). 
Table 4: GM information 
Cell line GM Supplements 
RT4 
McCoy’s 5A Medium (Modified) 
(BioWhittaker) 
 10% foetal bovine serum (FBS, Gibco) 
 1% Penicillin and streptomycin (50 
IU/ml, Britannia Pharmaceuticals Ltd) 




Minimum Essential Medium 
(EMEM, BioWhittaker) 
 10% FBS (as above) 
 1% Penicillin and streptomycin (as 
above) 
T24 
Dulbecco’s Modified Eagle’s 
Medium (DMEM, Bio-
Whittaker), with 4500 mg/L 
glucose  
 10% FBS (as above) 
 1% Penicillin and streptomycin (as 
above) 
 1% L-glutamine solution (as above) 
TCCSUP 
Eagle’s Minimum Essential 
Medium in Earle’s BSS 
(BioWhittaker) with non-
essential amino acids 
 10% FBS (as above) 
 1% Penicillin and streptomycin (as 
above) 
 90% 1mM sodium pyruvate (Sigma) 
BdSMC 
SmBM Basal Medium (Lonza) 
with no growth factors 
SmGM-2 SingleQuots Kit (supplements 
and growth factors, Lonza): 
 Human epidermal growth factor (hEGF), 
0.5ml 
 Insulin 0.5ml 
 Human fibroblast growth factor-B 
(hFGF-B) 1.0ml 
 FBS 25ml 
 Gentamicin/Amphotericin B using at 
1:1000 ratio (GA-1000) 0.5ml 
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2.1.3.2 Serum Free Media (SFM) 
SFM was used in all experiments unless otherwise stated, and bovine serum 
albumin (BSA) was added as a supplement to provide the necessary protein 
while depleting available growth factors to cause cells to quiesce in the G0 
stage. All cell lines used the same SFM shown below (see Table 5). 
Table 5: SFM information 
Cell Line SFM Supplements 





Phenol Red)  
 
 Apo-Transferrin (Sigma); 5mg:  
final concentration: 0.01mg/ml 
 Sodium bicarbonate (NaHCO3, 
Sigma); 600mg: final concentration: 
1.2mg/ml 
 Bovine serum albumin (BSA, Sigma); 
100mg: final concentration 0.2mg/ml 
 1% L-glutamine solution (as above) 
 1% Penicillin and streptomycin (as 
above) 
 
2.1.3.3 Phosphate Buffered Saline (PBS) 
PBS was prepared by dissolving 1 PBS tablet (Cat. # 524650-1EA, Calbiochem) 
tablet in 1L of dH2O. Once dissolved, it was autoclaved and stored at room 
temperature. 
2.1.3.4 HEPES buffered saline solution (HEPES-BSS) 
HEPES-BSS was purchased from Lonza (Cat. #CC-5024). It was aliquotted and 
stored at -20˚C. 
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2.1.3.5 Cell Dissociation Solution (CDS) 
CDS (non-enzymatic) was purchased from Biological Industries (Cat. # 03-
071-1B) and stored at -4˚C. 
2.1.3.6 Trypsin: EDTA Solution (TE) 
Trypsin-versene EDTA 10X liquid (Lonza, Cat. # BE 02-007E) was diluted 1X 
with sterile dH2O, aliquotted and stored at -20°C. 
2.1.3.7 Trypan Blue Dye 
Trypan blue dye (Sigma) was diluted with sterile PBS from 0.4% to 0.165% to 
form a working stock and this was stored at room temperature. 
2.1.4 Cell Maintenance 
2.1.4.1 Cell Passage 
For stocks, 10-15ml of fresh GM was replenished every two or three days and 
cells were passaged when they reached approximately 80% confluency. 
Solutions used for cell passaging were allowed to reach room temperature and 
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Table 6: application of solutions in cell passaging 
Step Solution Cell line 




RT4, UMUC3, T24, 
TCCSUP 
10 
HEPES-BSS BdSMC 10 
2. Cell 
disassociation 
CDS RT4, UMUC3, TCCSUP 3 
3. Trypsinisation 
TE:CDS (1:1) RT4, UMUC3, TCCSUP 3 
TE T24, BdSMC 3 
4. Trypsinisation  
     termination 
GM All cell lines 10 
 
1. Media was aspirated from the flasks and cells were pre-washed once 
with PBS or HEPES-BSS to neutralise the complex proteins in GM which 
may inactivate the trypsin during the trypsinisation procedure.  
2. CDS was then applied to certain cell lines for 5-10 minutes at 37˚C 
before trypsinisation to disengage attached and clumped cells without 
the risk of damage associated with protein digestive enzymes like 
trypsin.  
3. Cells were then incubated in TE with or without additional fresh CDS in 
a 1:1 (v/v) ratio at 37˚C for 5-10 minutes under observation until about 
90% of cells were rounded up and detached.  
4. After trypsinisation, fresh warm GM was added to neutralise the TE. 
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2.1.4.2 Determination of Cell Number and Viability 
Cell pellets then were collected after the cell suspension was 
centrifuged at 1200rpm for 3-5 minutes, and then cells were 
resuspended in 15ml fresh GM with a 5ml syringe (Greiner Bio-One) 
and a 21G needle (Terumo).  
50µl of cell suspension was added to an equal volume of working stock 
of trypan blue (0.165%) (1:1).  
A 50µl trypan blue cell suspension was loaded onto a hemocytometer 
by capillary action. With the aid of a microscope, both viable and dead 
cells were observed. Viable cells remained colourless, and dead cells 
were stained blue because the trypan blue dye was taken up through a 
permeable plasma membrane.  
Cells observed in the centre squares of both top and bottom grids were 
counted as Nt and Nb, and the number of cells per ml in the cell 
suspension (N) equals the sum of Nt and Nb and multiplied by 1x104 
(per ml) (see Figure 8). 
Cell number was determined before a new passage was re-seeded into 
appropriate fresh vessels at specific densities as new stocks or for 
experiments (see Table 7). Cells were then incubated in humidified 
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RT4 0.5 0.8 0.2 0.1 0.03 0.049 0.1 1.0 
UMUC3 0.5 - - - - - - - 
T24 0.2 0.4 0.1 0.05 0.02 0.028 0.08 0.5 
TCCSUP 0.2 0.4 0.1 0.05 0.02 0.042 0.08 0.5 
BdSMC 0.4 0.8 - - - 0.032 - - 
 “-”: not applicable in this study. 
 
Trypan blue dye exclusion assay is a standard method that is commonly used 
to measure cell viability. However, imprecision and inconsistency could be 
caused by several factors such as sample preparation and subjective judgment. 
By dealing with samples carefully and determining cell-staining differences 
consistently, these problems could be largely overcome. Although this method 
does not distinguish apoptotic from necrotic cells, it does reflect cell viability. 
Chapter 2 - Materials and Methods 
Page | 56  
 
 
Figure 8: the structure of a hemocytometer and cell counting calculation 
equation 
 
2.1.5 Cell Freezing and Retrieval 
Cells needed to be periodically frozen down, especially at low passage 
numbers, for long term sustainability of the cell lines. 
2.1.5.1 Cell Freezing Solution 
The freezing solution is composed of GM supplemented with 
dimethylsulphoxide (DMSO, analytical grade, Fisher) and extra FBS in certain 
ratios for different cell lines respectively (see Table 8). The solution was left to 
cool before use. 
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Table 8: cell freezing solution 
Freezing Solution 















8:1:1 BdSMC DMSO 50 
FBS 50 
 
2.1.5.2 Cell Freezing 
0.5ml GM cell suspension containing 1-4x106 cells was mixed drop-
wise with a 0.5ml freezing solution in each cryogenic vial. 
Then the cryogenic vials were stored at -20°C first and then -80°C (for 
at least 24 hours) before being transferred to liquid nitrogen tanks. 
2.1.6 Cell Retrieval 
Cells taken from the liquid nitrogen tank were warmed at 37˚C till just 
defrosted, and then pre-warmed GM was gently added inside the wall 
of the cryogenic vial, 1ml/vial.  
For BdSMC, the cell solution was transferred directly into a T25cm2 
flask with 4ml of pre-warmed GM and then incubated at 37˚C. 
For the other four cancer cell lines, RT4, UMUC3, T24 and TCCSUP, the 
cell solution was transferred into a 30ml universal container with 15ml 
of pre-warmed GM and then centrifuged at 1200rpm for 3 minutes. 
After the supernatant was aspirated, the cell pellet was re-suspended 
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with 5ml fresh pre-warmed GM and the cell suspension was transferred 
into a T25cm2 flask for incubation at 37˚C. 
All cells were allowed to adhere to the flask (several hours or overnight) 
before fresh GM was replenished.  
2.1.7 Cell Treatment 
Cells were split and re-seeded into appropriate vessels with GM for 
experiments. GM was removed after 24 hours and SFM was applied for the 
following 24 hours before treatments. Then cells were dosed with different 
chemicals and the treatment varied as detailed in the text. 
2.2 Analysis of Cell Growth and Survival 
2.2.1 Analysis of Cell Proliferation 
Along with cell counting by Trypan Blue Exclusion Assay, which was described 
in 2.1.4.2, to assess total cell numbers; cell proliferation was also measured by 
a Tritiated Thymidine Incorporation (TTI) Assay by directly measuring 
DNA synthesis. TTI is based on determining the metabolic incorporation of 
[3H]-Thymidine into new strands of chromosomal DNA during DNA replication 
in mitotic cell division. 
2.2.1.1 Equipment 
β-Scintillation Counter (Beckman, LS6500, CA, USA) 
Scintillation vials (Pony vials, PerkinElmer, USA) 
Chapter 2 - Materials and Methods 
Page | 59  
 
Plate Rocker Platform (Bellco Biotech, NJ, USA) 
Incubator (Thermo Electron Corporation, REVCO, Asheville NC USA) 
2.2.1.2 Reagents 
[3H]-Thymidine: 1mCi/ml stock (GE Healthcare, Buckinghamshire, UK), 
stored at 4°C. 
Trichloroacetic acid (TCA, Merck Ltd, Middlesex, UK) solution: 5% w/v; 
5g TCA was added into 100mls dH2O and stored at 4°C. 
Sodium Hydroxide (NaOH, Fisher Scientific Ltd, Leicestershire, UK) 
solution: 1M; 20g NaOH was dissolved into 500mls dH2O and stored at 
room temperature. 
Scintillation fluid (Ultima Gold, Packard Bioscience Ltd, USA) 
2.2.1.3 Method 
3µl of the [3H]-Thymidine stock was diluted with 750µl SFM to make 
0.004µCi/µl working solution. 25µl of the working solution was spiked 
into each well of a 24-well plate (0.1µCi/well). 
The 24-well plates were incubated under normal cell culture conditions 
for the last 4 hours of the experiment.  
The supernatant was aspirated and 500µl TCA solution was added to 
each well for 10 minutes at 4°C. 
The TCA was aspirated and 500µl 1M NaOH was added for incubation 
at room temperature on a plate rocker for 1 hour. 
The cell lysate suspension was transferred into labelled scintillation 
vials and 2mls of scintillation fluid were added in advance. 
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The vials were shaken vigorously and analysed using the β-Scintillation 
Counter. Raw data were recorded as disintegration per minute (DPM). 
2.2.2 Assessment of Cell Death 
All cells, both attached to cell culture vessels and in the supernatant, were 
harvested by trypsinisation (see 2.1.4.1) and spinning. Levels of cell death 
were determined by Trypan Blue Exclusion Assay as described in2.1.4.2. The 
number of cells staining positive for trypan blue dye were calculated as a 
percentage of the total cell number to give the percentage of dead cells. 
2.3 Western Blotting (WB) 
Western blotting, also called immunoblotting, is a widely used analytical 
technique to detect or confirm the change in levels of specific proteins of 
interest.  
In this study, to measure proteins secreted by cells into culture media, a 
method of supernatant concentration was used to enhance the sensitivity of 
detection, and for non-secreted proteins, cells were lysed after treatment to 
release cellular compounds. Then protein samples were run on Sodium 
Dodecyl Sulphate–Polyacrylamide Gel Electrophoresis (SDS-PAGE) to 
separate the proteins, and then the proteins were blotted onto a nitrocellulose 
membrane and probed with corresponding antibodies. 
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2.3.1 Supernatant Concentration 
The secretory protein that was assessed in this study was IGFBP-2 (36 KDa), 
and two sizes of centrifugal filter units with the same type of cellulose 
membrane (molecular weight cut-off: 30 KDa) were applied according to the 
difference in supernatant volume. Samples were concentrated 10 -60 times. 
2.3.1.1 Equipment 
For sample volume less than 3ml: 
Amicon® Ultra-0.5 mL Centrifugal Filters (Merck Millipore, Cat 
#.UFC503024, Hertfordshire, UK)  
Labnet Prism™ R Refrigerated Microcentrifuge (Labnet International, 
USA) 
For sample volume more than 3ml: 
Amicon® Ultra-4 Centrifugal Filter Units (Merck Millipore, Cat 
#.UFC803024, Hertfordshire, UK) 
Centrifuge (see 2.1.1) 
2.3.1.2 Reagent 
PBS (see 2.1.3.3) 
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2.3.1.3 Method 
Supernatant samples were placed into the centrifugal filter units in 
appropriate volumes and spun for 30 minutes at full speed. 
The flow-through was removed and the filter units were topped with 
samples and spun again until the volume of the added sample was 
reduced to less than 10µl. 
The concentrated samples were recovered and collected by reversing the filter 
units and spinning (for samples with an original volume less than 3ml, see 
Figure 9) or by using the appropriate volume of PBS to rinse the inside of the 
filter units. 
The concentrated samples were transferred into labelled eppendorfs, 
ready to use for the next steps, or they were stored at -20˚C for later use. 
 
Figure 9: Supernatant concentration workflow demonstration 
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2.3.2 Non-secreted Protein Extraction of Samples 
2.3.2.1 Equipment 
Syringes/needles (Terumo, Leuven, Belgium) 
Centrifuge (see 2.1.1) 
2.3.2.2 Reagents 
Lysis buffer 
Tris HCL (Sigma, USA), 10mM 
Sodium Chloride (Sigma, USA), 50mM 
EDTA (Sigma, USA), 5mM 
Sodium Pyrophosphate (Sigma, USA), 15mM 
Sodium Fluoride (Sigma, USA), 50mM 
Triton X-100 (Sigma, USA), 1% 
Sodium Orthovanadate (Sigma, USA), 100µM 
The lysis buffer was adjusted to pH 7.6 and then stored at 4°C. 10µl/ml of 
protease inhibitor cocktail (Sigma P8340) and 10µl/ml of phosphatase 
inhibitor cocktail (Sigma P5726) were added before use. 
2.3.2.3 Method 
Cell pellets were obtained following the same procedure as described 
in 2.1.4.1. The pellets were re-suspended in PBS and the cell 
suspensions were transferred into eppendorf tubes. 
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The supernatants were centrifuged and removed leaving the pellets as 
dry as possible to maximise the concentration of the protein extract. 
An appropriate volume of lysis buffer was made up and added to the 
pellets. 
The pellets were resuspended and incubated on ice for 5-10 minutes. 
The eppendorf tubes were centrifuged at maximum speed (~ 16,000 x 
g) for 5 minutes to spin down the cellular debris.  Then the supernatant 
(protein extract) was collected and transferred into another pre-chilled 
eppendorf tube and the debris was discarded. 
The samples were stored at -20°C. 
2.3.3 Protein Quantification 
To ensure that samples were loaded equally onto gels for WB, the 
concentration of total protein in the samples prepared in 2.3.2 was determined 
via a colorimetric reaction using the Bicinchoninic Acid (BCA) Protein Assay 
Kit. 
2.3.3.1 Equipment 
96-well plates (Greiner Bio-one, Gloucester, UK) 
Plate reader (LabSystem Multiskan, Thermo Scientific, Cheshire, UK) 
2.3.3.2 Reagents 
BCA Protein Assay Kit (Thermo Scientific, Cheshire, UK) 
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BCA reagent A containing sodium carbonate, sodium bicarbonate, 
bicinchoninic acid and sodium tartrate in 0.1 M sodium hydroxide. 
BCA reagent B containing 4% cupric sulphate. 
Albumin standard Ampules, 2.0 mg/ml, containing bovine serum 
albumin (BSA) at 2.0 mg/ml in 0.9% saline and 0.05% sodium azide. 
2.3.3.3 Method 
The standards were prepared by diluting Albumin Standard Ampules (stock, 
2.0 mg/ml) with lysis buffer as described in Table 9. 




BSA (µl) Lysis buffer (µl) 
A 2000 300 of stock 0 
B 1500 375 of stock 125 
C 1000 325 of stock 325 
D 750 175 of vial B 175 
E 500 325 of vial C 325 
F 250 325 of vial E 325 
G 125 325 of vial F 325 
H 25 100 of vial G 400 
 
5µl of the standards and 5µl of the protein extracts prepared in 2.3.1.3 
were loaded into each well of the 96-well plate in duplicate. 
Reagents A and B were mixed in a ratio of 50:1 and 200µl were added 
into each occupied well. 
The plate was incubated at room temperature for 30 minutes. 
The plate was read using Genesis Software package under 540nm filter. 
Chapter 2 - Materials and Methods 
Page | 66  
 
2.3.4 Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) 
2.3.4.1 Equipment 
Glass Plate (Bio-Rad, Hertfordshire, UK) 
Clamps (Bio-Rad, Hertfordshire, UK) 
Casting Base (Bio-Rad, Hertfordshire, UK) 
Gel Tank (Bio-Rad, Hertfordshire, UK) 
Power Pack (Pharmacia, LK-BPS 500/400, Bio-Rad, Hertfordshire, UK) 
pH Meter (Whatman, PHA 230, Sigma, USA) 
Magnetic Stirrer (SMI, Stuart Scientific, Germany) 
2.3.4.2 Reagents 
40% Acrylamide Gel Solution Bis-acrylamide 37.5:1(Severn Biotech, 
Worcestershire, UK), stored at 4°C. 
1.5M Tris Base (Sigma, USA): 18.16g was added into 70mls dH2O; pH 
adjusted to 8.9 before the solution was made up to 100mls; stored at 
4°C. 
1.1M Tris HCL (Sigma, USA): 17.33g was added into 70mls dH2O; pH 
adjusted to 6.8 before the solution was made up to 100mls; stored at 
4°C. 
10% Sodium dodecyl sulphate (SDS) (Sigma, USA): 50g was added into 
400mls dH2O with gentle warming to assist dissolution; pH was 
adjusted to 7.2 before the solution was made up to 500mls; stored at 
room temperature. 
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10% Ammonium Persulphate (APS) (Sigma, USA): 1g was added into 
10mls dH2O; the solution was used up within 4 months; stored at 4°C. 
N,N,N,N-tetramethyethylenediamine (TEMED) (Sigma, USA): stored at 
room temperature. 
Butanol ((Fisher Scientific, UK): 50:50 mix of Butanol and dH2O 
Sample Buffer (Sigma, USA): Laemmli 2x Concentrate. 
Precision Plus Protein Standards (BIO-RAD, Cat. # 161-0375) 
10x Running Buffer: 
 Dissolve the components shown below in Table 10 in 1 litre of 
dH2O and adjusted to pH 9.65; stored at room temperature. 
 1x Running Buffer was prepared by diluting 10x Running Buffer 
with dH2O in a ratio of 1:9. 
Table 10: 10x Running buffer preparation 
Tris Base (Sigma, USA) 30.3g 
Glycine (Fisher Scientific, UK) 144g 
SDS (Sigma, USA) 10g 
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Constituents of gels are listed below in Table 11. 
 Percentage refers to the final percentage of acrylamide in the gel, 
and the thickness of all gels was 1.5mm. 
 The interaction of APS and TEMED caused polymerisation of the 
gels and they were added at the last. 
2.3.4.3 Method 
2.3.4.3.1 Preparation of PAGE gels 
Each gel is discontinuous consisting of a resolving or separating (lower) part 
and a stacking (upper) part. Proteins samples pass through the stacking gel to 
be concentrated before undergoing complete separation when entering the 
resolving gel. 
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The spacer plates and short plates were assembled and clipped with 
clamps to be placed in casting bases. 
The resolving portion was prepared according to Table 11 and poured 
into the gap between the spacers and short plates to a certain level, and 
then covered with a small volume of hydrated butanol (butanol:dH2O 
in a 1:1 ratio) to avoid air preventing the polymerization of the gels. 
Gels were allowed to set for about 30 minutes and then butanol was 
washed off. 
The stacking portion was also prepared according to the Table 11 and 
it was poured to the top. The 1.5mm thick combs were placed into the 
assembled gel sandwich. 
Gels were allowed to set for another 30 minutes and then combs were 
removed, vertically with care. 
The gels were moved from the clamps into the tank complex to be 
loaded. 
2.3.4.3.2 Loading samples and running gels 
 The amount of sample loaded was measured according to the result of 
the BCA protein assay. The samples were mixed with the same volume 
of 2x sample buffer. 
 Mixed samples were boiled at 100°C for 5 minutes. 
 Samples were loaded into each well of the gels slowly and gently to 
avoid cross contamination. 
Chapter 2 - Materials and Methods 
Page | 70  
 
 Gels were run by limited volts of 125-200V depending on the number 
of gels being analysed and for approximately 35-90 minutes depending 
on the separation required and protein size. 
2.3.5 Transfer 
2.3.5.1 Equipment 
Transfer tank (Bio-Rad, Hertfordshire, UK) 
Power pack (Pharmacia, LK-BS5 500/400, Bio-Rad, Hertfordshire, UK) 
Cassettes (Bio-Rad, Hertfordshire, UK) 
Sponges (Pharmacia, LK-BPS 500/400, Bio-Rad, Hertfordshire, UK) 
Nitrocellulose membrane (Amersham, GE Healthcare Life Sciences, 
Buckinghamshire, UK) 
Filter paper (Whatman, Sigma, USA) 
PH Meter (2.3.4.1) 
Magnetic Stirrer (2.3.4.1) 
2.3.5.2 Reagents 
10x Transfer Buffer: 
Dissolve the components shown in  
 Table 12 in 1 litre of dH2O and adjusted to pH 9.65; stored at 4°C. 
 1x Transfer Buffer was prepared by mixing 10x Transfer Buffer 
with Methanol (Fisher Scientific, UK) and dH2O in a ratio of 
1:2:7. 
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Table 12: 10x Transfer buffer preparation 
Tris Base (Sigma, USA) 30.3g 
Glycine (Fisher Scientific, UK) 144g 
dH2O Make up to 1 litre 
 
2.3.5.3 Method 
Gels with separated proteins were made up into transfer sandwiches with 
other components inside of a transfer cassette, and the sequence below was 
followed to ensure that the current went from the gels to the membranes: 
Black side 
Sponge (1-2) 
Thick filter paper (1) 
Gel (1) 
Nitrocellulose membrane (1) 
Thin paper (2) 
Sponge (1-2) 
Clear side 
The transfer occurred with the electronic current set to limited volts of 100V 
for about 1 hour. 
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Orbital shaker (IKA, Sigma, USA) 
Rotator (SB1, Stuart Scientific, Staffordshire, UK) 
Polythene bag (Jencons, Leighton Buzzard, UK)  
Bag sealer (Astrapac 500105, Walsall, UK) 
2.3.6.2 Reagents 
10x Tris-buffered saline with Tween (TBST), (pH 7.6):  
 Dissolve Tris HCL and NaCl as shown in Table 13 in 1 litre of 
dH2O. Add tween 20 after the solution was adjusted to pH 7.6; 
stored at room temperature. 
 1x TBST was prepared by adding 10x TBST with dH2O in a ratio 
of 1:9. 
Table 13: 10x TBST preparation 
Tris HCL (Sigma, USA) 24.2g 
NaCl (Sigma, USA) 80g 




TBST based Blocking Solutions: 
 1 X TBST with 5% milk: 2.5g skimmed dried milk in 50mls 
 1 X TBST with 2% milk: 1g skimmed dried milk in 50mls 
 1 X TBST with 1% milk: 0.5g skimmed dried milk in 50mls 
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 1 X TBST with 5% BSA: 2.5g BSA (Sigma) in 50mls 
 1 X TBST with 3% BSA: 1.5g BSA (Sigma) in 50mls 
Antibody solutions listed below in Table 14. 





& Cat. No. 




92 Cell Signaling 









95 Cell Signaling 









95 Santa Cruz 
































































GAPDH 35 Chemicon 







IGFBP-2 36 Santa Cruz 







*2˚ Ab: anti-rabbit (Sigma, #A0545); anti-mouse (Sigma, #A0944); anti-goat (Sigma, #A5420). 
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2.3.6.3 Method 
The membranes with transferred proteins were cut into separate 
pieces according to the size of the proteins to be analysed, and they 
were blocked with the blocking solutions according to the Table 14 for 
over two hours at room temperature to prevent non-specific binding of 
proteins. 
The membranes were then probed overnight in a cold room at 4°C with 
a primary antibody of interest in sealed bags on a rotator. 
After incubation with a primary antibody, the membranes were washed 
3 times for 5-15 minutes with TBST and then incubated with an 
appropriate secondary antibody for one hour at room temperature. 
The membrane was subsequently washed 5-15 minutes for a further 3 
times with TBST before visualisation. 
2.3.7 Detection and Calculation 
2.3.7.1 Equipment 
ChemiDoc MP Imaging System (Bio-Rad, Hertfordshire, UK) 
Image LabTM Software (version 5.0) 
ImageJ Software (version 1.46r) 
2.3.7.2 Reagents 
Super signal west dura substrate (Pierce Biotechnology, Cat.# 34075, 
Thermo Scientific, Cheshire, UK) 
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Super signal west femto substrate (Pierce Biotechnology, Cat.# 34094, 
Thermo Scientific, Cheshire, UK) 
2.3.7.3 Method 
Membranes were washed for 5 minutes with Super signal west dura 
substrate (West femto was used for antibodies requiring more 
sensitive detection). 
The chemiluminescence signal was detected using Image LabTM 
Software by the ChemiDoc MP Imaging System. 
Densitometry was performed using ImageJ software. 
2.4 Cellular Fractionation 
The Thermo Scientific NE-PER Nuclear and Cytoplasmic Extraction Reagents 
enabled stepwise separation and preparation of non-denatured, active 
proteins of cytoplasmic and nuclear extracts from mammalian cultured cells 
or tissue in less than two hours. The first two reagents (CER I and CER II) were 
added to the cell pellets resulting in cell membrane disruption and release of 
cytoplasmic contents. And the third reagent (NER) was added to yield the 
nuclear extract. 
All centrifugation steps were performed at 4°C and all samples and 
extracts, as well as reagents, were kept on ice to avoid protein 
degradation. 
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Protease inhibitors and phosphorylation inhibitors were added into 
CER I and NER to maintain extract integrity and function 
2.4.1 Equipment 
 Labnet Prism™ R Refrigerated Microcentrifuge (see 2.3.1.1) 
 Autovortex Mixer SA2 (Stuart Scientific, UK) 
2.4.2 Reagents 
 Trypsin: EDTA Solution (TE) as described in 2.1.3.6. 
 PBS as described in 2.1.3.3. 
 NE-PER Nuclear and Cytoplasmic Extraction Reagents Kit (Thermo 
Scientific, Cheshire, UK) 
 Cytoplasmic Extraction Reagent I (CER I) 
 Cytoplasmic Extraction Reagent II (CER II) 
 Nuclear Extraction Reagent (NER) 
 Lysis buffer with a protease inhibitor and phosphorylation inhibitor as 
described in 2.3.2.2. 
2.4.3 Method 
 Cells were harvested following the same procedure as described in 
2.1.4.1 and 2.1.4.2 and then centrifuged at 500x g for 5 minutes. 
 The cells were washed by suspending the cell pellets with PBS to wash 
off any traces of media and then the cell suspension was transferred 
into pre-chilled eppendorf tubes. 
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 The cell suspension was centrifuged again at 500 x g for 2-3 minutes. 
 The supernatant was removed carefully and the pellets were left as dry 
as possible. 
 The ice-cold CER I was added to the cell pellets and then Cytoplasmic 
and Nuclear Protein Extraction using the reagent volumes shown in            
Table 15 below was performed. The volume ratio of CER I: CER II: NER 
reagents was maintained at 200:11:100 respectively. 
           Table 15: reagent volumes for different packed cell volumes 
Packed Cell 
Volume (µl) 
CER I (µl) CER II (µl) NER (µl) 
10 100 5.5 50 
20 200 11 100 
50 500 27.5 250 
100 1000 55 500 
 
After adding CER I, the tubes were agitated vigorously on a vortex on 
the highest setting (2500rpm) for 15 seconds to fully suspend the cell 
pellets, and then incubated on ice for 10 minutes. 
The ice-cold CER II was added to the eppendorf tubes. 
The tubes were agitated on the highest setting (2500rpm) for 5 seconds 
and then incubated on ice for 1 minute. 
The tubes were agitated for another 5 seconds on the highest setting 
(2500rpm) and then centrifuged for 5 minutes at maximum speed (~ 
16,000 x g). 
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The supernatants (cytoplasmic extract) were immediately transferred 
into clean pre-chilled eppendorf tubes and the tubes were placed on ice 
until used or were stored at -80˚C. 
The pellets (intact nuclei) were washed with ice-cold PBS and 
centrifuged 2-3 times to remove leftover cytoplasmic extract to avoid 
contamination. 
The ice-cold NER was added into the insoluble pellets that contained 
nuclei and was re-suspended. 
The samples were agitated on the highest setting (2500rpm) for 15 
seconds and then placed on ice for 10 minutes. The 15-second vortex 
and 10-minute incubation on the ice were repeated at least 4 times to 
release the nuclear extract. 
The tubes were centrifuged at a maximum speed (~ 16,000 x g) in the 
microcentrifuge for 10 minutes. 
The supernatant (nuclear extract) fraction was immediately 
transferred to a clean pre-chilled eppendorf tube and placed on ice till 
used or was stored at -80°C. 
2.5 Immunofluorescence 
Fluorescently labelled antibodies were utilised to detect specific target 
proteins of interest in cells by using immunofluorescent imaging. 
2.5.1 Equipment 
 Polylysine-coated coverslips (BD Biosciences, USA) 
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 6-well plates (Greiner Bio-one, Gloucester, UK) 
 Parafilm (Bemis Company, USA) 
 Leica DMI 6000B microscope (Leica Microsystems, Germany) 
2.5.2 Reagents 
 PBS as described in2.1.3.3: 1ml/coverslip. 
 Formaldehyde (PFA) (Polysciences, Germany): 3%, 500µl/coverslip, 
methanol free, stored at -20°C. 
 Glycine (Fisher Scientific, Loughborough, UK): 30mM; 1ml/coverslip, 
decide volume by demand, e.g. weigh 22.5mg Glycine to resolve in 10ml 
PBS. 
 Triton X-100 (see 2.3.2.2): 0.5%; 1ml/coverslip, decide volume by 
requirement, e.g. add 50µl from stock into 10ml PBS. 
 BSA (Sigma, USA): 3%; made up in PBS, used for blocking 
(1ml/coverslip) as well as antibodies dilution, decide volume by 
requirement, e.g. weigh 0.3g BSA to resolve in 10ml PBS. 
 Fluorescent secondary antibodies (Fisher Scientific, Loughborough, 
UK):  
 Alexa Fluor 568 Phalloidin: orange fluorescent, staining actin for 
the cytoskeleton. 
 Alexa Fluor 488 Goat Anti-Mouse IgG (H+L) (green fluorescent) 
 Alexa Fluor 568 Goat Anti-Mouse IgG (H+L) (red fluorescent) 
 Alexa Fluor 488 Donkey Anti-Rabbit IgG (H+L) (green 
fluorescent) 
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 Alexa Fluor 568 Goat Anti-Rabbit IgG (H+L) (red fluorescent) 
 Alexa Fluor 488 Donkey Anti-Goat IgG (H+L) (green fluorescent) 
 Alexa Fluor 568 Donkey Anti-Goat IgG (H+L) (red fluorescent 
 DAPI (Vectashield mounting medium for fluorescence with DAPI, 
Vector Laboratories, Peterborough, USA): preserves fluorescence, 
prevents rapid photobleaching of fluorescent reagents and retains 
fluorescence during prolonged storage. 
 Nail varnish 
2.5.3 Method 
 Cells were seeded on poly-lysine coated coverslips in 6-well plates and 
allowed to grow prior to treating according to different experiments. 
 The coverslips were washed with PBS in the plates by adding PBS to the 
side of the well gently for 3 x 5 minutes to remove any traces of media. 
 The PBS was removed and 3% PFA was added gently directly to the 
edge of coverslips for 15 minutes to fix the cells. 
 PFA was removed and PBS was added to wash off any traces of PFA. 
 The PBS was removed and 30mM glycine was added to the sides of the 
wells and left for 5 minutes to quench the cells. 
 The glycine was removed and PBS was added to wash the cells again. 
 The PBS was removed and 0.5% Triton was added to permeabilize the 
cells. The permeability of an outer membrane would be achieved in 5 
minutes and that of the nuclear membrane would be achieved in 15 
minutes in total. 
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 The 0.5% Triton was removed and cells were washed with PBS. 
 The PBS was removed and 3% BSA (1ml/coverslip) was added for 1 
hour at room temperature to block the non-specific sites on the 
membranes. 
 Primary antibodies were made up in 3% BSA on ice and details of the 
antibodies as well as dilution factors will be given in the relevant 
chapters. 
 50µl of antibody solution was dripped onto parafilm that was placed on 
the bench: each coverslip was placed onto the droplet of the antibody 
with cells facing towards the droplet. 
 The coverslips were covered with an inverted plastic box with a 
roll of damp tissue to create a humid chamber. 
 The primary antibody was left to incubate for 1 hour. 
 The coverslips were taken back to 6-well plates, cell side up and then 
washed with PBS for 5 minutes, 3 times to remove any unbound 
antibody. 
 Fluorescent secondary antibodies were also made up in 3% BSA on ice 
in dilution of 1:500, avoiding light. Together with the secondary 
antibody solutions, Phalloidin was added in dilution of 1:250 if needed. 
 As with the primary antibody, a 50µl solution of secondary antibody 
was applied to each coverslip and left in dark, humid conditions for 1 
hour at room temperature. 
 The coverslips were taken back to the 6-well plates again with cell side 
up and then washed with PBS for a further 3 x 5 minutes in dark 
conditions. 
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 Coverslips were mounted in darkness onto slides with DAPI, cell side 
down and sealed with nail varnish to avoid movement. 
 Coverslips were then imaged using a Leica DMI 6000B microscope. 
2.6 Small Interference RNA (siRNA) Transfection 
Small interfering RNA (siRNA) is also known as short interfering RNA or 
silencing RNA featuring a class of double-stranded RNA molecules with only 
20-25 base pairs in length.  
siRNA transfection is a technique to silence sequence-specific target genes by 
introducing exogenously derived antisense RNA molecules to interfere with 
the complementary messenger RNA followed by the degradation of the 
messenger RNA after transcription which results in no translation of target 
genes (Agrawal, Dasaradhi et al. 2003). 
2.6.1 Equipment 
 6-well plates (Greiner Bio-one, Gloucester, UK) 
 Pipette filter Tips (Starstedt, Germany) 
 RNase, DNase and Pyrogen free microcentrifuge tubes (Appleton Wood, 
Birmingham, UK) 
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2.6.2 Reagents 
Hs_IGFBP-2 _4 FlexiTube siRNA 
 Target sequence: 5’-CCCGGAGCAGGTTGCAGACAA-3’ 
(Qiagen, Cat #. SI02623859, Germany) 
Non-silencing negative control (Qiagen, Cat #. 1027310, Germany) 
SIRNA transfection reagent SAINT-RED Kit (Synvolux Therapeutics, Cat 
#. SR-1003-04, The Netherlands) 
 SAINT-RED (transfection reagent) 
 HBS 1x (siRNA suspension buffer) 
2.6.3 Method 
 A 20μM stock solution was made by re-suspending the lyophilised 
supplied siRNA (5nmol) in 250µl of siRNA suspension buffer. 
 After re-suspension, the tube was heated to 90°C for 1 minute and then 
left at 37°C for 1 hour to remove aggregates. Then the stock solution 
was aliquoted and stored at -20°C. 
 2μM working stock of siRNA was prepared fresh by extracting 10μl of 
siRNA 20μM stock and adding to 90μl of HBS buffer. 
 siRNA solutions were made by adding the 2µM siRNA/HBS dropwise 
into a mixture of SFM and SAINT-RED transfection reagent, giving a 
final concentration of 30nM of IGFBP-2 siRNA/SAINT-RED complex 
(15µl per well). Non-silencing negative control was made at the same 
concentration. 
 The siRNA/SAINT-RED complex was incubated at room temperature 
for 20 minutes. 
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 Cells were seeded at 0.4 x 106 in 800μl GM per well of a 6-well plate. 
 The siRNA/SAINT-RED complex was added dropwise with gentle 
agitation of the wells at 200μl per well according to the plate layout. 
 The cells were incubated at 37°C for 24 hours. 
 Cells were switched and exposed to SFM for another 48 hours. 
 The impact of siRNA on the cells was assessed by WB as described in 
2.3. 
2.7 Combined Bisulphite Restriction Assay (COBRA) 
DNA methylation is an epigenetic mechanism, which occurs through the 
addition of a methyl (-CH3) group to DNA, that often results in gene silencing. 
Cytosine methylation of CpG dinucleotides happens commonly in mammals 
(Reinert, Modin et al. 2011). As a widely used molecular biology technique in 
cancer research and epigenetic studies, COBRA allows for sensitive 
quantification of DNA methylation levels at a specific gene locus in a small 
sample of genomic DNA. It introduces methylation-dependent sequence 
differences and combines bisulfite conversion based polymerase chain 
reaction (PCR) with restriction enzyme digestion to discriminate gene 
methylation levels according to the difference in DNA fragment production 
(see Figure 10). 
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Figure 10: COBRA workflow 
An example of DNA fragments cut from the digestion of BstUI, a restriction enzyme, of bisulfite 
conversion based PCR products with CpG sites. “M”: completely methylated DNA control; “UM”: 
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2.7.1 Equipment 
Desktop centrifuge (Heraeus, Micro Centaur, UK) 
1.5ml microcentrifuge tubes (Eppendorfs, Sigma, USA) 
Water bath (GRANT, JB2, UK) 
Vortex Mixer (Thermo Scientific, Cheshire, UK) 
PCR machine (MJ RESEARCH, Bio-Rad, Hertfordshire, UK) 
ChemiDoc MP Imaging System (see 2.3.7.1) 
Image LabTM Software (see 2.3.7.1) 
2.7.2 Reagents 
EZ DNA Methylation-DirectTM Kit (Zymo Research, Cat #. 5021, USA) 
HotStarTaq Plus PCR Kit (Qiagen, Cat. # 203603, Germany) 
IGFBP-2 primer (designed using MethPrimer tool and purchased from 
Thermo Fisher Scientific, UK) 
 size: 263bp 
 target sites: -413 to-150 
 Sequences:  F: 5’-GAT TGA AAT TTA TTT GAA GGT TAA AA-3’ 
   R: 5’-ACT CTA AAA ATT CCC TAC TCT TCC C-3’ 
 Anneal temperature: 57˚C 
Restriction Enzyme BstUI, 10,000 U/ml (BioLabs, Cat.# R0518L, 
Hitchin, UK) 
 Recognition site:  5´…. CG⬇CG… 3´ 
    3´…. GC⬆GC… 5´ 
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Water – Rnase/Dnase/Protease free (Fisher Scientific, Cat. #HYC-001-
218c, Loughborough, UK) 
Tris-Borate-EDTA buffer (TBE), 5x (QIAGEN, Cat. # 129217, Germany) 
50bp DNA ladder (Biolabs, Cat. # N3236S, Hitchin, UK) 
Agarose (Melford, Cat. # MB 1200, Suffolk, UK) 
Midori Green Advance (NIPPON Genetics EUROPE, Cat. # MG 04, Duren, 
UK) 
2.7.3 Method 
2.7.3.1 DNA Extraction and Bisulfite Conversion 
Cultured cells were trypsinized and collected as described in 2.1.4.1, 
and then cell counting was performed as described in 2.1.4.2. 
Cells were centrifuged and the supernatant was removed. 
Cell pellets resuspended in a certain volume of PBS to reach a cell/PBS 
suspension containing 10x106cells/ml. 
10µl cell/PBS suspension was taken from each sample containing 
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Digestion solutions for each sample: 
 M-Digestion buffer (2x)                            13µl 
    (EZ DNA Methylation-DirectTM Kit) 
 
   
 Sample (containing 0.1x106 cells)       10µl 
 Proteinase K          2µl 
 Water           1µl 
 Total          26µl 
All samples were then incubated in a water bath at 50˚C for 20 minutes. 
Samples were vortexed to mix the contents of the reaction thoroughly 
and then centrifuged at 10,000x g for 5 minutes. 
20µl of supernatant were added to 130µl of pre-prepared CT 
Conversion Reagent solution in a PCR tube. All samples were vortexed 
again and centrifuged briefly to avoid droplets in the tube lid. 
Samples in PCR tubes then were placed in a thermal cycle shown below: 
 98˚C 8 minutes 
 64˚C  3.5 hours 
 4˚C  up to 20 hours 
Each Zymo-Spin IC Column was filled with 600µl of M-Binding buffer 
and then placed into a Collection tube. Samples were then loaded in the 
columns individually and mixed well. 
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Samples were centrifuged at full speed for 30 seconds, and the flow-
through was discarded. 
100µl of M-Wash buffer (EZ DNA Methylation-DirectTM Kit) was added 
to each sample and centrifuged again at full speed for 30 seconds.  
200µl of M-Desulphonation buffer (EZ DNA Methylation-DirectTM Kit) 
were added to each sample and allowed to stand for 15-20 minutes at 
room temperature, and then once more centrifuged at full speed for 30 
seconds. 
Samples were then washed twice by adding 200µl of M-Wash buffer 
followed by 30 seconds full speed centrifugation. 
The columns with samples were then placed into new 1.5ml eppendorf 
tubes. 10µl of M-Elution buffer (EZ DNA Methylation-DirectTM Kit) was 
added directly to the column matrix at the bottom of the columns and 
then centrifuged at full speed for 30 seconds to elute the DNA. 
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2.7.3.2 PCR 
A PCR Master Mix (MM) was made as below (see  
 
    Table 16, in a total volume of 10µl). 
 
    Table 16: PCR master mix constituent 
Ingredients Final concentration 
10x Buffer 1x 
10mM dNTP 0.1mM 
25mM MgCl2 2.0mM 
10µM Forward primer 0.25µM 
10µM Reverse primer 0.25µM 
DMSO 5% 
5 U/µl Taq 0.25 U/10µl 
Water Add up to the total volume of 10µl 
 
PCR samples were prepared by adding 1µl of DNA sample extracted as 
in 2.7.3.1 into each PCR reaction tube pre-filled with 9µl of MM. Control 
DNA samples (UM: completely unmethylated DNA control; M: 
completely methylated DNA control; E: empty/water control) were 
prepared in the same way. 
PCR reaction tubes were placed into a pre-warmed PCR machine run 
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 94˚C  10 minutes 
 94˚C  45 seconds                 
                                    40x 
 57˚C  45 seconds   
 72˚C  45 seconds 
 72˚C  5 minutes 
The PCR products were ready for the following restriction enzyme 
digestion. 
2.7.3.3 Restriction Enzyme Digestion and DNA Detection 
An enzyme digestion solution was made as below (see     Table 17, in a 
total volume of 10µl) and mixed with equal volume of PCR products. 
The mixture of enzyme/PCR products was incubated for 4 hours at 60˚C. 
A 2.5% agarose gel was made by melting 2 grammes of agarose into 
100ml of 1x TBE buffer, with 5µl of Midori Green Advance added before 
pouring. 
10µl of digested PCR samples and 50bp DNA ladder were loaded into 
wells after the gel was set, and run at 100 volts for approximately 30 
minutes. 
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The migrated DNA on the gel was detected using Image LabTM Software 
by the ChemiDoc MP Imaging System. 
    Table 17: restriction enzyme used for COBRA 
Ingredients 
Concentration before 
adding PCR products 
Final concentration after 
adding PCR products 
10,000 U/ml BstUI 2 U/µl 1 U/µl 
10x Buffer 2x 1x 
100x BSA 2x 1x 
Water Add up to the total 
volume of 10µl 
--- 
 
2.7.3.4 DNA Methylation Level Calculation 
Densitometry of DNA bands was performed using ImageJ software. 
The percentage of DNA methylation level = sum of restricted enzyme 
cut DNA fragments/sum of the cut DNA fragments and uncut DNA x 100. 
A linear response of the COBRA assays was validated by correlating the 
percentage of input of completely methylated DNA control versus the 
COBRA-measured percentage methylation. 
2.8 Soft Agar Colony Formation Assay 
In cancer progression, the ability of cells to grow in an anchorage-independent 
manner is an important criterion of cell malignant transformation. And the soft 
agar colony formation assay is considered to be one of the most well-
established methods to test this capacity in vitro by suspending cells in agar 
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(see Figure 11), and it allows for semi-quantitative evaluation of cell 
transformation in response to various treatments. A colony is defined as a 
cluster of at least 50 cells and it is assumed to be the result of the anchorage-
independent proliferation of an individual cell (Cai, Chattopadhyay et al. 2011). 
In this assay, cells were cultured in appropriate conditions for 3-4 weeks, and 
then colonies that were formed were analysed using ImageJ software after a 
cell stain. 
 
Figure 11: Soft agar colony formation assay dish demonstration 
 “Base layer”: the bottom layer of agar prepared for set-up of experiments; “Cell seeding 
layer”: the middle layer of agar containing cells; “Feeding layer”: the upper layer of agar 
feeding cells with nutrients with or without chemicals as a treatment. 
 
2.8.1 Equipment 
Petri dishes (Corning, Cat #.430196, Sigma, USA) 
LEICA DM IRB (Leica Microsystems, UK) 
AxioCam ERc5s camera (Zeiss, Cambridge, UK) 
ImageJ software (see 2.3.7.1) 
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2.8.2 Reagents 
2x DMEM (see Table 18) 
3.5% stock agarose solution (see Table 18) 
FBS/L-glutamine solution/Penicillin and Streptomycin (see Table 4) 
 aliquots in small volume 
10% FBS Medium Mix (see Table 18) 
Crystal violet (Sigma, Cat #. C3886, USA) 
Ethanol (Fisher Scientific, Cat #. 64-17-5, Loughborough, UK) 
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Table 18: soft agar colony formation solutions 
  
 
 Ingredients Volume Preparation & Storage 
2x DMEM 
10x DMEM powder 
(Sigma) 
1x 
 The ingredients were 
mixed together and 
then adjusted to pH 7.4 
by adding about 2ml of 
a sterile aqueous stock 
of 1M NaOH. 
 The mixture was filter 
sterilised and stored at 
4˚C for at least 1 
month. 
7.5% NaHCO3  
(Gibco BRL) 
49.3ml 
100mM sodium pyruvate  
(Gibco BRL) 
5ml 






Low Melting Point (LMP) 
agarose (Sea Plaque LMP 
agarose, Lonza) 
3.5g 
 Dissolve the agarose in 
the water in the 
microwave. 
 Aliquot the solution 
into 15ml per glass 
universal. 
 Autoclave and store at 
room temperature. 





1x DMEM 36ml  Recipe for 12 dishes. 
 Prepare fresh or 
refrigerate for later 
use up to 1 week. 
 Equilibrate to 37˚C 
before use. 
2x DMEM 15ml 
FBS 7.5ml 








Crystal violet 10mg 
 Weigh up and dissolve 
in pure ethanol. 
 Store at room 
temperature. 
Ethanol 25ml 
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2.8.3 Method 
2.8.3.1 Preparation of dishes with agar base layer 
The stock agarose solution was pre-melted and equilibrated to 37˚C. 
12.5ml of the agarose solution was added into 50ml of pre-warmed 10% 
FBS medium and pipetted up and down several times to mix well. 
5ml of the base agar was added to each Petri dish. Any bubbles were 
removed by using a Pasteur pipette attached to a vacuum pump. 
The dishes were placed in the fridge (4˚C) on a flat platform for at least 
20 minutes to allow the agar to set. The dishes could be left in the fridge 
overnight for next step on the second day. 
The set agar dishes were placed in the incubator (37˚C) to warm them 
before seeding the cells. 
2.8.3.2 Cell seeding 
Cells were trypsinized (see 2.1.4.1) and counted (see 2.1.4.2) in normal 
GM. 
The desired cell number was calculated for each dish depending on the 
cell type (see Table 7) and the cells were placed into a 1.5ml eppendorf 
in a total volume of 0.5ml (top up with GM if not enough) individually 
and placed in an incubator at 37˚C before seeding into dishes. 
2.5ml of pre-melted agarose solution was added to 10ml pre-warmed 
10% FBS medium mix to prepare for the cell seeding layer (both 
equilibrated to 37˚C before mixing): the solution was pipetted up and 
down several times gently to avoid bubbles. 
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Relevant chemicals were added into the 10% FBS medium mix before 
mixing with the agarose solution if cells were being treated. The 
chemical calculation needs to take multiple step dilutions into 
consideration to reach desired final concentration. 
1ml of 10% FBS medium mix/agarose (equilibrated to 37˚C) was added 
into each eppendorf containing cells and mixed gently to avoid bubbles. 
The 1.5ml cell/agarose medium mix was transferred into each pre-
warmed dish and the dishes labelled on both the lid and the side. 
The seeded dishes were placed in the fridge (4˚C) on a flat platform for 
about 20 minutes to allow the agar to set, and they were then returned 
to the incubator (37˚C) to complete cell seeding. 
2.8.3.3 Cell feeding 
Preparation of the feeding layer was the same as for the cell seeding 
layer described in 2.8.3.2: 4ml of stock agarose solution was added into 
22ml of 10% FBS medium mix. 
Any specific treatments were calculated and then added into the 10% 
FBS medium mix before mixing with the agarose solution. 
2ml of the feeding agar/medium mix was added to each dish and 
bubbles removed. 
The seeded dishes were placed in the fridge (4˚C) on a flat platform for 
about 20 minutes to allow the agar to set and then returned to the 
incubator (37˚C) to finish feeding. 
Cells were fed once a week for about 3-4 weeks until colonies grew into 
suitable sizes for counting. 
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2.8.3.4 Colony staining 
Colonies were stained using prepared 0.04% crystal violet by adding 
0.5ml to each dish and leaving them on the bench for 30 minutes. 
The dishes were rinsed a couple of times with distilled water until the 
background reached a suitable light colour for colony analysis. 
2.8.3.5 Analysis of colonies using ImageJ 
Colonies were observed under a LEICA DM IRB and pictures of the 
whole dish were taken individually using an AxioCam ERc5s camera. 
The number and size of the colonies present were analysed using 
ImageJ software according to the protocol from Paul O’Gorman Lifeline 
Centre shown below (see Table 19 and Figure 12). 
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Table 19: procedures of using ImageJ to analyse colonies 
Step Aim Procedure 
1 Open a selected picture “File” –- “Open” 
2 Convert the image to greyscale “Image” –- “Type” –- “8 bit” 
3 Optimise image quality “Process” --- “Sharpen” 
4 
Calibrate measurement scale 
applied to all images 
Draw a straight line along the length of a scale bar 
(such as 5mm) --- Measure the line using a ruler as 
precise as possible --- “Analyze” --- “Set scale”, enter 
“5000” into “known distance” box and change “unit of 
measurement” box to “microns” – “global”  
5 
Remove the particles 
unwanted to count  
“Drawing tools” --- “Eraser tool” 
6 
Select particles wanted to 
count 
“Image” --- “Adjust” --- “Threshold” 
7 Check measure parameters “Analyze” --- “Set measurements”  
8 Take measurement 
“Analyse” --- “Analyse particles” --- “OK”  
Note: set a minimum particle size to exclude noise (in 
this study, cell colonies with size being 2806µm^2 as 
the diameter of over 60µm is accepted as a colony). 
9 Export data 
The measurements will show up in a chart, and the 
results can be cut and paste into excel for analysing. 
 
Figure 12: A sample of a colony picture processing using ImageJ 
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2.9 Migration Assay 
Cell migration is defined as the movement of cells from one location to another 
individually or collectively (Vedula, Ravasio et al. 2013). It is of great 
importance in regulating various biological processes under either 
physiological conditions, such as cell growth and differentiation, or 
pathological ones, like cancer metastasis (Kramer, Walzl et al. 2013).  
Migration assays measure differences in cell migration rates under different 
treatment conditions in vitro. In this study, a modified wound-healing assay 
was performed using a special sticky insert to create a defined gap across 
which cells migrate (see Figure 13), and it offered an alternative to traditional 
scratch assay with higher reproducibility. Cell migration can be monitored 
both in real time and at the end point. 
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Figure 13: migration assay demonstration 
 
2.9.1 Equipment 
µ-Slide 2 well (Ibidi, Cat #. 80286, Germany) 
Culture-Inserts (Ibidi, Cat #. 80209, Germany) 
Tweezers (Fisher Scientific, Loughborough, UK) 
LEICA DM IRB microscope/ AxioCam ERc5s camera (see 2.8.1) 
ImageJ software (see 2.3.7.1) 
2.9.2 Reagents 
GM/SFM/PBS/CDS/TE (see 2.1.3) 
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2.9.3 Method 
Inserts were placed into the wells of the slides one for each and secured. 
Cells were trypsinized (see 2.1.4.1) and counted (see 2.1.4.2) in GM. 
Cells were centrifuged and resuspended in certain volumes of GM to 
achieve stock cell suspensions of different densities suitable for seeding 
depending on cell type (see Table 7). 
70µl of the stock cell suspension was added to each well of the inserts 
according to the experimental design and the outer area was filled with 
1.5ml of GM for each well of the slides. 
The slides were incubated at 37˚C for about 24 hours to let cells settle 
and reach approximately 70-80% confluency.  
The GM was replaced with fresh SFM (70µl for the inside of the insert 
well and 1.5ml for outside) after washing with PBS gently twice and 
then cells were incubated at 37˚C for another 24 hours till the cells had 
reached  90-95% confluency. Note:  over confluent cells should be 
avoided in case the cell-lawn is (partially) removed together with the 
inserts. 
The inserts were removed carefully and each well of the slides was 
filled with 2ml of fresh SFM for basal cell migration characterisation 
or 2ml of SFM containing chemicals of certain concentrations for 
experiments in which cells were treated.  
Cell migration was monitored under LEICA DM IRB microscope and 
pictures taken at the start point and every following 2 hours using 
AxioCam ERc5s camera focusing on the same area for each gap. 
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Cell migration rate was analysed using ImageJ software by measuring 
the area of the gap in the cell pictures (see   Table 20 and Figure 14).   
  Table 20: procedure of using ImageJ to measure cell migration rate 
Step Aim Procedure 
1 Open a selected picture “File” –- “Open” 
2 Select the area to measure “Freehand selections” 
3 Check measure parameters “Analyze” --- “Set measurements” 
4 Take measurements “Analyze” --- “Measure” 
5 Export data 
The measurements will show up in a chart, and 
the results can be cut and paste into excel for 
analysing. 
 
Figure 14: a sample of measurement of cell migration gap area using ImageJ 
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2.10  Invasion Assay 
Compared with cell migration, invasion refers to cell invasive migration into 
neighbouring tissues involving degradation and proteolysis of extracellular 
matrix (ECM) (Kramer, Walzl et al. 2013). It is a fundamental function 
underlying many cellular processes such as cancer cell invasion.  
Invasion assays monitor differences in cell movement through the 
extracellular matrix (ECM) under various treatment conditions in vitro. In this 
study, a model of trans-well migration assay with the collagen-coated porous 
membrane was used (see Figure 15). SFM was used for cell pre-starvation as 
well as preparation of cell suspensions seeded in the inserts, and GM 
supplemented with 10% FBS was placed in the lower chamber in the plate. The 
difference in the presence of cytokines and growth factors in the two 
compartments established a chemoattractant gradient which gave cells an 
incentive to invade the membrane. Cell invasion can only be examined at the 
end point. 
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Figure 15: invasion assay demonstration 
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2.10.1 Equipment 
24-well plate (Greiner Bio-one, Cat #. 662160, Gloucester, UK) 
Millicell Cell Culture Insert (Merck Millipore, Cat #. PI8P01250, 
Hertfordshire, UK) 
Tweezers (see 2.9.1) 
Scalpel blade (Swann Morton, Cat #. 7471312, Sheffield, UK) 
Leica DMI 6000B microscope (see 2.5.1) 
ImageJ software (see 2.3.7.1) 
2.10.2 Reagents 
Purified Bovine Collagen Solution (Advanced BioMatrix, Cat #. 5005, 
USA) 
GM/SFM/PBS/CDS/TE (see 2.1.3) 
Triton X-100 (see 2.3.2.2) 
Glycine/PFA/BSA/DAPI/Nail varnish (see 2.5.2) 
2.10.3 Method 
2.10.3.1 Coating cell culture inserts with collagen 
One insert was placed in each well of a 24-well plate in the cell culture 
hood. 
The purified bovine collagen solution was diluted with sterile dH2O and 
mixed gently to make a working solution of 10µg/ml. 
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200µl of working collagen solution was added to the surface of the 
insert membrane ensuring that the entire surface was covered. 
The plates containing coated inserts were left in the hood to stand 
overnight at room temperature until the surface was dry. 
The coated surface was rinsed with PBS carefully to avoid scratching 
the surface. 
Coated inserts can also be stored in the fridge (4˚C) for a short period 
of time as long as sterility is maintained. 
2.10.3.2 Cell preparation 
GM was replaced with fresh SFM to serum starve cells for about 15 
hours. 
2.10.3.3 Cell seeding 
500µl of GM were added per well of the 24-well plates. 
Cells were trypsinized (see 2.1.4.1) and counted (see 2.1.4.2) in SFM. 
Cells were centrifuged and resuspended in specific volumes of SFM to 
achieve stock cell suspensions of different densities suitable for seeding 
depending on the cell type (see Table 7). 
Stock cell suspensions were divided into several parts with treatments 
added to certain ones with appropriate final concentrations according 
to each experimental design. 
500µl of stock cell suspensions were added to each insert carefully to 
avoid scratching the coated insert membranes. 
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The inserts were then transferred into wells of the 24-well plates with 
pre-filled GM, one for each well, carefully without causing bubbles 
under the inserts. 
The cells were incubated at 37˚C for 18-24 hours depending on the cell 
type to allow for invasive migration through the collagen-coated 
membrane. 
2.10.3.4 Cell staining with DAPI 
Solutions used in this section were all applied to both compartments of the 
assay model. 
Media was removed from both compartments and replaced with 500µl 
of PBS to wash both sides of the membrane. 
 The PBS was replaced with 300µl of PFA to fix cells and the plates were 
left covered to stand for 15 minutes at room temperature. 
The PFA was removed and a PBS was performed. 
The PBS was removed and 300µl of 30mM glycine was added for 5 
minutes to quench the cells. 
This was replaced with PBS to wash the cells again. 
The cells were permeabilised by adding 300µl of 0.3% PBS-Triton 
solution and were left to stand for 20 minutes. 
Cells were washed twice by replacing with 500µl of 0.05% PBS-Triton 
solution. 
Any non-migrated cells were removed gently using a cotton bud. 
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The membrane was carefully cut out using a scalpel blade and placed 
on a cover slide with the migrated cells side up. 
dH2O was added dropwise gently by the side of the membrane and 
dried with tissue to wash away remaining floating cells. 
In the darkness, the membrane was mounted in DAPI on the coverslip 
and then it was applied to a slide and sealed with nail varnish to avoid 
movement. 
Membranes were then imaged using a Leica DMI 6000B microscope in 
10 random fields with at least two of the views away from the 
membrane edge to avoid counting non-migrated/unremoved cells. 
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2.10.3.5 Analysis of invaded cells using ImageJ 
Cell invasion was analysed by measuring the number of invaded cells under 
different treatments using ImageJ (see Table 21 and Figure 16). 
Table 21: procedure of using ImageJ to measure invaded cell numbers 
Step Aim Procedure 
1 Open a selected picture “File” –- “Open” 
2 Convert the image to greyscale “Image” –- “Type” –- “8 bit” 
3 Remove background noise “Process” --- “Subtract Background” 
4 Select cells wanted to count “Image” --- “Adjust” --- “Threshold” 
5 
Distinguish each cell from a 
cell cluster 
“Process” --- “Binary” --- “Convert to Mask” --- 
“Binary” ---“Watershed” 
6 Check measure parameters “Analyse” --- “Set measurements” 
7 Take measurement 
“Analyse” --- “Analyse particles” --- “OK”  
Note: set a minimum particle size to exclude noise, 
and tick “Exclude on edges” to remove cells on edge  
8 Export data 
The measurements will show up in a chart, and the 
results can be cut and paste into excel for analysing. 
 
Figure 16: a sample of an invasion assay picture processing using ImageJ 
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2.11 Statistical Analysis 
Unless otherwise stated, statistical analyses of all graphic results were 
performed by SPSS 23 statistical software (IBM, USA), and all data were from 
at least three independent experiments (n=3). 
Data were analysed and expressed as mean ± standard error (SE). The 
significance of the difference between groups was evaluated by analysis of 
variance (ANOVA) followed by least significant different (LSD) post-hoc test 
and Student’s t-test. 
For all tests, a two-sided p-value was shown for statistical significance and was 
depicted in asterisks as a single one for *p<0.05 and a double for **p<0.01. 
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3.1 Introduction 
With accumulating evidence indicating a relationship between IGF-activity 
and EMT in bladder cancer, as well as based on the work about IGFBP-2 has 
been done on other tumours in our laboratory, this study was conducted to 
investigate the association of IGFBP-2, the second most abundant IGFBP in 
human serum, with bladder cancer development. 
3.1.1 IGFBP-2 in cancer 
The role that IGFBP-2 plays in cancer progression remains unclear.  
Enhanced expression of IGFBP-2 is commonly observed in tumours with high 
grade, and it is thought to act as an oncogene to promote cancer development 
and progression. This has been observed in many cancers such as breast 
(Perks, Vernon et al. 2007, Mireuta, Darnel et al. 2010, Foulstone, Zeng et al. 
2013), prostate (Degraff, Aguiar et al. 2009, Uzoh, Holly et al. 2011), and 
glioma (Fukushima and Kataoka 2007, Moore, Holmes et al. 2009). 
However, contradictory results have also been reported in a number of studies, 
both in vitro and in vivo, even within the same cancer type: certain aggressive 
cancer types have little or no expression of IGFBP-2, that suggests IGFBP-2 
may also act in a tumour suppressive way (Pickard and McCance 2015). For 
example, high levels of IGFBP-2 are found in rapidly growing non-invasive 
brain tumours, whereas low/undetectable levels are observed in malignant 
invasive tumours (Shelton, Mukherjee et al. 2010). 
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3.1.2 EMT in cancer 
As mentioned in section 1.3, by allowing cells to alter from an adherent 
epithelial-like into a highly motile mesenchymal-like phenotype, oncogenic 
EMT is considered to play an essential part in cancer growth and progression. 
There are a number of well-established epithelial and mesenchymal markers, 
including surface proteins (such as E-cadherin and N-cadherin), cytoskeletal 
markers (such as β-catenin), changes in which have been widely used to 
determine the occurrence of EMT (Zeisberg and Neilson 2009). Common 
changes in these markers include a reduction in E-cadherin (an epithelial 
marker mediating intercellular adhesion) (McConkey, Choi et al. 2009), the 
acquisition of N-cadherin (a mesenchymal marker providing a mechanism for 
cell transendothelial migration) (Ramis-Conde, Chaplain et al. 2009), and 
translocation of β-catenin (which interacts with E-cadherin in cellular 
adhesions) from the cell membrane in normal epithelial cells and non-invasive 
tumour cells into the nucleus of cells undergoing EMT, where it 
transcriptionally activates Wnt target genes (Bienz 2005, Zeisberg and Neilson 
2009). 
Cells undergoing EMT exhibit a series of changes in phenotype referring to the 
loss of epithelial features and gain of mesenchymal characteristics, such as an 
increase in cell proliferation, enhanced migration and invasion, and an 
increase in colony formation in terms of the quantity and the average size (Son 
and Moon 2010, Thiery and Lim 2013, Wu, Sarkissyan et al. 2016). 
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3.1.3 Cisplatin 
Cisplatin is a member of a class of platinum-containing anticancer drugs 
triggering cell death by impeding DNA replication and transcription (Siddik 
2003, Massari, Santoni et al. 2015, Michel, Vordos et al. 2018). Administered 
intravenously, it has been commonly used for the treatment of many types of 
malignancies including bladder cancer. Neoadjuvant platinum-based 
combination chemotherapy applied before radical cystectomy has been 
reported to shrink the tumour size which leads to a significant improvement 
in patients’ overall survival at 5 yr after radical cystectomy (Sherif, Holmberg 
et al. 2004, International Collaboration of Trialists, Medical Research Council 
Advanced Bladder Cancer Working Party et al. 2011), and it is the established 
gold standard in the treatment of MIBC. Within the frontline chemotherapies 
for bladder cancer, cisplatin-based combination treatments represent the 
standard first-line therapy for patients suffering metastatic bladder cancer 
showing a relatively high response rate being approximately 50-70% (von der 
Maase, Sengelov et al. 2005). 
However, cancer recurrence with very poor prognoses due to the development 
of drug resistance after first-line chemotherapy has become an emerging issue 
(Yafi, North et al. 2011), and no consensus in the management of cisplatin-
resistant bladder cancer has been reached yet (Massari, Santoni et al. 2015). 
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3.2 Aims 
In this study, I aimed to assess the basal levels of IGFBP-2 in bladder cancer 
cell lines and its relationship with cancer phenotype as well as sensitivity to 
cisplatin. 
To achieve the aims above, I set the following goals: 
To determine the basal levels IGFBP-2 in bladder cancer cell lines. 
To manipulate the levels of IGFBP-2: 
o To decrease the expression of IGFBP-2 through gene silencing 
using siRNA. 
o To increase the abundance of IGFBP-2 by adding exogenous 
recombinant IGFBP-2. 
To assess relative changes in EMT markers, including abundance and 
localisation, and cancer phenotype (proliferation, migration, invasion 
as well as colony formation) in bladder cancer cells. 
To assess the sensitivity of bladder cancer cells to cisplatin in the 
presence or absence of IGFBP-2. 
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3.3 Materials and methods 
3.3.1 Cell culture 
Four human urinary bladder cancer cell lines including RT4, UMUC3, T24 and 
TCCSUP were used in this study. They were obtained and cultured as described 
in section 2.1. 
3.3.2 Characterisation and optimisation of the antibodies for 
the assessment of EMT markers  
Changes in the levels of E- and N-cadherin, as well as localisation of β-catenin, 
were used as markers of EMT in this study for the investigation relating to the 
levels of IGFBP-2. Since the antibodies for the three molecules were new to our 
laboratory, characterisation and optimisation using either Western blotting 
(WB, as described in section 2.3) or immunofluorescence (IF, as described in 
section 2.5) were carried out in RT4 and T24 cell lines by changing the solvent 
and/or the concentration of the antibody solutions, respectively. GAPDH and 
tubulin were used as loading controls in WB analyses.  
Product details and the conditions optimised for the EMT markers used in this 
study are summarised in Table 22, and the known information of antibody 
solutions of IGFBP-2 and the reference proteins (GAPDH and tubulin) used as 
a loading control is shown below in Table 23. 
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*2˚ Ab: anti-goat (Sigma, #A5420); anti-mouse (Sigma, #A0944). 
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3.3.3 Detection of protein abundance 
Protein levels of E- and N-cadherin in whole cell lysates and the levels of 
IGFBP-2 both in whole cell lysates and in the supernatant were determined by 
performing WB analyses as described in section 2.3. Tubulin was used as a 
loading control. The information of antibody solutions is summarised in Table 
22 and Table 23. 
 
3.3.4 Detection of protein localisation 
Cellular fractionation and IF were performed to look into the localisation of β-
catenin as described in section 2.4 and 2.5, respectively. 
Proteins of cytoplasmic and nuclear extracts from cultured cells were 
separated using cellular fractionation technique. Lamin and tubulin exist only 
in nuclei and cytoplasm, respectively, and they were therefore used as 
indicators of the efficiency of protein separation. The abundance of separated 
proteins was detected by WB as described above in 3.3.3. The information of 
antibody solutions of Lamin is listed below in Table 24, and the information of 
β-catenin and tubulin can be found in Table 22 and Table 23, respectively. 





& Cat. No. 
Blocking 1˚ Ab *2˚ Ab 
Lamin A/C 70 









*2˚ Ab: anti-rabbit (Sigma, #A0545). 
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3.3.5 Transfection with IGFBP-2 siRNA 
IGFBP-2 siRNA transfection was used to decrease IGFBP-2 expression by 
silencing the corresponding gene, and the technique was performed as 
described in section 2.6.  
3.3.6 Cell treatment 
3.3.6.1 Recombinant human IGFBP-2 protein 
The recombinant human IGFBP-2 protein (GroPep, #BP2BU020) is 
biotechnologically generated in E.coli with the recombinant human IGFBP-2 
gene. With correct amino acid sequence but non-glycosylated, it was used as 
an exogenous reagent in IGFBP-2 manipulation experiments.  
Lyophilized human IGFBP-2 was reconstituted at 500µg/ml by re-suspending 
20µg in 40µl sterile PBS and then aliquoted and stored at -20°C. 5000ng/ml 
working stock of IGFBP-2 was prepared fresh by extracting 15µl of 500µg/ml 
stock and adding to 1485µl of serum-free media (SFM: as described in section 
2.1.3.2). Different final concentrations of IGFBP-2 were achieved by diluting 
the working stock further with SFM. 
3.3.6.2 Cisplatin 
Cisplatin (Merck Chemicals Ltd, #232120) was prepared fresh for each 
experiment by dissolving 2mg in 4ml of 0.9% saline solution (made by adding 
45mg of NaCl to 5ml of dH2O) to reach a 500µg/ml working stock solution. The 
stock solution was then sterilised with 0.2µm filters. Different final 
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concentrations of cisplatin were accomplished by diluting the working stock 
further with SFM. Exposure of cisplatin to light was avoided during the entire 
process. 
3.3.7 Cell proliferation 
Tritiated thymidine incorporation (TTI) assay was used to assess DNA 
synthesis, and Trypan Blue Exclusion assay was performed for cell counting to 
determine cell survival as described in section 2.2. 
3.3.8 Cell migration 
Cell migration assay was performed as described in section 2.9 to measure 
differences in cell migration rates in response to different treatments. 
3.3.9 Cell invasion 
To investigate the differences in cell movement through the extracellular 
matrix (ECM) under different treatments in vitro, a cell invasion assay was 
used as described in section 2.10. 
3.3.10 Cell colony formation 
A soft agar colony formation assay was used as described in section 2.8 to 
measure cell malignant transformation activity under various treatments.  
For cells treated with siRNA, the first 24 hours of transfection were performed 
in universal tubes instead of 6-well plates to avoid the cells settling down: cells 
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were collected, resuspended and counted before being seeded in the soft agar 
plates with equivalent numbers of live cells.  
3.3.11 Statistical analysis 
Data were expressed as mean ± SEM and analysed with SPSS 23 for Windows 
using one-way analysis of variance (ANOVA) followed by least significant 
difference (LSD) post-hoc test and Student’s test. A two-sided p-value was 
shown for statistical significance and was depicted in asterisks as a single one 
for *p<0.05 and a double for **p<0.01. 
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3.4 Results 
3.4.1 Characterisation of EMT molecules: E-, N-cadherin and β-
catenin 
From the WB results we found that RT4 cells express abundant E-cadherin and 
undetectable amounts of N-cadherin; while T24 cells show the opposite having 
undetectable E-cadherin but abundant N-cadherin (see Figure 17-A & B). β-
catenin was found in both RT4 and T24 cells with more present in RT4 cells 
(Figure 17-C). And based on the results above, 60µg was used as an 
appropriate amount to load for each of these proteins in the following 
experiments unless otherwise noted.  
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Figure 17: characterisation of the levels of E-, N-cadherin and β-catenin in RT4 
and T24 cells 
Figures (A), (B) and (C) show the western blots for E-, N-cadherin and β-catenin, respectively, 
in both RT4 and T24 cells detected using WB. RT4 and T24 cells were seeded in GM at the 
same density to grow for 24 hours and then were left in SFM for 48 hours before sample 
harvest. Proteins in whole lysates were loaded with increasing amounts from 25 to 100μg. 
Proteins from MCF7 (a human breast adenocarcinoma cell line) and U251 (a human 
glioblastoma cell line) cell lysates were used as positive controls for E-cadherin & β-catenin 
and N-cadherin, respectively. They were loaded equally at 50μg. GAPDH was used as a 
reference protein. 
 
Basal localisation of β-catenin in RT4 and T24 cells was detected by cellular 
fractionation and IF. 
From the cellular fractionation data shown in Figure 18, β-catenin was located 
only in the cytoplasm of RT4 cells with no trace in the nuclear extracts (Figure 
18-A).  It was found in both the nuclear and cytoplasmic extracts of T24 cells: 
with the most abundant levels observed in the cytoplasm (Figure 18-B). And 
the IF results presented in Figure 18-C confirmed that in RT4 cells, β-catenin 
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was mainly localised on the cell membrane with a small amount in the 
cytoplasm, while in T24 cells it was also found on the cell membrane but to a 
greater level in the cytoplasm compared with RT4 cells with some also 
observed in the nucleus.  
 
Figure 18: localisation of β-catenin in RT4 and T24 cells 
(A) & (B): The WB blots show the characterisation of basal localisation of β-catenin in RT4 and 
T24 cells, respectively, using cellular fractionation. Both RT4 and T24 cells were seeded in GM 
at the same density to grow for 24 hours followed by serum starvation using SFM for another 
24 hours, and then cells were trypsinized and harvested for performing cellular fractionation 
to separate proteins of cytoplasmic and nuclear extracts. Isolated proteins extracted from the 
total cell lysates were loaded equally for protein detection using WB. Lamin and Tubulin exist 
only in nuclei and cytoplasm, respectively, and they are indicators of the efficiency of protein 
separation. “T”: total cell lysates; “C”: cytoplasmic extract; “N”: nuclear extract; “X”: blank lane. 
Proteins of MCF7 (a human breast adenocarcinoma cell line) were used as a positive control 
for β-catenin. And the blots demonstrate the typical results from three experiments each 
performed at least in triplicate (n=3). 
 (C): Images show the characterisation of basal localisation of β-catenin in both RT4 and T24 
cells using IF. Both RT4 and T24 cells were seeded in GM at the same density to grow for 24 
hours and then were left in SFM for 48 hours before stained. Images show β-catenin (in green) 
with counterstaining for DAPI (nuclei in blue) and overlaid version labelled as “Merged”. All 
images demonstrate the typical results from three experiments each performed in duplicate 
(n=3). All images shown are at x10 magnification. 
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3.4.2 Characterisation of basal levels of IGFBP-2 
Initially, four human urinary bladder cancer cell lines were used to investigate 
the basal levels of IGFBP-2 by performing WB analyses (see Figure 19). 
As shown in Figure 19, RT4 was the most epithelial-like phenotype cell line 
showing high levels of E-cadherin and no N-cadherin, and it was also shown to 
have the highest levels of IGFBP-2. T24 was the most mesenchymal-like 
phenotype demonstrating the highest levels of N-cadherin with undetectable 
levels of E-cadherin: we observed that this cell line had undetectable levels of 
IGFBP-2. Similarly, TCCSUP another mesenchymal cell line with low levels of 
N-cadherin and no E-cadherin also had very low levels of IGFBP-2. UMUC3 had 
low levels of IGFBP-2 with no E- or N-cadherin expression. 
 
Figure 19: basal levels of IGFBP-2 and EMT markers in bladder cancer cell lines 
Cells were seeded in GM at the same density and then were left in SFM for 48 hours before 
sample harvest. Proteins in whole lysates were loaded equally at 60µg and tubulin was 
assessed as the reference protein. IGFBP-2 in the supernatant was loaded equally at 25µl. 
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The levels of IGFBP-2 were reduced as the cells progressed to a more 
mesenchymal phenotype. To investigate a potential role for IGFBP-2, RT4 and 
T24 were selected as the two predominant cell lines exhibiting an epithelial-
like and a mesenchymal-like phenotype, respectively. The less mesenchymal 
TCCSUP cell line was also investigated in the late stage of the study to 
complement the data observed in the T24 cell line. Showing only low levels of 
IGFBP-2 with no E- or N-cadherin expression, UMUC3 was, therefore not 
studied further. 
As shown in Figure 20, these three cell lines all grew in discrete patches 
attaching to the substrate of the culture vessels. Compared with RT4 cells 
which proliferated slowly in clusters maintaining more epithelial 
characteristics, T24 and TCCSUP cells were faster growing in a less “organised” 
manner and presented with mesenchymal features such as diminution of the 
cell-to-cell adhesion with elongated structure. 
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Figure 20: cell images of RT4, T24 and TCCSUP cells 24 hours-post-seeding  
Cells were seeded in T75 flasks at a certain density (0.5x106 cells for RT4 and 0.2x106 cells for 
both T24 and TCCSUP) in 10ml of GM. Images were taken at the 24th hour after seeding. Images 
shown are at x10 and x20 magnification, respectively. 
 
3.4.3 Using siRNA to silence IGFBP-2 
As shown above in Figure 19, RT4 cells presented the strongest epithelial 
phenotypic characteristics along with abundant IGFBP-2 expression; therefore, 
specific siRNA for IGFBP-2 silencing was used in this cell line to examine the 
link between IGFBP-2 and cancer phenotype regarding cell growth, invasion, 
migration and colony formation. Changes in EMT markers were also 
investigated. 
3.4.3.1 Optimisation of an effective dose of siRNA 
Efficacy of IGFBP-2 siRNA for silencing IGFBP-2 was tested as described in 
section 2.6.3 by using different siRNA concentrations from 5nM to 30nM 
shown in Figure 21. WB analysis was performed after 72 hours of transfection 
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as this corresponded to the experimental set up for the phenotypic models. 
Using increasing concentrations of siRNA,  30nM was determined to be the 
most effective (about 70% silencing, p<0.001). 
 
Figure 21: WB analysis of IGFBP-2 protein in cell culture supernatant of RT4 
cells 
Cells were seeded at the same density in GM, and the supernatant was harvest at 72 hours 
after transfection with IGFBP-2 siRNA at concentrations of 5nM, 10nM, 20nM, and 30nM, 
respectively. “NS”: cells treated with non-silencing scrambled siRNA as control; “KD”: cells 
treated with IGFBP-2 siRNA for silencing IGFBP-2. All supernatants under different treatments 
were loaded equally at 25µl. 
(A): The blot presents levels of IGFBP-2 in cell culture supernatant under different treatments. 
(B): Graph shows the mean of the optical density measurements of IGFBP-2 from three 
experiments each performed at least in triplicate and error bars represent the standard error 
of the mean of experiments. 
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3.4.3.2 Effect of silencing IGFBP-2 on the growth of RT4 cells 
Cell counting was performed to determine the effect of IGFBP-2 silencing on 
cell growth in RT4 cells. As shown in Figure 22, with efficient gene knockdown 
of IGFBP-2 (Figure 22-A), compared with cells treated with scrambled non-
silencing siRNA, the growth of the cells with IGFBP-2 knocked down by IGFBP-
2 siRNA showed an increase in both total cell number by 27.2% (p<0.001) and 
live cell number by 21.6% (p<0.01) (Figure 22-B), and no significant change in 
the level of cell death observed between the two groups (Figure 22-C). 
 
Figure 22: effect of silencing IGFBP-2 on the growth of RT4 cells 
Cells were initially seeded into 6-well plates at a density of 0.1x106 cells/well in GM. “NS”: cells 
treated with non-silencing scrambled siRNA as control; “KD”: cells treated with IGFBP-2 siRNA 
for IGFBP-2 knocking down (both at a concentration of 30nM for 72 hours).  
 (A): WB blot shows the efficiency of IGFBP-2 knockdown achieved. Proteins were harvested 
from whole cell lysates and loaded equally at 50µg. Tubulin was assessed as reference protein. 
(B): Graph shows cell counting of live and total cell numbers of RT4 cells treated with different 
siRNA both at 30nM for 72 hours. (C): Graph presents the percentage cell death under the 
different treatments described above. Graphs in (B) and (C) represent the mean of three 
experiments each performed at least in triplicate, and error bars represent the standard error 
of the mean of the experiments. “NS*”: not significant. 
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3.4.3.3 Effect of silencing IGFBP-2 on cell invasion in RT4 cells 
An invasion assay was conducted (as described in section 2.10) following 72 
hours of siRNA transfection (as described in section 2.6) to examine the effect 
of silencing IGFBP-2 on cell invasion in RT4 cells. According to the results 
shown in Figure 23, with efficient IGFBP-2 silencing achieved (Figure 23-A), 
IGFBP-2 siRNA transfected RT4 cells invaded more (Figure 23-B) compared 
with cells treated with scrambled siRNA with a significant 68% increase in the 
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Figure 23: effect of silencing IGFBP-2 on cell invasion in RT4 cells 
Cells transfected with either scrambled or IGFBP-2 siRNA (“NS” for non-silencing scrambled 
siRNA as control and “KD” for IGFBP-2 siRNA) at a concentration of 30nM for 72 hours were 
trypsinized and then seeded in the collagen-coated inserts at a density of 0.1x106 cells/insert 
and allowed to invade for 24 hours. The supernatant was taken before cell trypsinization to 
assess levels of IGFBP-2 to determine the efficiency of IGFBP-2 silencing.  
(A): The blot shows the efficiency of IGFBP-2 knockdown achieved by loading the supernatant 
collected under each treatment equally at 25µl; (B): The image shows transwell migrated cells 
with nuclei (in blue) stained by DAPI; all images shown are at x10 magnification; (C): the graph 
shows the fold change of invaded cells between RT4 cells transfected with different siRNA. 
The graph represents the mean of three experiments each performed in triplicate +/- the 
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3.4.3.4 Effect of silencing IGFBP-2 on cell migration of RT4 cells 
By performing a migration assay as described in section 2.9, we observed that 
RT4 cells did not migrate with or without IGFBP-2 (see Figure 24 & Figure 25). 
 
Figure 24: characterisation of cell migration of RT4 cells 
Cells were seeded at a density of 0.049x106 cells into each chamber in GM and allowed to grow 
for approximately 24 hours to reach about 80% confluence. Cells were allowed to reach 90-
95% confluence during another 24 hours of serum starvation in SFM. Cell migration was 
investigated for up to 24 hours after the inserts were removed. “0hr”: the start point after the 
removal of inserts; “24hrs”: 24 hours after the removal of inserts. All images demonstrate the 
typical results from three experiments each performed in duplicate (n=3). All images shown 
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Figure 25: effect of silencing IGFBP-2 on cell migration in RT4 cells 
Untreated control RT4 cells (“CT”) and cells transfected with either scrambled or IGFBP-2 
siRNA (“NS” for non-silencing scrambled siRNA and “KD” for IGFBP-2 siRNA) at 30nM were 
seeded at a density of 0.049x106 cells into each chamber. Cells were allowed to grow for 
approximately 24 hours in GM to reach about 80% confluence and then were allowed to reach 
90-95% confluence during another 24 hours of serum starvation in SFM. Then cell migration 
was investigated for up to 48 hours after the inserts were removed. The supernatant was taken 
at 24 hours after the removal of the inserts for determining the efficiency of IGFBP-2 silencing.  
 (A): The blot shows the efficiency of IGFBP-2 knockdown achieved by detecting IGFBP-2 in 
samples loaded equally at 25µl; (B): images show cell patches after the removal of inserts. 
“0hr”: the start point after the removal of inserts; “18hrs”: 18 hours after the removal of inserts; 
“48hrs”: 48 hours after the removal of inserts. All images demonstrate the typical results from 
three experiments each performed in duplicate (n=3). All images shown are at x10 
magnification. 
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3.4.3.5 Effect of silencing IGFBP-2 on cell colony formation in RT4 cells 
After transfection with either scrambled or IGFBP-2 siRNA as described in 
section 2.6 , the ability of malignant transformation of RT4 cells was 
investigated by using a soft agar colony formation assay as described in section 
2.8. 
As shown below in Figure 26, with efficient IGFBP-2 silencing achieved (Figure 
26-A), compared with cells treated with scrambled siRNA, the IGFBP-2 siRNA 
treated RT4 cells formed more colonies (Figure 26-B), and with a significant 
15% increase in colony forming efficiency (CFE) (p<0.01) (Figure 26-C, left). 
In addition, IGFBP-2 silenced RT4 cells also formed bigger colonies with a fold 
change of 1.38 regarding the average size of each colony (p<0.01) (Figure 26-
C, right). 
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Figure 26: effect of silencing IGFBP-2 on cell colony formation in RT4 cells 
Cells transfected with either scrambled or IGFBP-2 siRNA (“NS” for non-silencing scrambled 
siRNA as control and “KD” for IGFBP-2 siRNA) at a concentration of 30nM for 72 hours were 
trypsinized and then seeded in the dishes with an even density at 10,000cell/dish. After being 
fed once a week for 3 weeks in total, the numbers as well as the average size of the colonies 
were counted and calculated by ImageJ. The supernatant was taken before trypsinization for 
determining the efficiency of IGFBP-2 silencing.  
(A): The blot shows the efficiency of IGFBP-2 knockdown achieved by detecting IGFBP-2 in 
samples loaded equally at 25µl; (B): images show cells were set up into dishes with even 
densities at the first day (“Day 1”), and colonies were stained at the end of the assay (“Day 21”); 
All images shown are at x10 magnification; (C): graphs present the difference in colony count 
(left) and fold change of the colony average size (right) normalised to the control. The graphs 
show the mean of three experiments each performed in triplicate, and error bars represent 
the standard error of the mean from three experiments (n=3). 
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3.4.3.6 Effect of silencing IGFBP-2 on EMT markers in RT4 cells 
As shown in Figure 19, compared with mesenchymal-like T24 cells, epithelial-
like RT4 cells express more abundant E-cadherin and β-catenin with 
undetectable N-cadherin, so WB analysis was performed to examine the 
change of these molecules regarding abundance following cell treatment with 
siRNA to silence IGFBP-2.  Translocalisation of β-catenin from the membrane 
into the nucleus is considered an important indicator of cancer progression, so 
cellular fractionation and IF were conducted to examine the change in its 
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3.4.3.6.1 Detection of changes in abundance of E-, N-cadherin and β-
catenin 
As shown in Figure 27, compared with control samples treated with scrambled 
siRNA, IGFBP-2 siRNA transfected RT4 cells demonstrated a significant 48% 
reduction in the abundance of E-cadherin (p<0.05) (Figure 27-A & B). No 
detectable induction of N-cadherin was observed (Figure 27-B), and no visible 
change in the abundance of β-catenin was noted (Figure 27-C & D). 
 
Figure 27: levels of EMT markers in RT4 cells with IGFBP-2 siRNA treatment 
RT4 cells transfected with either scrambled or IGFBP-2 siRNA (“NS” for non-silencing 
scrambled siRNA as control and “KD” for IGFBP-2 siRNA) at the concentration of 30nM for 72 
hours were trypsinized and harvested for the investigation of change of protein abundance 
using WB analysis. Samples from whole lysates were loaded equally at 60µg for protein 
detection, and tubulin was assessed as a reference protein in WB analysis. All blots 
demonstrate the typical results from three experiments each performed at least in triplicate 
(n=3). 
The blots show levels of E- and N-cadherin (A) and β-catenin (C) under treatment of different 
siRNA. And the graphs (B) and (D) demonstrate the mean of the optical density of E-cadherin 
and β-catenin, respectively, from three experiments each performed at least in triplicate, and 
error bars represent the standard error of the mean of experiments (n=3). “NS*”: not 
significant. 
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3.4.3.6.2 Detection of the change of localisation of β-catenin 
With efficient IGFBP-2 gene knockdown achieved in RT4 cells (Figure 28-A), 
no translocation of β-catenin into the nuclei was observed in the blots (Figure 
28-B) and this was confirmed by densitometry analysis which showed no 
significant difference between treated and untreated samples in the fold 
change of cytoplasmic β-catenin normalised to the β-catenin in total cell 
lysates (Figure 28-C). 
 
Figure 28: effects of silencing IGFBP-2 on the translocation of β-catenin in RT4 
cells using cellular fractionation 
RT4 cells were transfected with either scrambled or IGFBP-2 siRNA (“NS” for non-silencing 
scrambled siRNA as control and “KD” for IGFBP-2 siRNA) at the concentration of 30nM for 72 
hours to look into the change in the localisation of β-catenin using cellular fractionation. 
Separate proteins were obtained as mentioned above and loaded equally for protein detection 
using WB. IGFBP-2 proteins from whole lysates were assessed for the efficiency of IGFBP-2 
knocking down. All blots demonstrate the typical results from three experiments each 
performed at least in triplicate (n=3). 
(A): The blot shows the achievement of efficient IGFBP-2 silencing. (B): The blot show 
localisation of β-catenin in the presence or absence of siRNA to IGFBP-2 in RT4 cells using 
cellular fractionation. Lamin and Tubulin exist only in nuclei and cytoplasm, respectively, and 
they are an indicator of the efficiency of protein separation. “T”: total cell lysates; “C”: 
cytoplasmic extract; “N”: nuclear extract. (C): The graph presents the fold change of 
cytoplasmic β-catenin normalised to total β-catenin in the total cell lysates with error bars 
representing the standard error of the mean of experiments (n=3). “NS*”: not significant. 
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To complement cellular fractionation, IF was also performed to examine any 
nuclear translocation in RT4 cells with IGFBP-2 siRNA transfection. With 
efficient gene knockdown of IGFBP-2 (Figure 29-A), an obvious 
translocalization of β-catenin from the cytoplasm into the nuclei was observed 
with RT4 cells as shown in Figure 29-B. 
 
Figure 29: effects of silencing IGFBP-2 on the translocation of β-catenin in RT4 
cells using IF 
RT4 cells were transfected with either scrambled or IGFBP-2 siRNA (“NS” for non-silencing 
scrambled siRNA as control and “KD” for IGFBP-2 siRNA) at the concentration of 30nM for 72 
hours to assess changes in the localisation of β-catenin using IF. The supernatant was collected 
before samples were washed with PBS to examine the efficiency of IGFBP-2 silencing by using 
WB analysis. All images and the blot demonstrate the typical results from three experiments 
each performed in duplicate (n=3). 
(A): The blot shows the achievement of efficient IGFBP-2 silencing.  (B) Images demonstrate 
the detection of translocation of β-catenin in RT4 cells using IF. Images show β-catenin (in 
green) with counterstaining for DAPI (nuclei in blue) and overlaid version labelled as 
“Merged”. All images shown are at x10 magnification.  
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3.4.4 Exogenous IGFBP-2 treatment 
With undetectable levels of IGFBP-2, T24 cells were used as the predominant 
cell line to investigate the relationship between IGFBP-2 and bladder cancer of 
a mesenchymal phenotype by treating cells with exogenous recombinant 
human IGFBP-2. Alterations in cell proliferation, invasion, migration, colony 
formation, as well as EMT-related molecules compared with untreated cells 
were assessed.  
Another mesenchymal bladder cancer cell line, TCCSUP, was also used in the 
study with similar exogenous IGFBP-2 treatment, and the results of cells 
phenotypic changes were presented along with those of the T24 cells. 
3.4.4.1 Optimisation of effective dose of exogenous IGFBP-2 
TTI assay was used in T24 and TCCSUP cells to assess cell proliferation 
following the exogenous addition of IGFBP-2 (0-600ng/ml) for 24 hours. 
As shown in Figure 30, both cell lines showed a decrease in cell proliferation 
with increasing concentrations of IGFBP-2: the maximal decreases were found 
to be at 600ng/ml (by 57% in T24 cells, p<0.01; by 59% in TCCSUP cells, 
p<0.01). Therefore, this dose was chosen as an effective concentration for 
further experiments. 
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Figure 30: proliferative response to exogenous IGFBP-2 in T24 and TCCSUP 
bladder cancer cells 
Both cells were seeded at a density of 0.02x106 cells/well into 24-well plates in GM to grow 
for 24 hours followed by serum starvation for another 24 hours. Then TTI was performed to 
show the proliferative response to exogenous IGFBP-2 in T24 (A) and TCCSUP (B) cells at 0-
600 ng/ml for 24 hours. The graphs represent the mean of three experiments each performed 
in quadruplicate, and error bars represent the standard error of the mean of the experiments 
(n=3). “*”: p<0.05; “**”: p<0.01. The bars in the darker colour represent the chosen effective 
concentrations for further experiments. 
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3.4.4.2 Effect of adding exogenous IGFBP-2 on cell growth in T24 and 
TCCSUP cells 
Based on the effective dose of IGFBP-2 determined in 3.4.4.1, exogenous 
IGFBP-2 treatment experiments were conducted in both T24 and TCCSUP cells 
at the concentration of 600ng/ml for 48 hours, and cell growth was assessed 
by performing cell counting. 
Significant decreases in both total and live cell numbers were observed in both 
cell lines. As to T24 cells, compared with the control group, cells treated with 
IGFBP-2 showed a 25.8% decrease in total cell number (p<0.001) and a 25.9% 
reduction in live cell number (p<0.001) (Figure 31-A). Similarly, a 20.2% 
decrease in total cell number (p<0.001) and in live cell number by 21.1% 
(p<0.005) was detected in IGFBP-2 treated TCCSUP cells compared with the 
untreated cells (Figure 31-C).In both experiments using T24 or TCCSUP cells, 
no significant change in cell death between the control and IGFBP-2 treated 
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Figure 31: effect of dosing exogenous IGFBP-2 on cell growth in T24 and TCCSUP 
cells 
Both T24 and TCCSUP cells were seeded into 6-well plates in GM at a density of 0.05x106 
cells/well. After 24 hours of serum starvation, cells were labelled according to different 
treatments (“CT” for control group without any treatment and “IGFBP-2” for IGFBP-2 treated 
cells at a concentration of 600ng/ml for 48 hours).  
(A) & (C): Graphs show the cell counting of both live and total cell numbers under different 
treatments in T24 and TCCSUP cells, respectively. (B) & (D): Graphs represent the change in 
the percentage of cell death due to different treatments in T24 and TCCSUP, respectively. The 
graphs present the mean of three experiments each performed at least in triplicate, and error 
bars represent the standard error of the mean of the experiments (n=3). “NS*”: not significant. 
 
3.4.4.3 Effect of adding exogenous IGFBP-2 on cell invasion in T24 and 
TCCSUP cells 
Invasion assays were performed to study the effect of exogenous IGFBP-2 on 
the invasive ability of T24 and TCCSUP cells.  
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Compared to untreated cells, cells treated with exogenous IGFBP-2 in both cell 
lines exhibited a decrease in the numbers of invaded cells (Figure 32-A for T24 
and Figure 32-C for TCCSUP cells), and the reduction was significant in both 
T24 (by 55% in Figure 32-B) and TCCSUP (by 41% in Figure 32-D) cells. 
 
Figure 32: effect of adding exogenous IGFBP-2 on cell invasion of T24 and 
TCCSUP cells 
Cells of both cell lines were previously seeded in GM for 24 hours and then changed to SFM for 
16 hours before being prepared for an invasion assay. After serum-starvation, both T24 and 
TCCSUP cells were seeded into the collagen-coated inserts at a density of 0.08x106 cells/insert 
and allowed to migrate for 18 hours. Cells were labelled according to different treatments 
while seeding (“CT” for control cells without treatment, and “IGFBP-2” for cells treated with 
IGFBP-2 at the concentration of 600ng/ml).   
(A) & (C): The images show migrated T24 and TCCSUP cells, respectively, with nuclei (in blue) 
stained with DAPI. All images shown are at x10 magnification. (B) & (D) The graphs show the 
fold change of invaded T24 and TCCSUP cells, respectively, between exogenous IGFBP-2 
treatment group and control group. The graphs represent the mean of three experiments each 
performed in triplicate, up which the standard error of the mean of the experiments was 
presented (n=3). 
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3.4.4.4 Effect of adding exogenous IGFBP-2 on cell migration in T24 and 
TCCSUP cells 
Characterization of basal cell migration of T24 and TCCSUP cells was 
performed as described in section 2.9. As shown in Figure 33, both T24 and 
TCCSUP cells migrated toward the centre of the gap area after the inserts were 
removed. Migration was observed in T24 cells after the removal of inserts, and 
the gap had been closed after about 9 hours. 0nly a few TCCSUP cells were 
detected with morphological movement at the same time. 
 
Figure 33: characterisation of the migrating ability of T24 and TCCSUP cells 
Cells were seeded at a certain density (0.028x106 cells for T24 and 0.048x106 cells for TCCSUP) 
into each chamber in GM and allowed to grow for approximately 24 hours to reach about 80% 
confluence. And then cells were allowed to reach 90-95% confluence during another 24 hours 
of serum starvation in SFM. Then cell migration was observed for up to 12 hours with the 
inserts removed. “0hr”: the start point after the removal of inserts; “9hrs”: 9 hours after the 
removal of inserts. All images demonstrate the typical results from three experiments each 
performed in duplicate (n=3). All images shown are at x10 magnification. 
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T24 cells migrated as a sheet, and cells treated with exogenous IGFBP-2 moved 
more slowly than the control group with the relative gap area showing a 
significant difference at the sixth (p<0.001), ninth (p<0.01) and twelfth 
(p<0.001) hour (Figure 34-A & B).  
Although TCCSUP cells showed migration in individual cells only (Figure 34-
C),  a reduction in cell migration was still evident following exogenous IGFBP-
2 treatment compared with the control group (p<0.001 at the third and ninth 
hour, and p<0.01 at the sixth and twelfth hour) (Figure 34-D).
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Figure 34: effect of adding exogenous IGFBP-2 on cell migration in T24 and 
TCCSUP cells 
Cells were seeded at a certain density (0.028x106 cells for T24 and 0.048x106 cells for TCCSUP) 
into relative chambers in GM and allowed to grow for approximately 24 hours to reach about 
80% confluence. And then cells were allowed to reach 90-95% confluence during another 24 
hours in SFM. Then the inserts were removed leaving cell patches observed and gap closing 
process recorded for up to 12 hours with different treatment (“CT”: untreated cells as a control 
group; “IGFBP-2”: cells treated with IGFBP-2 at the concentration of 600ng/ml). Images of cell 
gaps were taken at several times with relative labels. “0hr”: the start point after the removal 
of inserts; “3hrs”: 3 hours after the removal of inserts; “12hrs”: 12 hours after the removal of 
inserts. All images demonstrate the typical results from three experiments each performed in 
duplicate (n=3). All images shown are at x10 magnification, and the area of the gaps in the 
images was analysed using ImageJ software.  
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(A) & (C) show the images of the gaps between cell patches of T24 and TCCSUP, respectively, 
with different treatments at the start point (“0hr”), 3 hours (“3hrs”), and 12 hours (“12hrs”) 
after the removal of inserts. The red dashed lines in (A) present the outline of migrating T24 
cells moving together, and the red circles in (C) show individual migrated TCCSUP cells.  
Accordingly, the graph in (B) shows the fold change of gap area per insert normalised to 
control with exogenous IGFBP-2 treatment in T24 cells, and the graph in (D) shows the 
number of migrated cells per insert (x104 cells/ml) in TCCSUP cells. The graphs represent the 
mean of three experiments each performed in duplicate, with the standard error of the mean 
of the experiments (n=3). “NS*”: not significant. 
 
3.4.4.5 Effect of adding exogenous IGFBP-2 on cell colony formation in 
T24 and TCCSUP cells 
A soft agar colony formation assay was used as described in section 2.8 to 
assess the effect of exogenous IGFBP-2 on the ability of T24 and TCCSUP cell 
lines to form colonies in soft agar. 
Visually, compared with untreated cells in control groups, both T24 (Figure 
35-A) and TCCSUP (Figure 35-D) cells formed less and smaller colonies with 
exogenous IGFBP-2 treatment. Significant decreases both in colony forming 
efficiency (CFE) and in the average size of each colony were found in the two 
cell lines. Regarding CFE, a reduction of 78.8% (p<0.001) (Figure 35-B) and of 
87.6% (p<0.001) (Figure 35-E) was found in IGFBP-2 treated T24 and TCCSUP 
cells, respectively. Similarly, the fold change of average size of each colony in 
IGFBP-2 treated T24 and TCCSUP cells were 0.60 (p<0.001) (Figure 35-C) and 
0.57 (p<0.01) (Figure 35-F) of untreated cells, respectively. 
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Figure 35: effect of adding exogenous IGFBP-2 on formation of colonies by T24 
and TCCSUP cells in soft agar  
Both T24 and TCCSUP cells were seeded in dishes under different treatments with 
corresponding labels (“CT”: untreated cells as a control group; “IGFBP-2”: cells treated with 
IGFBP-2 at the concentration of 600ng/ml 48 hours prior to seeding). All cells were seeded 
with an even density at 5,000cell/dish and fed once a week for four weeks in total, and then 
colony numbers, as well as average size, were measured by ImageJ software.  
(A) & (D): Images show T24 and TCCSUP cells, respectively, were set up into dishes with even 
densities at the first day (“Day 1”), and colonies were stained at the end of the assay (“Day 28”); 
All images shown are at x10 magnification; (B) & (E): Graphs present the change of colony 
count per dish under different treatments for T24 and TCCSUP cells, respectively. (C) & (F): 
Graphs demonstrate the fold change of average size of colonies due to different treatments for 
T24 and TCCSUP cells, respectively. All graphs present the mean of three experiments each 
performed in triplicate, and error bars represent the standard error of the mean from three 
experiments (n=3). 
 
3.4.4.6 Effect of adding exogenous IGFBP-2 on EMT markers in T24 cells 
As for characterisation of basal levels of EMT markers shown in 
 
Figure 19, T24 cells expressed abundant N-cadherin and β-catenin with 
undetectable levels of E-cadherin (which is an epithelial marker). When 
treated with exogenous IGFBP-2 at 600ng/ml for 48 hours, compared with 
control samples, a reduction of 59% (p<0.05) in the abundance of N-cadherin 
was observed with no detectable induction of E-cadherin (see Figure 36-A & 
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B). And, again, no visible or statistically significant change in the abundance of 
β-catenin was noted (Figure 36-C & D). 
 
Figure 36: effect of adding exogenous IGFBP-2 on EMT markers in T24 cells 
T24 cells were seeded in 6-well plates at a density of 0.05x106 cells/well in GM for 24 hours 
and serum-starved with SFM for another 24 hours. Then cells were separated according to 
different treatments (“CT”: untreated cells as a control group; “IGFBP-2”: cells treated with 
IGFBP-2 at the concentration of 600ng/ml for 48 hours). After 48 hours of treatment, cells 
were harvested to investigate changes in protein abundance using WB analysis. Samples from 
whole lysates were loaded equally at 60µg for protein detection, and GAPDH was assessed as 
reference protein in WB analysis. 
The blots show levels of E- and N-cadherin (A) and β-catenin (C) under different treatments. 
And the graphs (B) and (D) demonstrate the mean of fold change of the optical density of N-
cadherin and β-catenin, respectively, from three experiments each performed at least in 
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3.4.5  Relationship between IGFBP-2 and chemosensitivity 
To look into the effect of IGFBP-2 on chemo-sensitivity of bladder cancer cells 
to cisplatin, two cell lines were used including IGFBP-2-abundant RT4 cells and 
IGFBP-2-absent T24 cells. 
TTI assay was used to assess a dose response to cisplatin in RT4 and T24 cells 
regarding proliferation and cell counting was performed to examine changes 
in cell death.  
As shown in Figure 37-A, both RT4 and T24 cells showed a significant decrease 
in cell proliferation with increasing concentrations of cisplatin. A reduction to 
about half of the control cells (dosage at 0µg/ml) was achieved in both cell 
lines at 5µg/ml (p<0.001 for both cell lines): this concentration was chosen for 
further experiments in this study. 
Compared with the response in T24 cells, RT4 cells presented a sharper 
decrease in the fold change of cell proliferation with a relatively lower 
concentration of cisplatin treatment (1, 2.5µg/ml); however, the statistics 
showed no significant difference between the two cell lines at any dose of 
cisplatin.  
The images (Figure 37-B) taken at the end of the TTI experiments showed that 
RT4 cells started to lose cell structure and detached from the surface of the 
culture vessels when treated with cisplatin, and more detached cells were 
observed as the concentration of cisplatin increased from 1µg/ml. Compared 
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with RT4 cells, T24 cells were more robust and presented less floating cells 
which only started to increase when the dose of cisplatin reached 5µg/ml. 
 
  





Figure 37: dose response to cisplatin in RT4 and T24 bladder cancer cells 
Cells were seeded (0.03x106 cells/well for RT4, and 0.02x106 cells/well for T24) into 24-well plates and TTI was performed to assess the dose response 
to cisplatin in both cell lines at the concentration of 0/1/2.5/5/10/15 µg/ml for 24 hours.  
(A) The graph shows the mean of three experiments each performed in triplicate, and error bars represent the standard error of the mean from three 
experiments (n=3). “NS*”: not significant. (B) Images were taken at the end point (24 hours) of the same TTI experiments representing the typical change 
of cells in response to Cisplatin treatment. All images shown are at x10 magnification. 
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To further investigate the sensitivity of both cell lines to cisplatin treatment, 
cell counting was performed after cells were treated with cisplatin at 5µg/ml 
for 24 hours or 48 hours.  
As shown in Figure 38-A, with 24 hours treatment with cisplatin, there was a 
1.8 (p<0.001) fold increase in the percentage cell death in RT4 cells compared 
with the control group, and a 1.2 fold increase in percentage cell death in T24 
cells. With 48 hours of treatment shown in Figure 38-B, both cell lines 
demonstrated a greater fold increase in the sensitivity to cisplatin: compared 
to control group RT4 showed a 4.3 fold (p<0.001) higher percentage cell death 
than that of T24 cells being 3.1 fold higher (p<0.001). 
Figure 38: effect of Cisplatin on cell death in RT4 and T24 cells 
Both RT4 and T24 cells were seeded into 6-well plates in GM at a density of 0.1x106 cells/well 
and 0.05x106 cells/well, respectively, to grow for 24 hours. After 24 hours of serum starvation, 
cells were labelled according to different treatments. “CT”: control group without any 
treatment; “CIS”: Cisplatin treated cells at a concentration of 5µg/ml for 24 (A) or 48 hours 
(B). 
Graphs represent the fold change in the percentage of cell death due to cisplatin treatment in 
both RT4 and T24 cells for 24 and 48 hours, respectively. The graphs present the mean of three 
experiments each performed at least in triplicate, and error bars represent the standard error 
of the mean of the experiments (n=3). “NS*”: not significant.  
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3.4.5.1 Effect of cisplatin treatment on cell death in RT4 cells following 
silencing of IGFBP-2  
With IGFBP-2 abundant RT4 cells, treatment of cisplatin was combined with 
specific IGFBP-2 siRNA transfection to look into the effect of IGFBP-2 on cell 
chemosensitivity to cisplatin. 
With efficient IGFBP-2 knockdown achieved (Figure 39-A), no significant 
change was observed between control cells with either scrambled siRNA (“NS”) 
or IGFBP-2 siRNA (“KD”) transfection only. In comparison, a subtle but 
significant alteration was shown between cells which were treated with 
cisplatin following siRNA transfection. Cells treated with cisplatin after IGFBP-
2 siRNA transfection (“KD+CIS”) demonstrated a smaller fold change of cell 
death percentage (3.2) compared with those after scrambled siRNA (“NS+CIS”) 
(3.4) (p<0.01) (Figure 39-B). 
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Figure 39: effect of silencing IGFBP-2 on response to cisplatin in RT4 cells 
Cells were seeded into 6-well plates in GM at a density of 0.1x106 cells/well to grow for 24 
hours and were serum starved with SFM for another 24 hours. Then, after 72 hours of siRNA 
(“NS” for non-silencing scrambled siRNA as control and “KD” for IGFBP-2 siRNA) transfection, 
cisplatin (“CIS”) was added to cells at 5µg/ml for another 24 hours. Cell death was determined 
by performing cell counting. The supernatant was taken before cisplatin treatment for the 
detection of the efficiency of IGFBP-2 silencing. 
(A): The blot shows the efficiency of IGFBP-2 knockdown achieved by detecting IGFBP-2 in 
samples loaded equally at 25µl. (B): The graph shows the fold change of in percentage cell 
death due to different treatments in RT4 cells. “NS”: cell group treated with non-silencing 
scrambled siRNA only as control; ”KD”: cell group treated with IGFBP-2 siRNA only; ”NS+CIS”: 
cell group treated with non-silencing scrambled siRNA transfection followed by another 24 
hours of cisplatin dosing; ”KD+CIS”: cell group treated with IGFBP-2 siRNA transfection 
followed by another 24 hours of cisplatin dosing. The graph presents the mean of three 
experiments each performed in triplicate, and error bars represent the standard error of the 
mean of three experiments (n=3). “NS*”: not significant. 
 
3.4.5.2 Effect of adding exogenous IGFBP-2 on cell death in T24 cells in 
response to cisplatin treatment 
Exogenous IGFBP-2 was applied to IGFBP-2 absent T24 cells to further 
investigate the effect of IGFBP-2 on cell chemosensitivity to cisplatin treatment. 
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As we can see in Figure 40, regarding fold change of percentage cell death, no 
significant difference was observed in IGFBP-2-alone-treated cells (“BP-2”) 
compared with untreated control cells (“CT”). In comparison, when cells were 
treated with cisplatin, those with additional IGFBP-2 treatment (“BP-2 + CIS”) 
presented more cell death (fold change being 3.0) compared with control than 
cells which were treated with cisplatin alone (“CIS”) (fold change being 2.1) 
(p<0.01). 
 
Figure 40: effect of adding exogenous IGFBP-2 response of T24 cells to cisplatin 
Cells were seeded in 6-well plates in GM at a density of 0.05x106 cells/well to grow for 24 
hours and were serum starved with SFM for another 24 hours. Then, cisplatin (“CIS”) was 
added to cells at 5µg/ml for another 24 hours of incubation with or without previous 
treatments of exogenous IGFBP-2 (“BP-2”) for 24 hours at 600ng/ml. And then cell death was 
determined by performing cell counting. The graph represents the mean of three experiments 
each performed in triplicate, and error bars represent the standard error of the mean from 
three experiments (n=3). “NS*”: not significant. 
“CT”: control group; “BP-2”: cell group with only 48 hours of IGFBP-2 treatment; “CIS”: cell 
group with only 24 hours of Cisplatin treatment; “BP-2 + CIS”: cell group with previous 24 
hours of IGFBP-2 treatment alone and then another 24 hours of combination of IGFBP-2 and 
cisplatin treatment. 
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3.5 Discussion 
Three bladder cancer cell lines with the opposite phenotypes presenting 
distinct difference in the levels of IGFBP-2 were used in this study to examine 
the role that IGFBP-2 plays in bladder cancer progression. The epithelial-like 
RT4 cells express abundant IGFBP-2, while the mesenchymal-like T24 and 
TCCSUP cell lines possess little, which was found of the same pattern in 
Glioblastoma multiforme (GBM) (Shelton, Mukherjee et al. 2010).  
Two distinct ways were used to manipulate the levels of IGFBP-2 in specific 
bladder cancer cell lines. In IGFBP-2 abundant epithelial-like RT4 cells, the 
levels of IGFBP-2 were reduced significantly by using specific IGFBP-2 siRNA. 
In contrast with mesenchymal-like T24 and TCCSUP cell lines that had 
negligible IGFBP-2 with, we added exogenous recombinant human IGFBP-2. 
Following manipulation of IGFBP-2 levels in these cell lines we assessed any 
phenotypic changes that occurred. 
With IGFBP-2 knockdown in RT4 cells, a significant increase both in live and 
total cell number was observed with no difference in cell death. In contrast, by 
adding exogenous IGFBP-2, both live and total cell numbers were decreased 
significantly in T24 and TCCSUP cells, with again no significant changes in cell 
death. We observed that epithelial-like RT4 cells grow more slowly than 
mesenchymal-like T24 and TCCSUP cells and this has also been reported in the 
literature (Vallo, Michaelis et al. 2015). These data suggest that IGFBP-2 acts 
to inhibit cell proliferation in bladder cancer. Similar anti-proliferative effects 
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were reported in a human breast cancer cell line, Hs578T, by using an ELISA-
based and a flow cytometry-based apoptosis assay (Frommer, Reichenmiller 
et al. 2006) and in human embryonic kidney fibroblasts by using an MTT assay 
(Hoflich, Lahm et al. 1998). Whereas the opposite results have also been 
reported in some cancers such as breast cancer of different cell lines, MCF7 
and T47D, demonstrating the proliferative role of IGFBP-2 by using Trypan 
blue cell counting and Tritiated thymidine incorporation (TTI) assay 
(Foulstone, Zeng et al. 2013). 
With invasion, silencing IGFBP-2 in RT4 cells led to a substantial increase in 
the numbers of invading cells. The exogenous addition of IGFBP-2 to T24 and 
TCCSUP cells resulted in a significant reduction in the number of invaded cells, 
which suggested IGFBP-2 might also act in an inhibitory way in the process of 
cell invasion in bladder cancer. Similarly, a reduction of IGFBP-2 was 
correlated with the promotion of epithelial invasion in the progression of 
cervical cancer (Adam Pickard 2015), and loss of IGFBP-2 was also found at 
the invasive front of glioblastoma with high grade suggesting its association 
with enhanced invasive potential (Hoelzinger, Mariani et al. 2005). However, 
another study in bladder cancer showed that over-expression of IGFBP-2 
enhanced the invasive potential by generating an IGFBP-2 overexpressing cell 
subline, KoTCC/BP2, using cDNA transfection (Miyake, Hara et al. 2005).  
Regarding cell migration, epithelial-like RT4 cells showed no migration either 
basally or with IGFBP-2 silenced.  In contrast, mesenchymal bladder cancer 
cell lines were able to migrate basally and with different patterns.  T24 cells 
migrated as a sheet that was significantly slowed down with the exogenous 
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addition of IGFBP-2. TCCSUP cells migrated individually, and the number of 
migrating cells was similarly reduced when dosed with IGFBP-2. In contrast to 
our work showing that exogenous addition of IGFBP-2 inhibited cell migration, 
inhibition of IGFBP-2 in some cancers such as glioma (Patil, Railkar et al. 2015) 
and leukaemia (Chen, Zheng et al. 2013)was reported to reduce cell migration. 
Malignant transformation was investigated using a soft agar colony formation 
assay: the average colony counts formed per dish, and the average size of each 
colony were two quantitative read-outs from this assay reflected cell renewal 
and to measure the differences in cellular tumourigenicity in different contexts 
(Horibata, Vo et al. 2015). Considerable increases in both factors were 
observed in RT4 cells when IGFBP-2 was knocked down, and significant 
decreases were found in both T24 and TCCSUP cells with additional IGFBP-2. 
These data suggested that IGFBP-2 was playing a role in inhibiting malignant 
transformation in bladder cancer. In contrast, with certain human leukaemias 
inhibition of IGFBP-2 resulted in a reduction in cell colony formation activity 
in the mouse model (Chen, Zheng et al. 2013). 
A number of changes occur in specific markers during EMT: for example, a 
reduction in the levels of E-cadherin, an increase in the abundance of N-
cadherin as well as β-catenin nuclear translocation. With RT4 cells, the levels 
of E-cadherin were significantly reduced when IGFBP-2 was efficiently 
silenced. And compared with cellular fractionation, IF showed higher 
sensitivity presenting the detection of the β-catenin in the nuclei in IGFBP-2 
silenced RT4 cells. Due to the marked difference between the results by these 
two techniques, more work would be required to be sure about the effects on 
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β-catenin localisation. Changes in RT4 cells indicated that silencing IGFBP-2 
promoted a more EMT-like phenotype. While in mesenchymal-like T24 cells, 
adding exogenous IGFBP-2 led to a significant reduction of N-cadherin 
expression suggesting inhibition of EMT. These data indicate that the presence 
of IGFBP-2 may suppress EMT in bladder cancer. Again, different conclusions 
about the role of IGFBP-2 have been drawn in other types of cancers such as 
pancreatic ductal adenocarcinoma (PDAC), where IGFBP-2 promoted EMT: 
downregulation of N-cadherin and upregulation of E-cadherin followed 
knockdown of IGFBP-2 (Gao, Sun et al. 2016).  
I also investigated the chemo-sensitivity of bladder cancer cells to cisplatin 
using epithelial-like RT4 and mesenchymal-like T24 cells representing cancer 
types with less and more aggressiveness, respectively. Even though there were 
no differences in the levels of DNA synthesis as shown in the TTI assay 
between these two cell lines in response to cisplatin treatment, cell images 
suggested that RT4 cells were more susceptible to death which was confirmed 
by examination of cell death using cell counting. The manner of RT4 cells 
growing into dense clusters might be the reason why detection of DNA 
synthesis was not as sensitive as the images or cell counting. Then I treated 
RT4 cells with cisplatin following IGFBP-2 gene silencing and observed less 
cell death than the control group, suggesting IGFBP-2 might act to enhance cell 
sensitivity to cisplatin, or reduce cell survival, with higher levels of IGFBP-2 
indicating more sensitivity. To prove this hypothesis, I then conducted the 
experiments in T24 cells treated with exogenous IGFBP-2 and cisplatin, and 
the results showed that IGFBP-2 increased cisplatin-induced cell death in T24 
Chapter 3 - The Levels and Role of IGFBP-2 in Bladder Cancer 
Page | 164  
 
cells, therefore, indicating the chemo-sensitivity of cancer to cisplatin was 
enhanced in the presence of IGFBP-2. However, another study in bladder 
cancer reported opposite results demonstrating increased levels of IGFBP-2 in 
a cisplatin-resistant subline (BIU87-CisR), with enhanced cell sensitivity to 
cisplatin resulted from the inhibition of IGFBP-2 by gene silencing (Zhu H 
2015), which reflects the heterogeneity among cell lines. 
In summary, in the present study, knocking down IGFBP-2 in IGFBP-2 
abundant epithelial-like RT4 cells led to an increase in cell growth and 
promotion of cell invasion and colony formation, along with a reduction of E-
cadherin and observation of β-catenin nuclear translocalization. And adding 
exogenous IGFBP-2 to mesenchymal-like T24 and TCCSUP cells with negligible 
basal IGFBP-2 resulted in decreased cell growth, invasion, migration, colony 
formation as well as the expression of N-cadherin. According to the results 
above, IGFBP-2 was considered to play an important inhibitory role in bladder 
cancer by inhibiting cell proliferation, invasion, migration, malignant 
transformation and EMT-related cancer progression. Also, IGFBP-2 may be 
used as an indicator of cell chemosensitivity to cisplatin in bladder cancer. 
It is clear from my data and the literature that IGFBP-2 has the ability to act as 
a tumour promoter and tumour suppressor even in the same cancer. This can 
be the result of a number of different factors such as differences between cell 
types, culture conditions and in tumour stage, type and subtype. The most 
likely reason for these differences is the ability of IGFBP-2 to act in either an 
IGF-dependent or -independent manner, and each of these actions are context-
dependent (Yau, Azar et al. 2015). Therefore, an understanding of the 
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mechanism by which IGFBP-2 is acting and the context in which this is 
occurring is key when comparing different studies. The IGF- dependency of my 
results is addressed in chapter 4.  
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Chapter 4 - The Regulatory and 
Working Mechanisms of IGFBP-2 
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4.1 Introduction 
Results of chapter 3 indicated that IGFBP-2 might act as an important inhibitor 
of a number of processes occurring during bladder cancer progression, 
including proliferation, invasion, migration, malignant transformation, and 
EMT development. Therefore, further studies were carried out to investigate 
how the levels of IGFBP-2 are regulated and by which means it plays an 
inhibitory role in these cell activities. 
4.1.1 Regulation of the levels of IGFBP-2 
IGFBP-2 is mainly expressed by tissues of the liver, adipose, reproductive and 
central nervous system (Shimasaki and Ling 1991) and the levels are 
influenced by various factors. 
As a secreted protein, plasma IGFBP-2 levels are correlated with metabolic and 
dietary status including for example body fat and age.  For instance, IGFBP-2 
levels are inversely associated with the presence of obesity (Wheatcroft and 
Kearney 2009). 
Compared with circulating plasma levels, local levels of IGFBP-2, which can be 
found in both epithelial and mesenchymal cancer cells, appear to provide a 
more accurate association with disease progression (Pickard and McCance 
2015). And at the cellular level, levels of IGFBP-2 can be regulated in many 
different ways, including via epigenetic modifications such as gene 
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methylation (Yazawa, Sato et al. 2009), growth factors (Morrison, Liu et al. 
2014) and by proteases (Berg, Bang et al. 2007). 
4.1.2 DNA methylation of the IGFBP-2 gene in cancer 
Aberrant DNA methylation refers to a process by which methyl groups are 
added to DNA bases catalysed by methyltransferases (DNMT 1-3) (Dupont, 
Armant et al. 2009).  Methylation modifies the genes, and potentially their 
expression, rather than introducing a change in the actual DNA sequence and 
hence is reversible (Dupont, Armant et al. 2009). It has mostly been studied 
due to its effects on transcriptional repression or even loss of gene function 
that has been widely reported in cancers (Chen and Wu 2016). 
Methylation is characterised as the predominant modification in mammalian 
DNA (Dupont, Armant et al. 2009), and it happens exclusively at cytosine and 
guanine nucleotides with the intervening phosphate group (CpG) 
dinucleotides in mammals, with a methyl group added to carbon 5 of the 
cytosine (C) turning it into 5-methylcytosine (5mC). In the normal human 
genome, most (70-80%) cytosines within CpG dinucleotides are methylated, 
with unmethylated cytosines being located in specific GC-rich areas, named 
CpG islands (or CG islands, CGI) (Jabbari and Bernardi 2004). A CGI refers to a 
DNA patch of about 1,000 base pairs (bps), within which the CpG dinucleotide 
occupies a large percentage (about 65%) in base composition compared with 
the genome as a whole (about 40%) in humans (Suzuki and Bird 2008). CGIs 
are often associated with gene promoters, for instance, approximately 56% of 
human genes have CGI in their promoters (Suzuki and Bird 2008), and 
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aberrant hypermethylation in these promoters may lead to gene silencing by, 
for instance, preventing the binding of specific transcription factors to the gene 
(Dupont, Armant et al. 2009). 
Due to the nature of reversibility of epigenetic modifications, the methylation 
can be inverted by DNMT inhibitors, such as 5-AZA-2,-deoxycytidine (5-AZA-
dCyd, “AZA”). AZA can work as a demethylating agent removing the methyl 
groups from the CGIs of the DNA and therefore allows the re-expression of 
silenced genes (see Figure 41). 
 
Figure 41: schematic diagram showing the methylation and demethylation of 
cytosine 
 
Hypermethylation of the promoter region of IGFBP-2 gene has been reported 
in several types of cancer including lung (Yazawa, Sato et al. 2009), breast (Liu, 
Liu et al. 2014, Nickel and Stadler 2015), colorectal (Simons, van den Brandt 
et al. 2014), and hepatomas (Chiba, Yokosuka et al. 2005). The rates even vary 
within a cancer with different histological types. For example, in lung cancer, 
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the IGFBP-2 gene promoter was found to be methylated in 71% of 
adenocarcinomas and 29% of squamous cell carcinomas, with only 8% in 
small cell lung cancer (Yazawa, Sato et al. 2009). 
4.1.3 The molecular working mechanism of IGFBP-2 in cancer 
IGFBP-2 has been suggested to act in either an IGF-dependent or -independent 
manner. 
IGFBP-2 acts in an IGF-dependent way by binding to IGFs operating as a carrier 
to either transport IGFs to their receptors triggering relevant signalling, or 
sequester them to prolong their bioactivity as well as to prevent their binding 
to the receptors (Yau, Azar et al. 2015). It has also been found to interact with 
certain components of the extracellular matrix (ECM)(Russo, Schutt et al. 2005) 
and cell surface proteoglycan receptors (Shen, Xi et al. 2012) offering a peri-
cellular reservoir of bioactive IGFs. 
The IGF-independent actions of IGFBP-2 refer to the intrinsic activities of it 
occurring without the presence of IGFs as ligands. IGFBP-2 has been suggested 
to influence tumorigenesis, by either binding to integrin receptors, including 
αVβ3 or α5β1, on the cell membrane activating intracellular signalling 
(Frommer, Reichenmiller et al. 2006, Perks, Vernon et al. 2007, Foulstone, 
Zeng et al. 2013), or translocating into the cell and entering the nucleus via 
distinct nuclear transportation complexes to affect the expression of some 
genes, such as VEGF (Miyako, Cobb et al. 2009, Azar, Azar et al. 2011, Azar, 
Zivkovic et al. 2014). 
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4.1.4 NBI-31772 
NBI-31772 is a small non-peptide molecule (molecule weight: 341) which was 
identified almost two decades ago (Liu, Xie et al. 2001). With no biologic 
activity at the IGF receptors, it interacts with IGFBPs by competing specifically 
against IGF to bind all the six IGFBPs non-selectively with high affinity, and 
thus displaces free endogenous IGF-I and IGF-II from IGF:IGFBP complexes 
increasing the free levels of IGF-I and/or IGF-II (Liu, Xie et al. 2001). The freed 
IGF-I has been shown to be bioactive in both in vivo and in vitro studies 
(Mackay, Loddick et al. 2003, Choi, Gemberling et al. 2013); therefore, this 
molecule has been used as a nonspecific IGFBP inhibitor or IGF-potentiator 
enhancing IGF signalling. 
Differences in the binding activity of NBI-31772 toward six IGFBPs were 
identified with the highest being to IGFBP-2 and IGFBP-4, and the lowest to 
IGFBP-6 (Liu, Xie et al. 2001).  
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4.2 Aims 
To investigate the mechanism by which the level of IGFBP-2 is regulated and 
whether IGFBP-2 is working in an IGF-dependent or -independent manner to 
exert its effects on bladder cancer cells. 
IGFBP-2-null, aggressive bladder cancer cell lines, T24 and TCCSUP, 
were treated with AZA, to assess whether the expression of IGFBP-2 is 
switched off by DNA hypermethylation. 
o To determine the effect of AZA on the protein levels of IGFBP-2.  
o To confirm DNA methylation status by performing Combined 
Bisulphite Restriction Assay (COBRA). 
o To assess the associated phenotypic changes of bladder cancer 
cell lines in response to the treatment of AZA. 
NBI-31772 was used to examine the working mechanism of IGFBP-2. 
o To combine treatment of NBI-31772 with IGFBP-2 siRNA 
transfection in IGFBP-2-abundant epithelial-like RT4 cells. 
o To combine treatment of NBI-31772 with exogenous 
recombinant IGFBP-2 and IGF-I in IGFBP-2-null mesenchymal-
like T24 cells. 
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4.3 Materials and methods 
4.3.1 Cell culture 
Three human urinary bladder cancer cell lines including RT4 (an epithelial-
like phenotype) and T24 as well as TCCSUP (mesenchymal-like phenotypes) 
were used in this study. They were obtained and cultured as described in 
section 2.1.  
4.3.2 Cell treatments 
4.3.2.1 AZA 
0.5mg of AZA (Sigma, #A3656-50MG) were dissolved fresh in 0.5ml of sterile 
dH2O to make a 4382µM stock solution. The stock solution was sterilised with 
a 0.2µm filter and then diluted with SFM to achieve a 500µM working stock. 
The working stock was then diluted further with SFM into different final 
concentrations for cell treatment. 
4.3.2.2 NBI-31772 
Protected from light during the whole process, NBI-31772 (Sigma; #N8289) 
was reconstituted at 100mM by re-suspending 34.1mg in 1ml sterile DMSO 
and then aliquoted and stored at -20°C. 1mM working stock was prepared 
fresh by mixing 10µl of the 100mM stock to 990 µl of SFM and then diluted 
further with SFM to reach a final concentration of 1µM. NBI-31772 was added 
to the cells 1 hour before other treatments. NBI-31772 is a non-peptide 
inhibitor of the binding of IGFs to all 6 IGFBPs (which have similar IGF-binding 
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sites) that was developed from screening chemical libraries and has no 
interactions with IGF receptors (Liu, Xie et al. 2001).  
4.3.2.3 Recombinant human IGF-I 
IGF-I (Gropep; receptor grade, #CM001) was made up to 1µg/µl stock solution 
following product instruction, aliquoted and stored at -20°C. A 10µg/ml 
working stock was made fresh by adding 3µl of stock solution to 297µl of SFM 
that was diluted further with SFM to achieve final working concentrations. 
4.3.2.4 Recombinant human IGFBP-2 protein 
A final concentration of 600ng/ml of IGFBP-2 was prepared as described in 
section 3.3.6.1.  
4.3.1 Cell proliferation 
TTI assay was used to measure DNA synthesis, and Trypan Blue Dye Exclusion 
assay was performed for cell counting to assess cell survival as described in 
section 2.2.  
4.3.2 Cell colony formation 
A soft agar colony formation assay was used with both T24 and TCCSUP cells 
as described in section in 2.8 to examine the change in malignant 
transformation activity in response to AZA treatment. 
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4.3.3 COBRA 
COBRA was used to investigate the methylation status of the IGFBP-2 gene 
promoter as described in section 2.7. 
4.3.4 Detection of protein abundance 
Protein levels of E-cadherin, N-cadherin and IGFBP-2 in either whole lysates 
or supernatant were detected using WB analyses as described in section 2.3. 
GAPDH was used as a loading control, and the antibody solution information 
is listed in Table 25. 
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*2˚ Ab: anti-rabbit (Sigma, #A0545); anti-mouse (Sigma, #A0944); anti-goat (Sigma, #A5420). 
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4.3.5 Transfection with IGFBP-2 siRNA 
IGFBP-2 gene knockdown in RT4 cells was achieved by performing IGFBP-2 
siRNA transfection as described in section 2.6. Cells were transfected with 
IGFBP-2 siRNA at the concentration of 30nM for 72 hours as determined in 
section 3.4.3.1. 
4.3.6 Statistical analysis 
Data were expressed as mean ± SEM and analysed with SPSS 23 for Windows 
using one-way analysis of variance (ANOVA) followed by least significant 
difference (LSD) post-hoc test and Student’s test. A two-sided p-value was 
shown for statistical significance and was depicted in asterisks as a single one 
for *p<0.05 and a double for **p<0.01. 
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4.4 Results 
4.4.1 Optimisation of AZA Doses 
TTI assay was performed in both T24 and TCCSUP cells to investigate the 
antiproliferative response to AZA treatment to try to establish an appropriate 
dose for further experiments in this study. 
As shown in Figure 42 cell proliferation decreased with increasing 
concentrations of AZA in both cell lines: at 10µM proliferation was decreased 
by 63% in T24 cells, p<0.01 and by 48% in TCCSUP cells, p<0.01. This dose was 
selected for the following experiments. 
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Figure 42: proliferative response to AZA in T24 and TCCSUP bladder cancer 
cells 
Both T24 and TCCSUP cells were seeded at a density of 0.02x106 cells/well into 24-well plates 
in GM to grow for 24 hours followed by serum starvation for another 24 hours. Then both cell 
lines were dosed with AZA at 0-75µM for 24 hours, and TTI was performed to show the 
proliferative response to AZA in T24 (A) and TCCSUP (B) cells. 
The graphs represent the mean of three experiments each performed in quadruplicate, and 
error bars represent the standard error of the mean of the experiments (n=3).  “**”: p<0.01. 
The bars in the darker colour indicate the chosen concentration of AZA for both cell lines for 
further experiments.  
 
4.4.2 Effect of AZA on the levels of IGFBP-2 
Based on the chosen dose of AZA determined in 4.4.1, both T24 and TCCSUP 
cells were exposed to AZA (10µM) for 72 hours to investigate whether the loss 
of IGFBP-2 in bladder cancer potentially resulted from epigenetic regulation of 
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the gene promoter. The supernatant was collected, concentrated and analysed 
using WB to assess levels of IGFBP-2. 
With T24 cells, as shown in Figure 43-A, IGFBP-2 was found at an undetectable 
level in the control with a trace in AZA-treated samples when un-concentrated 
(“Neat”). When concentrated either 10 or 20 times, we clearly observed an 
increase in the abundance of IGFBP-2 following AZA-exposure compared with 
the control. There were significant changes in the densitometry analysis 
(approximately 11-fold with 10-times and 8-fold with 20-times concentration, 
both p<0.01) (Figure 43-C). 
Similar results were found with TCCSUP cells. According to the WB blot in 
Figure 43-B, little IGFBP-2 could be detected in the un-concentrated (“Neat”) 
supernatant in both control and AZA-treated samples. When concentrated 30 
times, a low level of IGFBP-2 was detected in the control sample with an 
induction observed in AZA-treated samples, with a more noticeable increase 
in IGFBP-2 when the supernatant was concentrated 60 times. Statistically, the 
levels of IGFBP-2 doubled under AZA treatment compared with the control 
samples (p<0.01) (Figure 43-D). 
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Figure 43: effect of AZA on the levels of IGFBP-2 
Both T24 and TCCSUP cells were seeded in 6-well plates at a density of 0.05x106 cells/well in 
GM to grow for 24 hours and serum starved in SFM for another 24 hours. Then cells were 
labelled according to different treatments (“CT”: untreated cells as a control group; “AZA”: 
cells treated with AZA at the concentration of 10µM for 72 hours). After 72 hours of treatment, 
the supernatant was collected and concentrated according to different concentrating factors 
(“Neat”: un-concentrated supernatant samples; “Concentrated X-fold”: X-times concentrated 
supernatant samples, “X” includes 10, 20, 30 and 60). WB was then performed to examine the 
levels of IGFBP-2 in the supernatant samples. 
(A) & (B): The blots show the levels of IGFBP-2 detected in the supernatant samples in T24 
and TCCSUP cells, respectively. (C) & (D): The graphs present the mean of fold change of 
optical density measurement of IGFBP-2 in T24 and TCCSUP cells, respectively, from three 
experiments each performed in triplicate, and error bars represent the standard error of the 
mean from three experiments (n=3). “*”: the bar selected as the control of normalisation. 
 
4.4.3 Assessment of the methylation status of IGFBP-2 gene 
using COBRA 
Having shown that IGFBP-2 was re-expressed in T24 and TCCSUP cells 
following AZA treatment, COBRA was then performed with these two cell lines 
to assess any alterations in gene methylation status of the IGFBP-2 promoter 
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and to confirm whether the loss of IGFBP-2 in mesenchymal-like bladder 
cancer cell lines could be the result of   methylation of the IGFBP-2 gene 
promoter. 
In T24 cells, as shown in Figure 44-A, the promoter region of the IGFBP-2 gene 
was completely methylated in the control samples (“CT”), and the treatment 
of AZA led to the demethylation of this gene with a significant increase in the 
percentage of unmethylated DNA bands from 0 (in control cells) to 39.9% (in 
AZA-treated cells) (p<0.001) (Figure 44-B). 
With TCCSUP cells, very low level of methylation was observed in the control 
cells. However, similar gene demethylation, but to a smaller extent than 
observed in T24 cells, was detected in TCCSUP samples upon AZA treatment 
(Figure 44-C), and the percentage of unmethylated DNA bands increased 
significantly from 74.8% (in control cells) to 88.6% (in AZA-treated cells) 
(p<0.01) (Figure 44-D). 
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Figure 44: demethylation of the IGFBP-2 gene in T24 and TCCSUP cells following 
AZA treatment using COBRA 
T24 and TCCSUP cells were seeded in 6-well plates at a density of 0.05x106 cells/well in GM 
for 24 hours and serum starved with SFM for another 24 hours. Then cells were labelled 
according to different treatments (“CT”: untreated cells as a control group; “AZA”: cells treated 
with AZA at the concentration of 10µM for 72 hours). After 72 hours of treatment, cells were 
harvested to investigate the methylation status of the IGFBP-2 gene promoter using COBRA.  
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“Ladder(bp)”: 50bp DNA ladder; “UM”: positive control of completely unmethylated samples; 
“M”: positive control of completely methylated samples; “CT”: untreated samples; “AZA”: AZA-
treated samples; “dH2O”: distilled water samples as a negative control; “M%”: percentage of 
methylated fragments; “UM%”: percentage of unmethylated bands. Both CT and AZA samples 
were loaded in duplicate. The images of gels are representative of experiments with at least 
three repeats (n=3) each performed in triplicate, and the graphs demonstrate the mean of the 
optical density measurements of the percentage of uncut (unmethylated) and cut fragments 
(methylated) from the three experiments upon which statistical analysis was performed. 
 (A) & (C): A representative image of the gels shows the density of unmethylated and 
methylated bands in T24 and TCCSUP cells, respectively. The red colour indicates 
overexposure of the bands. (B) & (D): Graphs show the portion percentage of unmethylated 
and methylated bands in T24 and TCCSUP cell, respectively. 
 
4.4.4 Effect of AZA on cancer phenotypes 
With the confirmation of the methylation of the IGFBP-2 gene promoter in 
mesenchymal-like bladder cancer cell lines using COBRA and the re-
expression of IGFBP-2 in T24 and TCCSUP cells following treatment with AZA, 
I next examined how AZA affected the phenotype of the cells. 
4.4.4.1 Effect of AZA on cell growth in T24 and TCCSUP cells 
With the treatment of AZA, T24 cells presented significant decreases both in 
total cell number (by 34.3%, p<0.001) and in live cell number (by 36.4%, 
p<0.001) (Figure 45-A). More cell death was also observed in AZA-treated cells 
increasing from 0.6% in control cells to 1.2% in treated cells (p<0.05) (Figure 
45-B). 
However, in TCCSUP cells, no significant changes were found between control 
and AZA-treated cells either in cell numbers (Figure 45-C) or percentage cell 
death (Figure 45-D). 
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Figure 45: effect of AZA on cell growth in T24 and TCCSUP cells 
Both T24 and TCCSUP cells were seeded in 6-well plates at a density of 0.05x106 cells/well in 
GM to grow for 24 hours and serum starved in SFM for another 24 hours. And then cells were 
labelled according to the different treatments (“CT”: untreated cells as a control; “AZA”: cells 
treated with AZA at the concentration of 10µM for 72 hours). After 72 hours of treatment, cell 
numbers were determined by cell counting. 
(A) & (C): Graphs show counting of both live and total cells after different treatments in T24 
and TCCSUP cells, respectively. (B) & (D): Graphs represent the change in percentage cell 
death following different treatments in T24 and TCCSUP, respectively. The graphs present the 
mean of three experiments each performed at least in triplicate, and error bars represent the 
standard error of the mean of the experiments (n=3). “NS*”: not significant. 
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4.4.4.2 Effect of AZA on cell colony formation in T24 and TCCSUP cells 
To assess the influence of AZA on malignant cell transformation in T24 and 
TCCSUP cells, soft agar colony formation assays were performed. 
As shown in Figure 46-A & D, with the treatment of AZA, less and smaller 
colonies were formed in both T24 and TCCSUP cells compared with the control, 
visually.  
AZA-treated T24 cells presented a significant reduction in colony counts per 
dish.  Colony forming efficiency (CFE) decreased by 36.7% (p<0.01) (Figure 
46-B), and the average size of each colony showed a 0.6 fold decrease (p<0.001) 
relative to control cells (Figure 46-C). 
Similarly, AZA-treated TCCSUP cells demonstrated a significant decrease in 
CFE of 67.4% (p<0.001) (Figure 46-E) and the same fold decrease in the 
average size of each colony (0.6, p<0.05) relative to untreated cells (Figure 46-
F). 
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Figure 46: effect of AZA on the formation of colonies by T24 and TCCSUP cells in 
soft agar 
Both T24 and TCCSUP cells were seeded in dishes under different treatments with 
corresponding labels (“CT”: untreated cells as a control group; “AZA”: cells treated with AZA 
at the concentration of 10µM for 72 hours before seeding). All cells were seeded at an even 
density of 5,000cells/dish and fed once a week for four weeks in total, and then colony 
numbers, as well as the average size, were measured by ImageJ software. 
 (A) & (D): Images show T24 and TCCSUP cells, respectively, that were seeded into dishes at 
even densities on the first day (“Day 1”), and colonies were stained at the end of the assay 
(“Day 28”); All images shown are at x10 magnification; (B) & (E): Graphs represent the change 
in colony count per dish under different treatments for T24 and TCCSUP cells, respectively. (C) 
& (F): Graphs demonstrate the fold change in the average size of colonies due to different 
treatments for T24 and TCCSUP cells, respectively. All graphs represent the mean of three 
experiments each performed in triplicate, and error bars represent the standard error of the 
mean from three experiments (n=3). 
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4.4.4.3 Effect of AZA on EMT markers in T24 cells 
As mentioned in 3.4.1, T24 cells express abundant β-catenin and N-cadherin, a 
mesenchymal marker, with no trace of E-cadherin, an epithelial marker. WB 
analysis was used to assess changes in abundance of these molecules following 
AZA treatment. As nuclear translocation of β-catenin from the membrane and 
cytoplasm is considered another key indicator of cancer progression, cellular 
fractionation was also used to assess this after treatment with AZA. 
4.4.4.3.1 Detection of changes in abundance of E-, N-cadherin and β-
catenin 
With the treatment of AZA at 10µM for 72 hours, the abundance of N-cadherin 
was reduced by of 65% (p<0.05) with no observed changes in E-cadherin 
(Figure 47-A & B). No visible or statistically significant change in the 
abundance of β-catenin was found (Figure 47-C & D). 
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Figure 47: effect of AZA on EMT markers in T24 cells 
T24 cells were seeded in 6-well plates at a density of 0.05x106 cells/well in GM for 24 hours 
and serum starved with SFM for another 24 hours. Then cells were separated according to 
different treatments (“CT”: untreated cells as a control group; “AZA”: cells treated with AZA at 
the concentration of 10µM for 72 hours). After 72 hours of treatment, cells were harvested to 
investigate the changes in protein abundance using WB analysis. Samples from whole lysates 
were loaded equally at 60µg for protein detection, and GAPDH was assessed as reference 
protein. 
The blots present the levels of E- and N-cadherin (A) and β-catenin (C) under different 
treatments. And the graphs (B) and (D) demonstrate the mean of fold change of the optical 
density measurements of N-cadherin and β-catenin, respectively, from three experiments 
each performed at least in triplicate, and error bars represent the standard error of the mean 
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4.4.4.3.2 Detection of a change in localisation of β-catenin 
No prominent nuclear translocation of β-catenin was observed following AZA 
treatment (Figure 48-A), and no significant difference in the fold change of 
cytoplasmic β-catenin normalised to this protein in total cell lysates was found 
between control and AZA-treated cells by densitometry analysis (Figure 48-B). 
 
Figure 48: effect of AZA on nuclear translocation of β-catenin in T24 cells using 
cellular fractionation 
T24 cells were seeded in 6-well plates at a density of 0.05x106 cells/well in GM for 24 hours 
and serum starved with SFM for another 24 hours. Then cells were labelled according to 
different treatments (“CT”: untreated cells as a control group; “AZA”: cells treated with AZA at 
the concentration of 10µM for 72 hours). After 72 hours of treatment, cells were harvested to 
investigate the change in the localisation of β-catenin using cellular fractionation. Separate 
proteins were obtained and loaded equally for protein detection using WB. All blots 
demonstrate typical results from three experiments each performed at least in triplicate (n=3). 
(A): The blot shows the localisation of β-catenin in the presence or absence of AZA treatment 
in T24 cells using cellular fractionation. Lamin and Tubulin exist only in nuclei and cytoplasm, 
respectively, and they are an indicator of the efficiency of protein separation. “T”: total cell 
lysates; “C”: cytoplasmic extract; “N”: nuclear extract. (B): The graph presents the fold change 
of cytoplasmic β-catenin normalised to total β-catenin in the total cell lysates with error bars 
representing the standard error of the mean of experiments (n=3). “NS*”: not significant. 
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4.4.5 Investigation of the mechanism of IGFBP-2 using NBI-
31772 
To examine the working mechanism of IGFBP-2 in bladder cancer, IGF-
dependent or -independent, or even both, NBI-31772 was used as an IGFBP-2 
inhibitor with RT4 and T24 cells by binding to six IGFBPs non-specifically and 
to IGFBP-2 with high affinity. Meanwhile, since using NBI-31772 could also 
elevate the level of bioactive IGF-I by displacing it from IGF-I:IGFBP complexes, 
exogenous recombinant human IGF-I was also used in the investigation. 
Alterations in cell proliferation and invasion were assessed. 
4.4.5.1 Assessment of the working mechanism of IGFBP-2 in RT4 cells 
In IGFBP-2-abundant epithelial-like RT4 cells, NBI-31772 was applied with or 
without IGFBP-2 siRNA transfection. 
As shown in Figure 49, pre-treatment with NBI-31772 alone led to a significant 
increase in cell growth (21.7% in non-silenced cells between “NS” and 
“NS+NBI”, p<0.05; see Figure 49-B), suggesting that IGFs had been released 
from IGFBPs, predominantly IGFBP-2 as this is the main one secreted by these 
cells, and was able to increase cell growth. This indicates that IGFBPs, 
predominantly IGFBP-2, acts at least partly by sequestering IGFs since when 
IGFs are displaced from the IGFBPs this stimulates cell growth and silencing 
IGFBP-2, when it can no longer sequester IGFs also results in cell growth. 
Silencing IGFBP-2, as we observed previously, caused an increase in cell 
growth ( by 40.9% in “NS” and “KD”, p<0.01; Figure 49-B).  In the presence of 
NBI-31772, silencing IGFBP-2 still induced a comparable increase in cell 
growth (36.7% in NBI-pre-treatment group between “NS+NBI” and “KD+NBI”, 
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p<0.001; see Figure 49-B) which was additive to the effects of NBI-31772 
alone on cell growth (66.3% between “NS” and “KD+NBI”, p<0.001; see Figure 
49-B). In the presence of NBI-31772, when any interaction of IGFBP-2 with 
IGFs is prevented, the observation that silencing IGFBP-2 still results in cell 
growth indicates that the presence of IGFBP-2 can inhibit cell growth 
independent of any interaction with IGFs. In combination these results suggest 
that the effects of IGFBP-2 on these cells are both IGF-dependent and -
independent. 
No significant changes in cell death were found under different treatments 
(Figure 49-C). 
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Figure 49: effect of NBI-31772 and IGFBP-2 siRNA transfection on cell 
proliferation in RT4 cells 
RT4 cells were seeded into 6-well plates at a density of 0.1x106 cells/well in GM for 24 hours. 
After 24 hours of serum starvation in SFM, cells were then dosed with scramble or IGFBP-2 
siRNA (both at a concentration of 30nM for 72 hours) with or without 1 hour of pre-treatment 
of NBI-31772 at 1µM. “NS”: non-silencing scramble siRNA only treated samples; “KD”: IGFBP-
2 siRNA treated samples; “NS+NBI”: scramble siRNA treated samples with 1 hour of NBI-
31772 pre-treatment; “IGFBP-2+NBI”: IGFBP-2 siRNA treated samples with 1 hour of NBI-
31772 pre-treatment. 
(A): WB blot shows the efficiency of IGFBP-2 knockdown achieved by loading the supernatant 
collected under each treatment equally at 25µl; (B) & (C): Graphs represent the change in the 
counting of total cell numbers and the percentage cell death following different treatments in 
RT4 cells, respectively. The graphs show the mean of three experiments each performed at 
least in triplicate, and error bars represent the standard error of the mean of the experiments 
(n=3). “NS*”: not significant. 
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Similarly, regarding cell invasion, as shown in Figure 50, a significant increase 
was observed with pre-treatment of NBI-31772 alone (17.3% in non-silenced 
cells between “NS” and “NS+NBI”, p<0.05; see Figure 50-B), which confirmed 
the enhancing effect of released free IGF on cell invasion, similar to the effect 
observed on cell growth. Silencing IGFBP-2 alone increased cell invasion (by 
33.1% in “NS” and “KD”, p<0.01; see Figure 50-B.  In the presence of NBI-31772, 
silencing IGFBP-2 still induced a comparable increase in invasion which was 
additive to the effects of NB1 alone on cell invasion growth (56.9% in “NS” and 
“KD+NBI”, p<0.01; see Figure 50-B), suggesting again both IGF-dependent and 
-independent effects of IGFBP-2 on invasion in RT4 cells. 
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Figure 50: effect of NBI-31772 and IGFBP-2 siRNA transfection on cell invasion 
in RT4 cells 
Cells were initially seeded into 6-well plates at a density of 0.1x106 cells/well in GM for 24 
hours. After 24 hours of serum starvation in SFM, cells were then transfected with non-
silencing scramble or IGFBP-2 siRNA (both at 30nM for 72 hours) with or without 1 hour of 
pre-treatment of NBI-31772 at 1µM. And then cells were trypsinised and then seeded in the 
collagen-coated inserts at a density of 0.1x106 cells/insert and allowed to invade for 24 hours. 
The supernatant was taken before cell trypsinisation to assess levels of IGFBP-2 to determine 
the efficiency of IGFBP-2 silencing. “NS”: non-silencing scramble siRNA only treated samples; 
“KD”: IGFBP-2 siRNA treated samples; “NS+NBI”: scramble siRNA treated samples with 1 hour 
of NBI-31772 pre-treatment at 1µM; “IGFBP-2+NBI”: IGFBP-2 siRNA treated samples with 1 
hour of NBI-31772 pre-treatment at 1µM. 
(A): WB blot shows the efficiency of IGFBP-2 knockdown achieved by loading the supernatant 
collected under each treatment equally at 25µl; (B): The graph shows the change of average 
invaded RT4 cells under different treatments; the graph represents the mean of three 
experiments each performed at least in triplicate, and error bars represent the standard error 
of the mean of the experiments (n=3); (C): The images show transwell invaded cells with 
nuclei (in blue) stained by DAPI; all images shown are at x10 magnification;  
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4.4.5.2 Assessment of the working mechanism of IGFBP-2 in T24 cells 
4.4.5.2.1 Optimisation of an effective dose of IGF-I 
TTI assay was used in T24 cells to assess cell proliferation following the 
exogenous addition of IGF-I (0-200ng/ml) for 24 hours. 
As shown in Figure 51, an increase in cell proliferation was observed with 
increasing concentration of IGF-I: the maximal increase was found to be at 
50ng/ml (by 105%, p<0.01). Therefore, this dose was chosen as an effective 
concentration to act as a control for further experiments. 
 
Figure 51: proliferative response to exogenous IGF-I in T24 bladder cancer cells 
T24 cells were seeded at a density of 0.02x106 cells/well into 24-well plates in GM to grow for 
24 hours followed by serum starvation for another 24 hours. Then TTI was performed to show 
the proliferative response to exogenous IGF-I in T24 cells at 0-200 ng/ml for 24 hours. The 
graph shows the means of three experiments each performed in quadruplicate, and error bars 
represent the standard error of the mean of the experiments (n=3). “**”: p<0.01. The bar in 
the darker colour represents the chosen effective concentration for further experiments. 
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4.4.5.2.2 Alterations in cell proliferation and invasion induced by NBI-
31772 and IGFBP-2 
As shown in Figure 52-A, compared with control cells (“CT”), exogenously 
added IGF-I induced a significant increase in total cell number (28.6%, p<0.001) 
while NBI-31772 did not (unnoticeable difference with non-significant p-
value), suggesting that no IGF was released from any IGFBPs present. 
Exogenous IGFBP-2 led to a decrease in cell growth compared with control 
cells (35.3%, p<0.001), and this effect was negated in the presence of NBI-
31772, suggesting that exogenously added IGFBP-2 reduces cell growth 
through sequestering endogenous IGFs and can no longer do this in the 
presence of NBI-31772: this implies an IGF-dependent action of the 
exogenously added IGFBP-2. 
No significant changes in percentage cell death were observed among cells 
under different treatments (Figure 52-B). 
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Figure 52: effect of IGF-I, exogenous IGFBP-2 and NBI-31772 on cell 
proliferation in T24 cells 
T24 cells were seeded into 6-well plates at a density of 0.05x106 cells/well in GM for 24 hours. 
After 24 hours of serum starvation in SFM, cells were then dosed with IGF-I (at 50ng/ml) or 
IGFBP-2 (at 600ng/ml) for 24 hours with or without 1 hour of pre-treatment of NBI-31772 at 
a concentration of 1µM. “CT”: control cells without treatment; “IGF-I”: cells treated with IGF-I 
only at a concentration of 50ng/ml for 24 hours; “NBI”: cells treated with NBI-31772 only at 
1µM for 1 hour; “IGFBP-2”: cells treated with IGFBP-2 only at a concentration of 600ng/ml for 
24 hours; “NBI + IGFBP-2”: cells dosed with 1 hour of pre-treatment of NBI-31772 followed by 
the treatment of IGFBP-2 at a concentration of 600ng/ml for 24 hours). 
 (A) & (B): Graphs represent the change in the counting of total cell numbers and the 
percentage cell death following different treatments in T24 cells, respectively. The graphs 
show the mean of three experiments each performed at least in triplicate, and error bars 
represent the standard error of the mean of the experiments (n=3). “NS*”: not significant. 
 
Regarding cell invasion, as shown in Figure 53-A, similar to data observed for 
cell proliferation, IGF-I induced a significant increase compared with control 
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cells (45.5%, p<0.001) while NBI-31772 did not (unnoticeable difference with 
non-significant p-value). 
Exogenous IGFBP-2 treatment (“IGFBP-2”) led to a decrease in cell invasion 
compared with control cells (35%, p<0.001), and this was unaffected by the 
presence of NBI-31772 (“NBI+IGFBP-2”) suggesting that IGFBP-2 effects on 
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Figure 53: effect of IGF-I, exogenous IGFBP-2 and NBI-31772 on cell invasion in 
T24 cells 
Cells were previously seeded into 6-well plates at a density of 0.05x106 cells/well in GM for 24 
hours and then changed to SFM for 16 hours before being prepared for an invasion assay. After 
serum-starvation, cells were dosed with or without 1 hour of pre-treatment of NBI-31772 at 
1 µM, and then trypsinised and seeded into the collagen-coated inserts at a density of 0.08x106 
cells/insert and allowed to migrate for 18 hours. Cells were labelled according to different 
treatments while seeding (“CT”: control cells without treatment; “IGF-I”: cells treated with 
IGF-I only at a concentration of 50ng/ml for 18 hours; “NBI”: cells treated with 1 hour of NBI-
31772 at 1µM followed by no other treatment; “IGFBP-2”: cells treated with IGFBP-2 only at a 
concentration of 600ng/ml for 18 hours; “NBI + IGFBP-2”: cells dosed with 1 hour of pre-
treatment of NBI-31772 followed by the treatment of IGFBP-2 at a concentration of 600ng/ml 
for 18 hours). 
(A): The graph shows the change of average invaded T24 cells under different treatments; the 
graph represents the mean of three experiments each performed at least in triplicate, and 
error bars represent the standard error of the mean of the experiments (n=3); (B): The images 
show transwell invaded T24 cells with nuclei (in blue) stained by DAPI; all images shown are 
at x10 magnification. 
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4.5 Discussion 
We observed in the previous chapter that IGFBP-2 plays an inhibitory role in 
the ability of bladder cancer cells to proliferate, invade, migrate and form 
colonies. In addition, its levels were altered depending on the aggressiveness 
of the cells, being abundant in the less advanced and absent in the most 
aggressive cells. Dysregulation of IGFBPs as a result of epigenetic 
modifications has been identified in many tumours, such as aberrant DNA 
methylation of the promoter of IGFBP-2 and  IGFBP-3 genes in hepatomas and 
breast cancers respectively (Chiba, Yokosuka et al. 2005) (Zeng, Jarrett et al. 
2013).  We next investigated if altered methylation may be the mechanism by 
which IGFBP-2 levels were being regulated in bladder cancer cells. 
The mesenchymal-like IGFBP-2-negative cell lines, T24 and TCCSUP, were 
exposed to AZA, a commonly used demethylating agent: re-expression of 
IGFBP-2 was observed in both cell lines, and the increase in abundance of 
IGFBP-2 was more significant in T24 cells. In addition to enabling the re-
expression of IGFBP-2, treatment with AZA also led to similar phenotypic 
changes that were observed on addition of exogenous IGFBP-2: with T24 cells, 
a reduction in abundance of the mesenchymal marker (N-cadherin), 
significant decreases in cell proliferation, colony formation together with an 
increase in cell death. With TCCSUP cells, however, only a reduction in colony 
formation was noted with no notable change in cell growth or death, which 
indicates the heterogeneity among cell lines with similar phenotypes. To build 
a clearer picture, future work should assess other phenotypic changes (such 
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as cell invasion and migration and changes in EMT-related molecules) affected 
by AZA in T24 and TCCSUP cells and additional bladder cancer cell lines.  
The application of COBRA confirmed that this increase in AZA-induced IGFBP-
2 was specifically due to changes in the methylation status of the promoter 
region of IGFBP-2 gene in the T24 cells. In TCCSUP cells, as the increase in 
demethylation in response to AZA was small, we suggest that other epigenetic 
changes such as histone modification, which has been reported in prostate 
cancer (Biernacka, Uzoh et al. 2013), might also contribute to the loss of IGFBP-
2 which requires further investigation. 
Based on the reversible nature of epigenetic modifications, compared with 
genetic mutations, these findings suggest IGFBP-2 is switched off in advanced 
bladder cancer which eliminates the inhibitory effects of this protein on cell 
proliferation, invasion, migration as well as colony formation in cancer 
development. Moreover, IGFBP-2 is considered as a potentially key mediator 
of the anti-tumorigenic effects of AZA on bladder cancer cells. This may 
provide the possibility of epigenetic-target cancer therapies for certain 
bladder cancer subtypes by aiming for the reversal of the phenotypes (Singh, 
Treas et al. 2012, Knowles and Hurst 2015). 
As it has been reported that IGFBP-2 can act in either an IGF-dependent or -
independent or both manners, NBI-31772, as an inhibitor of IGF/IGFBP-2 
interactions, was used to study how it works in bladder cancer. 
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Stimulatory effects of pre-treatment with NBI-31772 alone on both cell growth 
and invasion of RT4 cells indicated that NBI-31772 freed endogenous IGFs 
from IGF:IGFBP complexes, mainly IGF:IGFBP-2, to act on the cells to promote 
growth and invasion alone.  This suggested that endogenous IGFBP-2 was 
acting in an inhibitory manner in part through interactions with IGFs. 
Silencing IGFBP-2 in RT4 cells also exerted promoting effects on both cell 
growth and invasion, and this stimulatory effect the same percentage change 
in the presence or absence of NBI-31772, but the percentage change was 
additive to the effects of NBI-31772 lone, which suggested that IGFBP-2 has 
the ability to act in both an IGF-dependent and -independent manner in 
epithelial-like bladder cancers. 
In IGFBP-2-null mesenchymal-like T24 cells, compared with the increase in 
cell growth and invasion following the addition of exogenous IGF-I, no notable 
difference was found when cells were treated with NBI-31772 alone, which 
indicated little endogenous IGFs were released from IGF:IGFBP complexes in 
these cells. 
Exogenously added recombinant IGFBP-2 led to a significant reduction both in 
cell growth and invasion of T24 cells. The inhibitory effect on growth was 
inhibited by the addition of NBI-31772. This suggested exogenous IGFBP-2 
inhibited cell growth by sequestering endogenous IGFs and was no longer able 
to do this in the presence of NBI-31772, which implied an IGF-dependent 
action of the exogenously added IGFBP-2 on T24 cell proliferation which has 
been reported in colon cancer (Hoflich, Lahm et al. 1998). However, the 
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inhibitory effect of IGFBP-2 on cell invasion was not affected by adding NBI-
31772, thus indicating that IGFBP-2 acted in an IGF-independent manner to 
inhibit invasion of T24 cells. 
In summary, the results of the present study suggest that hypermethylation of 
the promoter region of the IGFBP-2 gene plays an important part in the loss of 
IGFBP-2 in progressive mesenchymal bladder cancers, which raises the 
possibility of epigenetic-target anti-cancer therapies for aggressive bladder 
cancers. 
IGFBP-2 acts in both IGF-dependent and -independent ways in bladder cancers 
despite the cancer phenotypes. In the presence of IGFs, IGFBP-2 reduces the 
effects of IGFs by sequestering free bioactive IGFs into inactive IGF:IGFBP-2 
complexes (Liu, Xie et al. 2001), and the intrinsic effects have been 
demonstrated in many cancers by binding, via their RGD sequence, to integrin 
receptors, similar to that reported in prostate (Uzoh, Holly et al. 2011). Thus 
more work to unravel the molecular basis is required. The IGFs are widespread 
regulators of most cell functions; their interactions with IGFBPs can reduce the 
clearance of IGFs, sequester IGFs in the extracellular matrix or on cell surfaces, 
via interactions with proteoglycans, and hence enhance targeting of the IGFs 
to specific sites of action and also constrain receptor binding by competition. 
In addition they can also have intrinsic actions for example through binding to 
integrin receptors. The different effects of IGFBPs depend on interactions with 
extracellular matrix, cell surfaces and extracellular proteases; all of which can 
vary in a tissue specific manner and therefore confer specificity, depending on 
context, to the multiple potential IGF actions (Holly and Perks 2012). 
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5.1 Introduction 
Results from Chapter 4 showed that exogenous IGF-I promoted cell growth 
and migration of the T24 cell line. In addition, that some of the effects of IGFBP-
2 in bladder cancer cell lines were at least in part mediated via an interaction 
with IGFs. 
5.1.1 IGF axis 
The IGF axis is a multifactorial system consisting of three ligands (IGF-I, IGF-II 
and insulin) and their receptors including the IGF-I receptor (IGF-IR), IGF-II 
receptor (IGF-IIR) and the insulin receptor (IR) (Foulstone, Prince et al. 2005, 
Samani, Yakar et al. 2007). 
IGFs and insulin can bind to each other’s receptors, though the binding affinity 
is much weaker than that of the preferred ligand (Zha and Lackner 2010). 
Compared with IGF-II, IGF-I has a higher affinity for the IGF-IR (Yu and Rohan 
2000). Meanwhile, in contrast with the IGF-IIR which mainly regulates levels 
of extracellular IGF-II through receptor-mediated endocytosis, the IGF-IR is 
structurally and functionally homologous to the IR and it has been found to 
play an important role in mediating signalling upon IGF-I binding, activating 
phosphatidylinositol 3-kinase (PI3K) (Baselga 2011) and mitogen-activated 
protein kinase (MAPK) pathways (Hermanto, Zong et al. 2000) which lead to 
activation of downstream substrates. 
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5.1.2 IGF-I and cancer 
As a critical regulator of many physiological processes such as cell 
proliferation and differentiation (Stewart and Rotwein 1996), the IGF axis is 
dysregulated in many different cancers exhibiting associations with increased 
risk of cancer formation and development. For example, high levels of 
circulating IGF-I are associated with an increased risk of certain types of 
cancers such as breast (Endogenous, Breast Cancer Collaborative et al. 2010), 
colorectal (Rinaldi, Cleveland et al. 2010) and prostate (Roddam, Allen et al. 
2008). Moreover, accumulating evidence has suggested that IGF-I induces 
EMT, which is involved in the progression of many cancers such as breast 
(Walsh and Damjanovski 2011, Liao, Wang et al. 2014). 
As there is very limited literature regarding the role of IGF-I in bladder cancer, 
I examined potential actions of IGF-I in bladder cancer cell lines, based on the 
increasing evidence indicating a role for IGF-I in other cancers and the results 
of previous chapters in my study suggesting its involvement. 
5.2 Aims 
In chapters 3 & 4 it was determined that RT4 cells contain high levels of IGFBP-
2 compared with T24 cells and that the role of IGFBP-2 in these cell lines was 
both dependent and independent of IGF-I. To understand these data further, 
the effects of exogenously added IGF-I to these cells were examined. 
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o To assess the effect of IGF-I on phenotypic changes in bladder 
cancer cells including cell growth, invasion, migration, and 
colony formation. 
o To assess which IGF signalling pathways (by PI3K/MAPK) may 
be involved in mediating the actions of IGF-I on cell phenotypes. 
o To investigate whether IGF-I induces EMT in bladder cancer cell 
lines. 
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5.3 Materials and methods 
5.3.1 Cell culture 
Two human urinary bladder cancer cell lines including RT4 and T24 were used 
in this study. They were obtained and cultured as described in section 2.1. 
5.3.2 Characterisation and optimisation of the antibodies for 
the assessment of EMT-related molecules 
Changes in the levels as well as localisation of ZEB-1, FOXO3a, FOXA1, and 14-
3-3 β in response to IGF-I were investigated in this study. Since the antibodies 
for these four molecules were new to our laboratory, characterisation and 
optimisation using Western blotting (WB, as described in section 2.3) were 
performed initially in RT4 and T24 cell lines by changing the solvent and/or 
the concentration of the antibody solutions, respectively. GAPDH and tubulin 
were used as loading controls in WB analyses. 
Product details and the conditions optimised for the EMT-related molecules 
used in this chapter are summarised in Table 26, and details of the reference 
proteins (GAPDH and tubulin) used as a loading control are shown in Table 2 
in section 3.3.2. 
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*2˚ Ab: ZEB-1 & FOXO3a: anti-rabbit (Sigma, #A0545); FOXA1: anti-mouse (Sigma, #A0944); 
14-3-3 β: anti-goat (Sigma, #A5420). 
 
5.3.3 Antibody solutions for assessment of IGF signalling 
pathways involved in the study 
IGF signalling pathways involved in mediating actions of IGF-I on bladder 
cancer cells were assessed in this study. The molecules potentially 
participating in the signalling activities have been identified in our laboratory, 
and the information of the antibody solutions is listed below in Table 27. 
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Table 27: antibody solutions information of IGF signalling pathway related 
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5% milk,  
anti-rabbit 
*2˚ Ab: anti-rabbit (Sigma, #A0545). 
 
5.3.4 Detection of protein abundance 
Levels of target proteins in whole cell lysates were determined by performing 
WB analyses as described in section 2.3. Tubulin and GAPDH were used as 
loading controls, and the information of antibody solutions are summarised in 
Table 26 above and Table 2 in section 3.3.2. 
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5.3.5 Detection of protein localisation 
Cellular fractionation was performed as described in section 2.4 to examine 
the localisation of target proteins including β-catenin, FOXO3a, FOXA1, and 14-
3-3 β. 
Proteins of cytoplasmic and nuclear extracts from cultured cells were 
separated using cellular fractionation. Lamin and tubulin exist only in nuclei 
and cytoplasm, respectively, and they were therefore used as indicators of the 
efficiency of protein separation from each fraction. The abundance of 
separated proteins was detected by WB as described in 5.3.3. The information 
of antibody solutions of Lamin is listed in Table 24 in 3.3.4 and the information 
of target proteins and tubulin can be found in Table 26 and Table 23 in section 
3.3.2, respectively. 
5.3.6 Cell treatment 
5.3.6.1 Recombinant human IGF-I 
Recombinant human IGF-I (Gropep; receptor grade, #CM001) was made up to 
a 1000µg/ml stock solution following product instructions, aliquoted and 
stored at -20°C. A 10µg/ml working stock was made fresh by adding 3µl of 
stock solution to 297µl of SFM that was diluted further with SFM to achieve 
final concentrations. 
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5.3.6.2 AG1024 
AG1024 (Santa Cruz, sc-205907) is a selective tyrosine kinase inhibitor (TKI) 
which inhibits IGF-IR signalling through interfering with its auto-
phosphorylation (Kisielewska, Ligeza et al. 2008).  
The concentration of stock AG1024 when purchased was 3267.8µM. The stock 
solution was aliquoted and stored at -20°C. A 200µM working stock was made 
fresh by adding 18.36µl of stock solution to 281.64µl of SFM which was diluted 
further with SFM to achieve final concentrations. 
5.3.6.3 LY294002 
2-(4-morpholinyl)-8-phenyl-chromone (LY294002; Millipore, #440204) is a 
specific signal transduction molecule inhibitor of PI3K (Zhu, Qi et al. 2011). 
10,000µM of LY stock solution was made up by dissolving 1mg LY294002 in 
325µl DMSO following the instructions. The stock solution was aliquoted and 
stored at -20°C. The LY stock solution was then made fresh by adding 3µl of 
stock solution to 297µl of SFM to make a 50µM final concentration and cells 
were pre-treated with LY for 30 minutes before treatment with other reagents. 
5.3.7 Cell proliferation 
A TTI assay was used to measure DNA synthesis, and Trypan Blue Dye 
Exclusion assay was performed for cell counting to examine both live and dead 
cells, from which the percentage cell death could be calculated as described in 
section 2.2. 
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5.3.8 Cell migration 
A cell migration assay was performed as described in section 2.9 to measure 
differences in cell migration rates in response to relevant treatments. 
5.3.9 Cell invasion 
A cell invasion assay was used as described in section 2.10 to investigate the 
differences in cell movement through the extracellular matrix (ECM) under 
different treatments in vitro. 
5.3.10 Cell colony formation 
A soft agar colony formation assay was used with both RT4 and T24 cells as 
described in section 2.8 to assess the change in malignant cell transformation 
in response to IGF-I treatment. 
5.3.11 Statistical analysis 
Data were expressed as mean ± SEM and analysed with SPSS 23 for Windows 
using one-way analysis of variance (ANOVA) followed by least significant 
difference (LSD) post-hoc test and Student’s test. A two-sided p-value was 
shown for statistical significance and is depicted as asterisks; a single one for 
*p<0.05 and a double for **p<0.01. 
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5.4 Results 
5.4.1 Phenotypic changes observed in bladder cancer cells 
following IGF-I treatment 
RT4 and T24 cells were used to investigate the effects of IGF-I on bladder 
cancer cell proliferation, invasion, migration and colony formation. 
5.4.1.1 Optimisation of an effective dose of IGF-I in RT4 cells 
A dose-response to IGF-I (0-200 ng/ml) was performed previously for T24 
cells, and changes in cell proliferation were assessed using a TTI assay 
(described in 4.4.5.2.1). And this indicated that 50ng/ml IGF-I was an effective 
dose. The same experiment was performed in RT4 cells to assess cell 
proliferation following the exogenous addition of IGF-I (0-200 ng/ml) for 24 
hours. 
As shown in Figure 54, an increase in cell proliferation was observed with 
increasing concentrations of IGF-I, and the maximal increase was found to be 
at 50ng/ml (by 27%, p<0.01). Therefore, this dose was chosen as an effective 
concentration for further experiments. 
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Figure 54: proliferative response to exogenous IGF-I in RT4 bladder cancer cells 
RT4 cells were seeded at a density of 0.03x106 cells/well in 24-well plates in GM and 
allowed to attach and grow for 24 hours followed by serum starvation for another 24 hours. 
Then TTI was performed to assess the proliferative response to exogenous IGF-I in RT4 cells 
at 0-200 ng/ml for 24 hours. The graph shows the means of three experiments each performed 
in quadruplicate, and error bars represent the standard error of the mean of the experiments 
(n=3). “**”: p<0.01. The bar in the darker colour represents the chosen effective concentration 
for further experiments. 
 
5.4.1.2 Effect of adding exogenous IGF-I on cell growth in RT4 and T24 
cells 
Based on the effective dose of IGF-I determined previously (in 4.4.5.2.1 and 
above in 5.4.1.1), dosing of exogenous IGF-I was conducted in both RT4 and 
T24 cells at the concentration of 50ng/ml for 48 hours to assess changes in 
total cell number by performing cell counting. 
In RT4 cells, no significant changes were found between control and IGF-I-
treated cells either in total or live cell number (Figure 55-A) or the percentage 
of cell death (Figure 55-B).  
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However, compared to untreated cells, IGF-I-treated T24 cells showed a 
significant increase both in total cell number (by 20.8%, p<0.05) and in live 
cell number (by 19.5%, p<0.05) (Figure 55-C). No significant change in 
percentage cell death was observed between control and treated cells (Figure 
55-D). 
 
Figure 55: effect of dosing exogenous IGF-I on cell growth in RT4 and T24 cells 
RT4 and T24 cells were seeded into 6-well plates in GM at a density of 0.1x106 cells/well and 
0.05x106/well, respectively. After 24 hours of serum starvation, cells were labelled according 
to different treatments (“CT” for control group without any treatment and “IGF-I” for IGF-I 
treated cells at a concentration of 50ng/ml for 48 hours).  
(A) & (C): Graphs show the cell counting of both live and total cell numbers under different 
treatments in RT4 and T24 cells, respectively. (B) & (D): Graphs represent the change in the 
percentage of cell death due to different treatments in RT4 and T24, respectively. The graphs 
present the mean of three experiments each performed at least in triplicate, and error bars 
represent the standard error of the mean of the experiments (n=3). “NS*”: not significant. 
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5.4.1.3 Effect of adding exogenous IGF-I on cell invasion of RT4 and T24 
cells 
An invasion assay was conducted to assess the effect of adding IGF-I on the 
ability of RT4 and T24 cells to invade. 
With the treatment of IGF-I, both RT4 and T24 cells exhibited an increase in 
the numbers of invaded cells compared with control cells (Figure 56-A for RT4 
and Figure 56-C for T24 cells), and the increase was significant in both RT4 (by 
46.9% in Figure 56-B) and T24 (by 111.6% in Figure 56-D) cells. 
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Figure 56: effect of adding exogenous IGF-I on cell invasion of RT4 and T24 cells 
Both cell lines were previously seeded in GM for 24 hours and then changed to SFM for 16 
hours before being prepared for an invasion assay. After serum-starvation, both RT4 and T24 
cells were trypsinised and then seeded into the collagen-coated inserts at a certain density 
(RT4: 0.1x106 cells/insert and T24: 0.08x106 cells/insert) and allowed to invade (RT4: 24 
hours and T24: 18 hours). Cells were labelled according to different treatments while seeding 
(“CT” for control cells without treatment, and “IGF-I” for cells treated with IGF-I at the 
concentration of 50ng/ml). 
(A) & (C): The images show invaded RT4 and T24 cells, respectively, with nuclei (in blue) 
stained with DAPI. All images shown are at x10 magnification. (B) & (D) The graphs show the 
fold change of invaded RT4 and T24 cells, respectively, between exogenous IGF-I treatment 
group and control group. The graphs represent the mean of three experiments each performed 
in triplicate, upon which the standard error of the mean of the experiments was presented 
(n=3). 
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5.4.1.4 Effect of adding exogenous IGF-I on cell migration in RT4 and T24 
cells 
A migration assay was performed to examine the effect of IGF-I on cell 
migration in RT4 and T24 cells. 
As characterised in the previous chapter (see 3.4.3.4 in chapter 3), RT4 cells 
did not migrate with or without IGFBP-2. With the treatment of IGF-I, still, no 
cell migration was observed compared to the control cells (see Figure 57). 
 
Figure 57: effect of adding exogenous IGF-I on cell migration in RT4 cells 
RT4 cells were seeded at a density of 0.049x106 cells into each chamber in GM and allowed to 
grow for approximately 24 hours to reach about 80% confluence. Cells reached 90-95% 
confluence during an additional 24 hours in SFM. The inserts were removed leaving an 
observed gap, and gap closure was recorded for up to 48 hours with different treatment (“CT”: 
untreated cells as a control group; “IGF-I”: cells treated with IGF-I at the concentration of 
50ng/ml). 
Images of cell gaps were taken at different times with relative labels. “0hr”: the start point after 
the removal of inserts; “48hrs”: 48 hours after the removal of inserts. All images demonstrate 
the typical results from three experiments each performed in duplicate (n=3). All images 
shown are at x10 magnification, and the area of the gaps in the images was analysed using 
ImageJ software. 
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In T24 cells, cells treated with IGF-I moved faster than the control group with 
the gap being significantly reduced at the sixth (p<0.001), ninth (p<0.01) and 
twelfth (p<0.001) hour (Figure 58-A & B). 
 
 
Figure 58: effect of adding exogenous IGF-I on cell migration in T24 cells 
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T24 cells were seeded at a density of 0.028x106 cells into each chamber in GM and allowed to 
grow for approximately 24 hours to reach about 80% confluence. Cell reached 90-95% 
confluence during an additional 24 hours in SFM. The inserts were removed leaving an 
observed gap, and gap closure was recorded for up to 12 hours with different treatment (“CT”: 
untreated cells as a control group; “IGF-I”: cells treated with IGF-I at the concentration of 
50ng/ml). 
Images of cell gaps were taken at different times with relative labels. “0hr”: the start point after 
the removal of inserts; “3hr”, “4hr”, “6hr”, “9hr” and “12hr”: 3, 4, 6, 9 and 12 hours after the 
removal of inserts. All images demonstrate the typical results from three experiments each 
performed in duplicate (n=3). All images shown are at x10 magnification, and the area of the 
gaps in the images was analysed using ImageJ software. 
(A) shows the images of the gaps between cell patches of T24 cells with different treatments 
at the start point (“0hr”), 4 hours (“4hrs”), and 12 hours (“12hrs”) after the removal of inserts. 
The red dashed lines present the outline of migrating T24 cells moving together. (B) shows 
the fold change of gap area per insert normalised to control with exogenous IGF-I treatment 
in T24 cells. The graph represents the mean of three experiments each performed in duplicate, 
with the standard error of the mean of the experiments (n=3). “NS*”: not significant. 
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5.4.1.5 Effect of adding exogenous IGF-I on cell colony formation in RT4 
and T24 cells 
A soft agar colony formation assay was conducted to assess the effect of IGF-I 
on the ability of RT4 and T24 cells to form colonies in soft agar. 
Visually, compared with control groups, both RT4 (Figure 58-A) and T24 
(Figure 58-D) cells formed more and larger colonies with the treatment of IGF-
I. 
Statistically, the average size of each colony formed was significantly increased 
in IGF-I-treated cells in both cell lines with the fold change in IGF-I-treated RT4 
and T24 cells being 1.31 (p<0.05) (Figure 58-C) and 1.13 (p<0.05) (Figure 58-
F), respectively, compared with the control cells. As to colony forming 
efficiency (CFE), a significant induction of 59.4% (p<0.01) (Figure 58-E) was 
found in IGF-I-treated T24 cells compared with control cells. However, no 
significant change was found in RT4 cells (Figure 58-B).  
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Figure 59: effect of adding exogenous IGF-I on formation of colonies by RT4 and 
T24 cells in soft agar 
Both RT4 and T24 cells were seeded in dishes under different treatments with corresponding 
labels (“CT”: untreated cells as a control group; “IGF-I”: cells treated with IGF-I at the 
concentration of 50ng/ml 48 hours before seeding). Cells were seeded at an even density at 
10,000 cells/dish and 5,000 cells/dish, respectively, and fed once a week for four weeks in 
total, and then colony numbers, as well as average size, were measured by ImageJ software.  
(A) & (D): Images show RT4 and T24cells, respectively, were set up into dishes with even 
densities at the first day (“Day 1”), and colonies were stained at the end of the assay (“Day 28”). 
All images shown are at x10 magnification; (B) & (E): Graphs present the change of colony 
count per dish under different treatments for RT4 and T24 cells, respectively. (C) & (F): Graphs 
demonstrate the fold change of average size of colonies due to different treatments for RT4 
and T24 cells, respectively. All graphs present the mean of three experiments each performed 
in triplicate, and error bars represent the standard error of the mean from three experiments 
(n=3). 
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5.4.2 Assessment of the IGF signalling pathway involved in 
mediating the actions of IGF-I on cell phenotype in 
bladder cancer cells 
Assessment of activation, as well as specific inhibition, of IGF/PI3K/Akt and 
IGF/MAPK/ERK signalling pathways, was carried out to investigate how IGF-I 
induced phenotypic changes in bladder cancer. 
5.4.2.1 Characterisation of IGF/PI3K/Akt and IGF/MAPK/ERK signalling 
pathways 
I characterised the basal abundance of IGF-IR and IR in both RT4 and T24 cells 
and treated both cell lines with exogenous IGF-I for 5, 10, and 30 minutes, 
respectively, to assess IGF-IR activation by monitoring phosphorylation of the 
IGF-IR, of Akt and MAPK - key downstream molecules of the IGF-IR. 
Both the IGF-IR and IR were expressed in both bladder cancer cell lines being 
more abundant in RT4 than that in theT24 cells (see Figure 60). 
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Figure 60: characterisation of the levels of IGF-IR and IR in RT4 and T24 cells 
(A) and (B) show the western blots for IGF-IR and IR, respectively, in both RT4 and T24 cells 
detected using WB. RT4 and T24 cells were seeded in GM at the same density to grow for 24 
hours and then were left in SFM for 48 hours before sample harvest. Proteins in whole lysates 
were loaded with increasing amounts from 25 to 100μg. Proteins from Du145 (a human 
prostate carcinoma cell line) and U251 (a human glioblastoma cell line) cell lysates were used 
as positive controls for IGF-IR and IR, respectively. They were loaded equally at 60μg. Tubulin 
was used as the reference protein. 
 
As shown in Figure 61, in response to IGF-I treatment (up to 30 minutes), 
activation of phosphorylation of the IGF-IR was observed in RT4 cells from 5 
minutes to 30 minutes with the total amount of the IGF-IR being significantly 
decreased at the 30-minute time point. In T24 cells, the activation of the IGF-
IR (p-IGF-IR) was not stimulated until 30 minutes by IGF-I treatment, but the 
total amount of the IGF-IR was decreased from 5 minutes to 30 minutes.  
Both RT4 and T24 cells expressed Akt, and a significant increase in activated 
Akt (p-Akt) activation from 5 to 30 minutes was shown in both cell lines in 
response to IGF-I treatment, with no changes observed in the total amount of 
Akt (see Figure 61). 
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MAPK presents as a double band with p44 (ERK 1) and p42 (ERK 2) which can 
be phosphorylated through activation of loop residues Thr202/Tyr204 and 
Thr185/Tyr187, respectively. ERK 2 was measured in this study to represent 
the total amount of MAPK. As shown in Figure 61, no activation of phospho-
MAPK (p-MAPK) or changes in the levels of ERK 2 was observed in either RT4 
or T24 cells following treatment with IGF-I. 
Therefore, the IGF-IR/PI3K/Akt appears to be a dominant signalling pathway 
associated with the actions of IGF-I on bladder cancer cells, with the 
MAPK/ERK axis not seeming to be playing a role. 
 
Figure 61: analysis of IGF-IR activation in RT4 and T24 cells following treatment 
with IGF-I at 50ng/ml for 5, 10 and 30 minutes, respectively, using WB 
RT4 and T24 cells were seeded in 6-well plates at a density of 0.1 and 0.05x106 cells/well, 
respectively, in GM for 24 hours and serum starved with SFM for another 24 hours. Then cells 
were separated according to different treatments (“0’”: untreated cells harvested at the 
beginning of the experiment as a control group; “CT1”, “CT2” and “CT3”: untreated cells 
harvested along with IGF-I-treated cells for 5, 10, and 30 minutes, respectively, as a control; 
“5’”, “10’” and “30’”: cells treated with IGF-I at 50ng/ml for 5, 10, and 30 minute, respectively). 
Samples from harvested cells were used to investigate the changes in protein abundance of 
molecules involved in IGF signalling using WB (“p-Akt”: phospho-Akt; “p-MAPK”: phospho-
MAPK). Proteins in whole lysates were loaded equally at 60μg with GAPDH being used as the 
reference protein. All blots demonstrate typical results from three experiments each 
performed at least in triplicate (n=3). 
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5.4.2.2 Effects of inhibition of IGF/PI3K/Akt signalling pathway 
Having identified in both cell lines that activation of the IGF-IR was associated 
with increased phosphorylation of the IGF-IR and Akt, a specific IGF-IR 
tyrosine kinase inhibitor (TKI), AG1024, and a specific PI3K inhibitor 
LY294002, were used to examine whether the effects of IGF-I on cell 
phenotype were mediated by these changes in signalling molecules. 
5.4.2.2.1 Effects of inhibiting the IGF-IR on bladder cancer cell phenotype 
Alterations in cell proliferation, invasion, migration and colony formation 
were assessed to examine the effects of inhibiting the IGF-IR using AG1024, a 
specific IGF-IR inhibitor, on bladder cancer cells. 
5.4.2.2.1.1 Optimisation of an effective dose of AG1024 in RT4 and T24 
cells 
A TTI assay was used in RT4 and T24 cells to assess cell proliferation following 
treatment with AG1024 (0-10 µM) for 24 hours. 
As shown in Figure 62, a decrease in cell proliferation in response to a dose of 
increasing concentrations of AG1024 was observed in both RT4 and T24 cells. 
At a dose of AG1024 at 1.25µM, a reduction of 63.7% (p<0.01) and 55.7% 
(p<0.01) was found in RT4 and T24 cells, respectively. As both cell lines were 
maximally inhibited by 96% (p<0.01) at 2.5µM, 2µM was selected as an 
effective concentration for further experiments. 
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Figure 62: assessment of the proliferative response to AG1024 in RT4 and T24 
bladder cancer cells using TTI  
RT4 and T24 cells were seeded at a density of 0.03 and 0.02x106 cells/well into 24-well plates 
in GM to grow for 24 hours followed by serum starvation for another 24 hours. Then both cell 
lines were dosed with AG1024 at 0-10 µM for 24 hours, and TTI was performed to show the 
proliferative response to AG1024 in RT4 (A) and T24 (B) cells. 
The graphs represent the mean of three experiments each performed in quadruplicate, and 
error bars represent the standard error of the mean of the experiments (n=3). “*”: p<0.05; “**”: 
p<0.01. 
 
5.4.2.2.1.2 Characterisation of the effectiveness of AG1024 
Based on the chosen dose of AG1024 determined above, both RT4 and T24 
cells were treated with a short exposure to IGF-I at 50ng/ml for 10 minutes 
with or without 1 hour of pre-treatment with AG1024 at 2µM. 
As shown in Figure 63-A, activation of phospho-IGF-IR (p-IGF-IR) by IGF-I was 
clearly observed in both RT4 and T24 cells without the pre-treatment of TKI. 
When pre-dosing TKI for 1 hour, the ability of IGF-I to activate its receptor was 
attenuated in both cell lines. Similar activation of phospho-Akt (p-Akt) by IGF-
I was observed in both cell lines with more abundance shown in T24 cells. 
Moreover, no changes were observed in phospho-MAPK (p-MAPK) in either 
cell line. 
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No obvious changes in the total amount of the IGF-IR, Akt and ERK 2 were 
found in either RT4 or T24 cells (see Figure 63-B). 
 
Figure 63: effect of AG 1024 on the activation of IGF-IR in RT4 and T24 cells 
RT4 and T24 cells were seeded at a density of 0.1 and 0.05x106 cells/well into 6-well plates in 
GM to grow for 24 hours followed by serum starvation for another 24 hours. Cells were then 
pre-dosed with or without AG1024 (“TKI”, IGF-IR tyrosine kinase inhibitor) at 2µM for 1 hour 
before spiked with or without IGF-I (50ng/ml) for 10 minutes. Samples from harvested cells 
were used to investigate the changes in protein abundance of molecules involved in IGF 
signalling using WB (“p-IGF-IR”: phospho-IGF-IR; “p-Akt”: phospho-Akt; “p-MAPK”: phospho-
MAPK). Proteins in whole lysates were loaded equally at 60μg with Tubulin being used as the 
reference protein. All blots demonstrate typical results from three experiments each 
performed at least in triplicate (n=3). 
 
5.4.2.2.1.3 Effect of inhibiting the IGF-IR on cell proliferation in RT4 and 
T24 cells 
Both RT4 and T24 cells were treated with IGF-I at 50ng/ml for 48 hours with 
or without pre-treatment of AG1024 at 2µM for 1 hour to assess the effects on 
cell proliferation upon inhibition of the IGF-IR. 
With RT4 cells, no significant changes in either total cell number (see Figure 
64-A) or percentage cell death (see Figure 64-B) were found when cells were 
treated with IGF-I (“IGF-I”), AG1024 (“TKI”) alone or in combination 
(“TKI+IGF-I”) compared to the control cells (“CT”). 
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In T24 cells, compared to control cells (“CT”), a dose of IGF-I alone (“IGF-I”) 
induced a significant increase in total cell number (by 22.7%, p<0.05; see 
Figure 64-C). Both the treatment of AG1024 alone (“TKI”) and in combination 
with IGF-I (“TKI+IGF-I”) led to a significant decrease in total cell number (by 
22.2%, p<0.05 and 20.6%, p<0.05, respectively; see Figure 64-C) compared 
with the control cells (“CT”), associated with a similar increase in percentage 
cell death by 40% (p<0.05) (see Figure 64-D), suggesting that IGF-I could not 
increase growth when the receptor was inhibited, and that inhibition of the 
IGF-IR alone reduced cell growth by promoting cell death. 
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Figure 64: effect of AG1024 and IGF-I on cell proliferation in RT4 and T24 cells 
RT4 and T24 cells were seeded at a density of 0.1 and 0.05x106 cells/well into 6-well plates in 
GM to grow for 24 hours followed by serum starvation for another 24 hours. Cells were then 
dosed with IGF-I (at 50ng/ml) with or without 1 hour of pre-dose of AG1024 at a concentration 
of 2µM. “CT”: control cells without treatment; “IGF-I”: cells treated with IGF-I alone at a 
concentration of 50ng/ml for 48 hours; “TKI”: cells treated with AG1024 (“TKI”, IGF-IR 
tyrosine kinase inhibitor) alone at 2µM for 48 hours; “TKI+IGF-I”: cells dosed with 1 hour of 
pre-treatment of AG1024 at the concentration of 2µM followed by addition of IGF-I at 50ng/ml 
for 48 hours. 
Graphs represent the change in the counting of total cell numbers (A & C) and the percentage 
cell death (B & D) following different treatments in RT4 and T24 cells, respectively. The graphs 
show the mean of three experiments each performed at least in triplicate, and error bars 
represent the standard error of the mean of the experiments (n=3). “NS*”: not significant. 
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5.4.2.2.1.4 Effect of inhibiting the IGF-IR on cell invasion in RT4 and T24 
cells 
An invasion assay was conducted to assess the effect of dosing with AG1024 to 
inhibit the IGF-IR on the ability of RT4 and T24 cells to invade in response to 
IGF-I. 
As shown previously in 5.4.1.3, dosing with IGF-I alone (“IGF-I”) induced a 
significant increase in cell invasion in both RT4 (by 56.1%, p<0.01; see Figure 
65-B) and T24 cells (by 93.1%, p<0.01; see Figure 65-D). Treatment of AG1024 
alone (“TKI”) led to a significant decrease in cell invasion in both RT4 (by 
around 50%, p<0.01; see Figure 65-B) and T24 cells (by around 50%, p<0.01; 
see Figure 65-D) and in combination (“TKI+IGF-I”) the ability of IGF-I to 
increase invasion in both cell lines was blocked. 
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Figure 65: effect of AG1024 and IGF-I on cell invasion in RT4 and T24 cells 
Cells of both cell lines were previously seeded in GM for 24 hours and then changed to SFM for 
16 hours before being prepared for an invasion assay. After serum-starvation, 1 hour of pre-
treatment of AG1024 at a concentration of 2µM was performed in both cells accordingly. Cells 
were then trypsinised and then seeded into the collagen-coated inserts at a certain density 
(RT4: 0.1x106 cells/insert and T24: 0.08x106 cells/insert) and allowed to invade (RT4: 24 
hours and T24: 18 hours). Cells were labelled according to different treatments while seeding : 
“CT”: control cells without treatment; “IGF-I”: cells treated with IGF-I alone at a concentration 
of 50ng/ml (RT4: 24 hours and T24: 18 hours); “TKI”: cells treated with AG1024 (“TKI”, IGF-
IR tyrosine kinase inhibitor) alone at 2µM (RT4: 25 hours and T24: 19 hours); “TKI+IGF-I”: 
cells dosed with 1 hour of pre-treatment of AG1024 at the concentration of 2µM followed by 
addition of IGF-I at 50ng/ml (RT4: 24 hours and T24: 18 hours). 
(A) & (C): The images show invaded RT4 and T24 cells, respectively, with nuclei (in blue) 
stained with DAPI. All images shown are at x40 magnification. (B) & (D) The graphs show the 
fold change of invaded RT4 and T24 cells, respectively, normalised to the control group. The 
graphs represent the mean of three experiments each performed in triplicate, upon which the 
standard error of the mean of the experiments was presented (n=3). “*”: p<0.05; “**”: p<0.01. 
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5.4.2.2.1.5 Effect of inhibiting the IGF-IR on cell migration in T24 cells 
A migration assay was performed to investigate the effect of inhibiting the IGF-
IR using AG1024 on cell migration in T24 cells in response to IGF-I. 
As determined previously in 5.4.1.4, the treatment of IGF-I alone (“IGF-I”) 
enhanced cell migration causing the gap to close faster compared with the 
control group (see Figure 66-B). In contrast, compared to the control, the 
dosing of AG1024 alone (“TKI”) led to a slower decrease in the gap area, this 
was unaffected following the addition of IGF-I (“TKI + IGF-I”) (Figure 66-B). 
Chapter 5 - Effects of IGF-I on Bladder Cancer Cells 
Page | 237  
 
 
Figure 66: effect of AG1024 and IGF-I on cell migration in T24 cells 
T24 cells were seeded at a density of 0.028x106 cells into each chamber in GM and allowed to 
grow for approximately 24 hours to reach about 80% confluence. Cell reached 90-95% 
confluence during an additional 24 hours in SFM. After 1 hour of pre-dosing with fresh SFM or 
AG1024 at 2µM, the inserts were removed leaving an observed gap, and gap closure was 
recorded for up to 12 hours with different treatment (“CT”: untreated cells as a control group; 
“IGF-I”: cells treated with IGF-I alone at the concentration of 50ng/ml; “TKI”: cells treated with 
AG1024 alone at the concentration of 2 µM; “TKI+IGF-I”: cells dosed with 1 hour of pre-
treatment of AG1024 at the concentration of 2µM followed by addition of IGF-I at 50ng/ml). 
Images of cell gaps were taken at different times with relative labels. “0hr”: the start point after 
the removal of inserts; “3hr”, “4hr”, “6hr”, “9hr” and “12hr”: 3, 4, 6, 9 and 12 hours after the 
removal of inserts. All images demonstrate the results from three experiments performed in 
duplicate (n=3). All images shown are at x10 magnification, and the area of the gaps in the 
images was analysed using ImageJ software. “*”: p<0.05; “**”: p<0.01. 
Chapter 5 - Effects of IGF-I on Bladder Cancer Cells 
Page | 238  
 
5.4.2.2.1.6 Effect of inhibiting the IGF-IR on cell colony formation in RT4 
and T24 cells 
A soft agar colony formation assay was performed to assess the effect of 
inhibiting the IGF-IR on the ability of RT4 and T24 cells to form colonies in 
response to IGF-I. 
In RT4 cells, the treatment of IGF-I alone (“IGF-I”) induced a significant 
increase in the average size of each colony formed (with the fold change of 
colony average size normalised to the control increased by 37%, p<0.05, see 
Figure 67-C), but no significant changes in the colony forming efficiency, “CFE” 
compared to the control (see Figure 67-B). Dosing with AG1024 alone (“TKI”) 
led to a significant decrease in both fold change of CFE (by 38%, p<0.01; see 
Figure 67-B) and average colony size (by 25%, p<0.05; see Figure 67-C) 
normalised to the control. Adding IGF-I in the presence of AG1024 (“TKI + IGF-
I”) could still increase CFE (p<0.05) (Figure 67-B) but did not affect the fold 
change of average colony size (Figure 67-C) when compared to the control 
cells. 
In T24 cells, the treatment of IGF-I alone (“IGF-I”) led to a significant increase 
in both CFE (by 73%, p<0.01, see Figure 67-E) and average colony size (by 13%, 
p<0.05, see Figure 67-F). AG1024 alone (“TKI”) induced a significant decrease 
in both fold change of CFE (by 84%, p<0.01; see Figure 67-E) and colony 
average size (by 13%, p<0.05; see Figure 67-F) normalised to the control. 
Moreover, these reductions by AG1024 were not negated following co-
treatment with IGF-I (“TKI + IGF-I”) (Figure 67-E & F). 
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Figure 67: effect of AG1024 and IGF-I on cell colony formation in RT4 and T24 
cells 
Both RT4 and T24 cells were seeded in dishes under different treatments with corresponding 
labels (“CT”: untreated cells as a control group; “IGF-I”: cells treated with IGF-I alone at the 
concentration of 50ng/ml 48 hours before seeding; “TKI”: cells treated with AG1024 alone at 
the concentration of 2 µM for 48 hours before seeding; “TKI+IGF-I”: cells dosed with 1 hour of 
pre-treatment of AG1024 at the concentration of 2µM followed by addition of IGF-I at 50ng/ml 
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for 48 hours before seeding). Cells were seeded at an even density at 10,000 cells/dish and 
5,000 cells/dish, respectively, and fed once a week for four weeks in total, and then colony 
numbers, as well as average size, were measured by ImageJ software.  
 (A) & (D): Images show RT4 and T24cells, respectively, with colonies were stained at the end 
of the assay (“Day 28”). All images shown are at x10 magnification; (B) & (E): Graphs present 
the fold change of colony forming efficiency (CFE) normalised to the control under different 
treatments in RT4 and T24 cells, respectively. (C) & (F): Graphs demonstrate the fold change 
of average size of colonies due to different treatments for RT4 and T24 cells, respectively. All 
graphs present the mean of three experiments each performed in triplicate, and error bars 
represent the standard error of the mean from three experiments (n=3). “*”: p<0.05; “**”: 
p<0.01. 
 
5.4.2.2.2 Effects of inhibiting PI3K on bladder cancer cell phenotype 
Changes in cell invasion and migration were examined to investigate the effect 
of inhibiting PI3K using LY294002 on bladder cancer cells in response to IGF-
I.  
5.4.2.2.2.1 Characterisation of effectiveness of LY294002 
Both RT4 and T24 cells were treated with a short exposure to IGF-I at 50ng/ml 
for 10 minutes with or without 1 hour of pre-treatment of LY294002 at 50µM. 
As characterised in 5.4.2.1, activation of the IGF-IR (p-IGF-IR) by IGF-I was 
clearly observed in RT4 cells and to a lesser extent in T24 cells in the presence 
or absence of LY294002 (Figure 68-A). The activation of p-IGF-IR led to a high 
induction of phospho-Akt (p-Akt) in both RT4 and T24 cells in response to IGF-
I which was reduced by the pre-treatment with LY294002:  the reduction in p-
Akt was more obvious in T24 cells than that in RT4 cells suggesting higher 
efficiency of inhibition of activation of PI3K in T24 cells by LY294002 (Figure 
68-A). Abundant p-Akt was observed in the control group of T24 cells with 
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little found in the control of RT4 cells showing a higher basal level of activation 
of PI3K in T24 cells (Figure 68-A). 
No obvious changes in phospho-MAPK (p-MAPK) (Figure 68-A), the total 
amount of IGF-IR, Akt and ERK 2 (Figure 68-B) were found in RT4 or T24 cells. 
 
Figure 68: effect of LY294002 on the activation of PI3K in RT4 and T24 cells 
RT4 and T24 cells were seeded at a density of 0.1 and 0.05x106 cells/well into 6-well plates in 
GM to grow for 24 hours followed by serum starvation for another 24 hours. Cells were then 
pre-dosed with or without LY294002 (“LY”) at 50µM for 1 hour before spiked with or without 
IGF-I (50ng/ml) for 10 minutes. Samples from harvested cells were used to investigate the 
changes in protein abundance of molecules involved in IGF signalling using WB (“p-IGF-IR”: 
phospho-IGF-IR; “p-Akt”: phospho-Akt; “p-MAPK”: phospho-MAPK). Proteins in whole lysates 
were loaded equally at 60μg with Tubulin being used as the reference protein. All blots 
demonstrate typical results from three experiments each performed at least in triplicate (n=3). 
 
5.4.2.2.2.2 Effect of inhibiting PI3K on cell invasion in RT4 and T24 cells 
An invasion assay was performed to assess the effect of inhibiting PI3K on cell 
invasion in both RT4 and T24 cells. 
Similar to the pattern of results obtained for inhibiting the IGF-IR using 
AG1024 described in 5.4.2.2.1.4, the dosing of IGF-I alone (“IGF-I”) induced a 
significant increase in cell invasion in both RT4 (by 58%, p<0.01; see Figure 
69-B) and T24 cells (by 90%, p<0.01; see Figure 69-D). Treatment of 
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LY294002 alone (“LY”) significantly decreased in cell invasion in both RT4 (by 
around 49%, p<0.01; see Figure 69-B) and T24 cells (by around 57%, p<0.01; 
see Figure 69-D) and the effect of IGF-I on invasion was negated when in 
combination with LY.  
 
Figure 69: effect of LY294002 and IGF-I on cell invasion in RT4 and T24 cells 
Cells of both cell lines were previously seeded in GM for 24 hours and then changed to SFM for 
16 hours before being prepared for an invasion assay. After serum-starvation, 1 hour of pre-
treatment of LY294002 at a concentration of 50µM was performed in both cells accordingly. 
Cells were then trypsinised and then seeded into the collagen-coated inserts at a certain 
density (RT4: 0.1x106 cells/insert and T24: 0.08x106 cells/insert) and allowed to invade (RT4: 
24 hours and T24: 18 hours). Cells were labelled according to different treatments while 
seeding : “CT”: control cells without treatment; “IGF-I”: cells treated with IGF-I alone at a 
concentration of 50ng/ml (RT4: 24 hours and T24: 18 hours); “LY”: cells treated with 
LY294002 alone at 50µM (RT4: 25 hours and T24: 19 hours); “LY+IGF-I”: cells dosed with 1 
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hour of pre-treatment of LY294002 at the concentration of 50µM followed by addition of IGF-
I at 50ng/ml (RT4: 24 hours and T24: 18 hours). 
(A) & (C): The images show invaded RT4 and T24 cells, respectively, with nuclei (in blue) 
stained with DAPI. All images shown are at x40 magnification. (B) & (D) The graphs show the 
fold change of invaded RT4 and T24 cells, respectively, normalised to the control group. The 
graphs represent the mean of three experiments each performed in triplicate, upon which the 
standard error of the mean of the experiments was presented (n=3). “**”: p<0.01. 
 
5.4.2.2.2.3 Effect of inhibiting PI3K on cell migration in T24 cells 
A migration assay was performed to investigate the effect of inhibiting PI3K 
using LY294002 on cell migration in T24 cells in response to IGF-I. 
The treatment of IGF-I alone (“IGF-I”) enhanced the migration showing a 
significantly faster reduction in the gap area compared to the control group 
(see Figure 70-B). In contrast, compared to the control, LY294002 alone (“LY”) 
significantly slowed the decrease in the gap area showing the migratory 
activity of cells was inhibited. However, the inhibitory effect of LY294002 was 
attenuated upon treatment with IGF-I (“LY + IGF-I”) (Figure 70-B). 
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Figure 70: effect of LY294002 and IGF-I on cell migration in T24 cells 
T24 cells were seeded at a density of 0.028x106 cells into each chamber in GM and allowed to 
grow for approximately 24 hours to reach about 80% confluence. Cell reached 90-95% 
confluence during an additional 24 hours in SFM. After 1 hour of pre-dosing with fresh SFM or 
LY294002 at 50µM, the inserts were removed leaving an observed gap, and gap closure was 
recorded for up to 12 hours with different treatment (“CT”: untreated cells as a control group; 
“IGF-I”: cells treated with IGF-I alone at the concentration of 50ng/ml; “LY”: cells treated with 
LY294002 alone at the concentration of 50µM; “LY+IGF-I”: cells dosed with 1 hour of pre-
treatment of LY294002 at the concentration of 50µM followed by addition of IGF-I at 50ng/ml). 
Images of cell gaps were taken at different times with relative labels. “0hr”: the start point after 
the removal of inserts; “3hr”, “4hr”, “6hr”, “9hr” and “12hr”: 3, 4, 6, 9 and 12 hours after the 
removal of inserts. All images demonstrate the results from three experiments performed in 
duplicate (n=3). All images shown are at x10 magnification, and the area of the gaps in the 
images was analysed using ImageJ software. “*”: p<0.05; “**”: p<0.01. 
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5.4.3 Does IGF-I induce changes in EMT-related molecules in 
bladder cancer cells? 
In addition to E, N-cadherin and β-catenin that were examined in the previous 
chapters, changes in ZEB-1, FOXO3a, FOXA1, and 14-3-3 β were also assessed 
in response to IGF-I. 
5.4.3.1 Characterisation of ZEB-1, FOXO3a, FOXA1, and 14-3-3 β in RT4 
and T24 cells 
A range of protein concentrations was used to identify the optimum amount 
for each antibody in each cell line. T24 cells express high levels of ZEB-1; while 
RT4 cells show the opposite having undetectable amounts (see Figure 71-A). 
Both RT4 and T24 cells express FOXO3a, FOXA1 and 14-3-3 β (see Figure 71-
B & C & D), with both FOXO3a and FOXA1 being more abundant in the RT4 
cells (see Figure 71-B). It was also determined that 60µg would be an 
appropriate amount to load for each of these proteins unless noted otherwise. 
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Figure 71: characterisation of the levels of ZEB-1, FOXO3a, FOXA1, and 14-3-3 β 
in RT4 and T24 cells 
Figures (A), (B), (C) and (D) show the western blots for ZEB-1, FOXO3a, FOXA1 and 14-3-3 β, 
respectively, in both RT4 and T24 cells detected using WB. RT4 and T24 cells were seeded in 
GM at the same density to grow for 24 hours and then were left in SFM for 48 hours before 
sample harvest. Proteins in whole lysates were loaded with increasing amounts from 25 to 
100μg. Proteins from U251 (a human glioblastoma cell line), MDA (MDA-MB-231, a human 
breast cancer cell line), and MCF7 (a human breast adenocarcinoma cell line) cell lysates were 
used as positive controls for ZEB-1, FOXO3a, and FOXA1 & 14-3-3 β, respectively. They were 
loaded equally at 50μg. Tubulin and GAPDH were used as the reference protein. 
 
Basal localisation of these molecules in RT4 and T24 cells was detected by 
cellular fractionation. Consistent with the results of western blotting (Figure 
71-A), no ZEB-1 was detected in RT4 cells (see Figure 72-A); and in T24 cells, 
ZEB-1 was located only in the nuclear fraction (Figure 72-C). FOXO3a was 
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found both in the nuclei and cytoplasm of RT4 and T24 cells, and it was more 
abundant in the nuclear component in both cell lines (see Figure 72-B & C). 
FOXA1 was located both in the nuclei and cytoplasm of T24 cells with more 
abundance observed in the nuclei (see Figure 72-C); while in RT4 cells, FOXA1 
was detected at high levels but only in the nuclei (see Figure 72-B). 14-3-3 β 
was found only in the cytoplasm in RT4 cells (see Figure 72-B); 14-3-3 β was 
also located in the cytoplasm of T24 cells, with an almost undetectable 
presence in the nuclear fraction (see Figure 72-C). 
 
Figure 72: characterisation of the localisation of ZEB-1, FOXO3a, FOXA1 and 14-
3-3 β in RT4 and T24 cells using cellular fractionation 
Figure (A), (B) and (C) show western blots characterising the basal localisation of ZEB-1, 
FOXO3a, FOXA1 and 14-3-3 β in RT4 and T24 cells, respectively, using cellular fractionation. 
Both RT4 and T24 cells were seeded in GM at the same density to grow for 24 hours followed 
by serum starvation using SFM for another 24 hours, and then cells were trypsinised and 
harvested for performing cellular fractionation to separate proteins of cytoplasmic and 
nuclear extracts. Isolated proteins extracted from the total cell lysates were loaded equally for 
protein detection using WB. Lamin and Tubulin exist only in nuclei and cytoplasm, 
respectively, and they are indicators of the efficiency of protein separation. “T”: total cell 
lysates; “C”: cytoplasmic extract; “N”: nuclear extract; “X”: blank lane. Proteins of MCF7 (a 
human breast adenocarcinoma cell line) and MDA (MDA-MB-231, a human breast cancer cell 
line) were used as a positive control for target molecules. And the blots demonstrate the 
typical results from three experiments each performed at least in triplicate (n=3). 
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5.4.3.2 Assessment of changes in EMT-related molecules following IGF-I 
treatment 
RT4 and T24 cells were dosed with exogenous IGF-I at a concentration of 
50ng/ml for 48 hours, and changes in abundance and localisation of EMT-
related molecules including N- and E-cadherin, β-catenin, ZEB-1, FOXO3a, 
FOXA1 as well as 14-3-3 β in both cell lines were investigated using cellular 
fractionation and WB analysis. 
As we determined previously, N-cadherin, the mesenchymal marker, was 
expressed abundantly in aggressive mesenchymal-like T24 cells, with no 
detectable levels found in epithelial-like RT4 cells. With the treatment of 
increasing concentrations of IGF-I, an enhancement of N-cadherin expression 
was observed in T24 cells (by 21.4% at the concentration of 50ng/ml, p<0.05; 
see Figure 73-A & C) compared to the control, with no observed changes in E-
cadherin (Figure 73-A). Enhanced expression of N-cadherin in both total cell 
lysates and the cytoplasmic extract in response to exogenously added IGF-I 
was confirmed in the cellular fractionation analysis (see Figure 73-B). With no 
N-cadherin in cell nuclei, the fold change of cytoplasmic N-cadherin 
normalised to untreated controls in T24 cells presented a similar increase (by 
25%, p<0.05; see Figure 73-D) to that observed in whole lysates. 
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Figure 73: effect of IGF-I on N-cadherin in RT4 and T24 cells 
RT4 and T24 cells were seeded in 6-well plates at a density of 0.1 and 0.05x106 cells/well, 
respectively, in GM for 24 hours and serum starved with SFM for another 24 hours. Then cells 
were separated according to different treatments (“CT”: untreated cells as a control group; 
“25”, “50”, “100”: cells treated with IGF-I at the concentration of 25, 50, and 100ng/ml for 48 
hours, respectively; “IGF-I”: cells treated with IGF-I at the certain concentration of 50ng/ml 
for 48 hours). After 48 hours of treatment, cells were harvested to investigate the changes in 
protein abundance and localisation using WB and cellular fractionation analysis, accordingly. 
All blots demonstrate typical results from three experiments each performed at least in 
triplicate (n=3). 
(A): The blot shows the abundance of N-cadherin in RT4 and T24 cells in response to an 
increased dosage of IGF-I treatment. Samples from whole lysates were loaded equally at 60µg 
for protein detection, and GAPDH was assessed as reference protein. Proteins from U251 (a 
human glioblastoma cell line) cell lysates were used as positive controls for N-cadherin. (B): 
The blot presents the localisation of N-cadherin in the presence or absence of IGF-I treatment 
in T24 cells using cellular fractionation. Lamin and Tubulin exist only in nuclei and cytoplasm, 
respectively, and they are an indicator of the efficiency of protein separation. “T”: total cell 
lysates; “C”: cytoplasmic extract; “N”: nuclear extract. (C): The graph shows the mean of fold 
change of the optical density measurements of N-cadherin in response to increased dosage of 
IGF-I (from 0 to 100ng/ml for 48 hours) from three experiments each performed at least in 
triplicate; and error bars demonstrate the standard error of the mean of experiments (n=3). 
“*”: p<0.05. (D): The graph represents the mean of fold change of the optical density 
measurements of N-cadherin in cytoplasmic extracts in response to treatment with and 
without the presence of IGF-I (at 50ng/ml for 48 hours), from three experiments each 
performed at least in triplicate; and error bars demonstrate the standard error of the mean of 
experiments (n=3). 
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In response to increasing doses of IGF-I, the levels of E-cadherin, the epithelial 
marker, in RT4 cells was reduced (see Figure 74-A): the fold change 
normalised to the control showed a significant reduction of 12% (p<0.05) 
when treated with exogenous IGF-I at 50ng/ml for 48 hours (see Figure 74-C). 
With no presence in the nuclear extract, E-cadherin demonstrated an 11% 
(p<0.05) reduction in fold change of cytoplasmic expression compared with 
the control (see Figure 74-B & D). No induction of E-cadherin in T24 cells was 
observed in response to the treatment with IGF-I (see Figure 74-A).  
 
Figure 74: effect of IGF-I on E-cadherin in RT4 and T24 cells 
RT4 and T24 cells were seeded in 6-well plates at a density of 0.1 and 0.05x106 cells/well, 
respectively, in GM for 24 hours and serum starved with SFM for another 24 hours. Then cells 
were separated according to different treatments (“CT”: untreated cells as a control group; 
“25”, “50”, “100”: cells treated with IGF-I at the concentration of 25, 50, and 100ng/ml for 48 
hours, respectively; “IGF-I”: cells treated with IGF-I at the certain concentration of 50ng/ml 
for 48 hours). After 48 hours of treatment, cells were harvested to investigate the changes in 
protein abundance and localisation using WB and cellular fractionation analysis, accordingly. 
All blots demonstrate typical results from three experiments each performed at least in 
triplicate (n=3). 
 (A): The blot shows the abundance of E-cadherin in RT4 and T24 cells in response to an 
increased dosage of IGF-I treatment. Samples from whole lysates were loaded equally at 60µg 
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for protein detection, and Tubulin was assessed as reference protein. Proteins from MCF7 (a 
human breast adenocarcinoma cell line) cell lysates were used as positive controls for E-
cadherin. (B): The blot presents the localisation of E-cadherin in the presence or absence of 
IGF-I treatment in RT4 cells using cellular fractionation. Lamin and Tubulin exist only in nuclei 
and cytoplasm, respectively, and they are an indicator of the efficiency of protein separation. 
“T”: total cell lysates; “C”: cytoplasmic extract; “N”: nuclear extract. (C): The graph shows the 
mean of fold change of the optical density measurements of E-cadherin in response to 
increased dosage of IGF-I (from 0 to 100ng/ml for 48 hours) from three experiments each 
performed at least in triplicate; and error bars demonstrate the standard error of the mean of 
experiments (n=3). “*”: p<0.05. (D): The graph represents the mean of fold change of the 
optical density measurements of E-cadherin in cytoplasmic extracts in response to treatment 
with and without the presence of IGF-I (at 50ng/ml for 48 hours), from three experiments 
each performed at least in triplicate; and error bars demonstrate the standard error of the 
mean of experiments (n=3). 
 
No visible (see Figure 75-A) or statistical (see Figure 75- B & C) changes in the 
abundance of β-catenin were observed in RT4 or T24 cells with the treatment 
of IGF-I. However, the treatment of exogenously added IGF-I at 50ng/ml for 48 
hours led to nuclear translocation of β-catenin in both cell lines with an 
induction in the fold change of cytoplasmic β-catenin normalised to this 
protein in total cell lysates found between control and IGF-I-treated cells being 
50% (p<0.05; see Figure 75-F) in RT4 cells and 20% (p<0.05; see Figure 75-G) 
in T24 cells. 
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Figure 75: effect of IGF-I on β-catenin in RT4 and T24 cells 
RT4 and T24 cells were seeded in 6-well plates at a density of 0.1 and 0.05x106 cells/well, 
respectively, in GM for 24 hours and serum starved with SFM for another 24 hours. Then cells 
were separated according to different treatments (“CT”: untreated cells as a control group; 
“25”, “50”, “100”: cells treated with IGF-I at the concentration of 25, 50, and 100ng/ml for 48 
hours, respectively; “IGF-I”: cells treated with IGF-I at the certain concentration of 50ng/ml 
for 48 hours). After 48 hours of treatment, cells were harvested to investigate the changes in 
protein abundance and localisation using WB and cellular fractionation analysis, accordingly. 
All blots demonstrate typical results from three experiments each performed at least in 
triplicate (n=3). 
Chapter 5 - Effects of IGF-I on Bladder Cancer Cells 
Page | 253  
 
 (A): The blot shows the abundance of β-catenin in RT4 and T24 cells in response to an 
increased dosage of IGF-I treatment. Samples from whole lysates were loaded equally at 60µg 
for protein detection, and GAPDH was assessed as reference protein. Proteins from MCF7 (a 
human breast adenocarcinoma cell line) cell lysates were used as positive controls for β-
catenin. (B) & (C): The graphs show the mean of fold change of the optical density 
measurements of β-catenin in RT4 and T24 cells, respectively, in response to increased dosage 
of IGF-I (from 0 to 100ng/ml for 48 hours) from three experiments each performed at least in 
triplicate; and error bars demonstrate the standard error of the mean of experiments (n=3). 
(D) & (E): The blots present the localisation of β-catenin in the presence or absence of IGF-I 
treatment in RT4 and T24 cells, respectively, using cellular fractionation. Lamin and Tubulin 
exist only in nuclei and cytoplasm, respectively, and they are an indicator of the efficiency of 
protein separation. “T”: total cell lysates; “C”: cytoplasmic extract; “N”: nuclear extract. (F) & 
(G): The graphs present the densitometry fold change of cytoplasmic β-catenin normalised to 
total β-catenin in the total cell lysates in RT4 and T24 cells, respectively, in response to 
treatment with and without the presence of IGF-I (at 50ng/ml for 48 hours), with error bars 
representing the standard error of the mean of experiments (n=3). 
 
Similar to N-cadherin, ZEB-1 was expressed only in T24 cells. Moreover, 
treatment with IGF-I induced an increase in the levels of ZEB-1 in T24 cells (by 
28.8% when treated with IGF-I at 50ng/ml for 48 hours, p<0.05; see Figure 76-
C) compared with the control, with no induction of this protein in RT4 cells 
(see Figure 76-A). Existing only in the nuclei of T24 cells, the levels of ZEB-1 
increased in both whole lysates and nuclear extracts (see Figure 76-B). 
Moreover, the treatment with IGF-I at 50ng/ml for 48 hours led to an 
enhancement in the fold change of nuclear ZEB-1 by 20% (p<0.05; see Figure 
76-D) normalised to the untreated control. 
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Figure 76: effect of IGF-I on ZEB-1 in RT4 and T24 cells 
RT4 and T24 cells were seeded in 6-well plates at a density of 0.1 and 0.05x106 cells/well, 
respectively, in GM for 24 hours and serum starved with SFM for another 24 hours. Then cells 
were separated according to different treatments (“CT”: untreated cells as a control group; 
“25”, “50”, “100”: cells treated with IGF-I at the concentration of 25, 50, and 100ng/ml for 48 
hours, respectively; “IGF-I”: cells treated with IGF-I at the certain concentration of 50ng/ml 
for 48 hours). After 48 hours of treatment, cells were harvested to investigate the changes in 
protein abundance and localisation using WB and cellular fractionation analysis, accordingly. 
All blots demonstrate typical results from three experiments each performed at least in 
triplicate (n=3). 
(A): The blot shows the abundance of ZEB-1 in RT4 and T24 cells in response to an increased 
dosage of IGF-I treatment. Samples from whole lysates were loaded equally at 60µg for protein 
detection, and GAPDH was assessed as reference protein. Proteins from U251 (a human 
glioblastoma cell line) cell lysates were used as positive controls for ZEB-1. (B): The blot 
presents the localisation of ZEB-1 in the presence or absence of IGF-I treatment in T24 cells 
using cellular fractionation. Lamin and Tubulin exist only in nuclei and cytoplasm, respectively, 
and they are an indicator of the efficiency of protein separation. “T”: total cell lysates; “C”: 
cytoplasmic extract; “N”: nuclear extract. (C): The graph shows the mean of fold change of the 
optical density measurements of ZEB-1 in response to increased dosage of IGF-I (from 0 to 
100ng/ml for 48 hours) from three experiments each performed at least in triplicate; and 
error bars demonstrate the standard error of the mean of experiments (n=3). “*”: p<0.05. (D): 
The graph represents the mean of fold change of the optical density measurements of ZEB-1 
in nuclear extracts in response to treatment with and without the presence of IGF-I (at 
50ng/ml for 48 hours), from three experiments each performed at least in triplicate; and error 
bars demonstrate the standard error of the mean of experiments (n=3). 
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With the treatment of IGF-I, the abundance of FOXO3a was increased in both 
RT4 and T24 cells (see Figure 77-A & B) with an induction by 33.8% (p<0.05; 
see Figure 77-C) and 23.0% (p<0.05; see Figure 77-D), respectively, compared 
to the control. Along with the increased expression in whole cell lysates, 
decreased levels of nuclear FOXO3a were observed in both cell lines (see 
Figure 77-E & F), and a significant reduction by 40% (p<0.05; see Figure 77-G) 
and 30% (p<0.05; see Figure 77-H) was found in RT4 and T24 cells, 
respectively, in the fold change of nuclear FOXO3a normalised to this protein 
in total cell lysates of control and IGF-I-treated cells. 
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Figure 77: effect of IGF-I on FOXO3a in RT4 and T24 cells 
RT4 and T24 cells were seeded in 6-well plates at a density of 0.1 and 0.05x106 cells/well, 
respectively, in GM for 24 hours and serum starved with SFM for another 24 hours. Then cells 
were separated according to different treatments (“CT”: untreated cells as a control group; 
“25”, “50”, “100”: cells treated with IGF-I at the concentration of 25, 50, and 100ng/ml for 48 
hours, respectively; “IGF-I”: cells treated with IGF-I at the certain concentration of 50ng/ml 
for 48 hours). After 48 hours of treatment, cells were harvested to investigate the changes in 
protein abundance and localisation using WB and cellular fractionation analysis, accordingly. 
All blots demonstrate typical results from three experiments each performed at least in 
triplicate (n=3). 
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 (A) & (B): The blots show the abundance of FOXO3a in RT4 and T24 cells, respectively, in 
response to an increased dosage of IGF-I treatment. Samples from whole lysates were loaded 
equally at 60µg for protein detection, and GAPDH was assessed as reference protein. Proteins 
from MCF7 (a human breast adenocarcinoma cell line) cell lysates were used as positive 
controls for β-catenin. (C) & (D): The graphs show the mean of fold change of the optical 
density measurements of FOXO3a in RT4 and T24 cells, respectively, in response to increased 
dosage of IGF-I (from 0 to 100ng/ml for 48 hours) from three experiments each performed at 
least in triplicate; and error bars demonstrate the standard error of the mean of experiments 
(n=3). (E) & (F): The blots present the localisation of FOXO3a in the presence or absence of 
IGF-I treatment in RT4 and T24 cells, respectively, using cellular fractionation. Lamin and 
Tubulin exist only in nuclei and cytoplasm, respectively, and they are an indicator of the 
efficiency of protein separation. “T”: total cell lysates; “C”: cytoplasmic extract; “N”: nuclear 
extract. (G) & (H): The graphs present the densitometry fold change of nuclear FOXO3a 
normalised to total FOXO3a in the total cell lysates in RT4 and T24 cells, respectively, in 
response to treatment with and without the presence of IGF-I (at 50ng/ml for 48 hours), with 
error bars representing the standard error of the mean of experiments (n=3). 
 
Levels of FOXA1 was also elevated by exogenous IGF-I in RT4 cells both 
visually (see Figure 78-A) and statistically (by 42.5% when treated with IGF-I 
at 50ng/ml for 48 hours, p<0.05; see Figure 78-C) compared to the control, 
with a slight yet not significant decrease found in T24 cells (see Figure 78-B & 
D). Both RT4 (see Figure 78-E) and T24 (see Figure 78-F) cells showed a slight 
decrease of nuclear FOXA1 expression with IGF-I treatment (at 50ng/ml for 48 
hours) compared to the control, but the difference in the fold change of nuclear 
FOXA1 normalised to this protein in total cell lysates of control and IGF-I-
treated cells was not significant in either cell line (see Figure 78-G & H). 
Chapter 5 - Effects of IGF-I on Bladder Cancer Cells 
Page | 258  
 
 
Figure 78: effect of IGF-I on FOXA1 in RT4 and T24 cells 
RT4 and T24 cells were seeded in 6-well plates at a density of 0.1 and 0.05x106 cells/well, 
respectively, in GM for 24 hours and serum starved with SFM for another 24 hours. Then cells 
were separated according to different treatments (“CT”: untreated cells as a control group; 
“25”, “50”, “100”: cells treated with IGF-I at the concentration of 25, 50, and 100ng/ml for 48 
hours, respectively; “IGF-I”: cells treated with IGF-I at the certain concentration of 50ng/ml 
for 48 hours). After 48 hours of treatment, cells were harvested to investigate the changes in 
protein abundance and localisation using WB and cellular fractionation analysis, accordingly. 
All blots demonstrate typical results from three experiments each performed at least in 
triplicate (n=3). 
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(A) & (B): The blots show the abundance of FOXA1 in RT4 and T24 cells, respectively, in 
response to an increased dosage of IGF-I treatment. Samples from whole lysates were loaded 
equally at 60µg for protein detection, and GAPDH was assessed as reference protein. Proteins 
from MCF7 (a human breast adenocarcinoma cell line) cell lysates were used as positive 
controls for β-catenin. (C) & (D): The graphs show the mean of fold change of the optical 
density measurements of FOXA1 in RT4 and T24 cells, respectively, in response to increased 
dosage of IGF-I (from 0 to 100ng/ml for 48 hours) from three experiments each performed at 
least in triplicate; and error bars demonstrate the standard error of the mean of experiments 
(n=3). (E) & (F): The blots present the localisation of FOXA1 in the presence or absence of IGF-
I treatment in RT4 and T24 cells, respectively, using cellular fractionation. Lamin and Tubulin 
exist only in nuclei and cytoplasm, respectively, and they are an indicator of the efficiency of 
protein separation. “T”: total cell lysates; “C”: cytoplasmic extract; “N”: nuclear extract. (G) & 
(H): The graphs present the densitometry fold change of nuclear FOXA1 normalised to total 
FOXA1 in the total cell lysates in RT4 and T24 cells, respectively, in response to treatment with 
and without the presence of IGF-I (at 50ng/ml for 48 hours), with error bars representing the 
standard error of the mean of experiments (n=3). “NS*”: not significant. 
 
Significant increases in the levels of 14-3-3 β was observed in RT4 cells when 
treated with IGF-I at 50ng/ml (p<0.05) and 100ng/ml (p<0.05) for 48 hours 
compared to the control (see Figure 79-B), with no changes found in T24 cells 
(see Figure 79-C). No 14-3-3 β was detected in the nuclear extracts in either 
RT4 or T24 cells, and an induction of cytoplasmic expression of this protein 
was observed in both cell lines (see Figure 79-D & E). Statistically, when 
treated with IGF-I at 50ng/ml for 48 hours, a significant enhancement by 40% 
(p<0.05; see Figure 79-F) and 20% (p<0.05; see Figure 79-G) was found in RT4 
and T24 cells, respectively, in the densitometry fold change of cytoplasmic 14-
3-3 β expression compared to the control. 
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Figure 79: effect of IGF-I on 14-3-3 β in RT4 and T24 cells 
RT4 and T24 cells were seeded in 6-well plates at a density of 0.1 and 0.05x106 cells/well, 
respectively, in GM for 24 hours and serum starved with SFM for another 24 hours. Then cells 
were separated according to different treatments (“CT”: untreated cells as a control group; 
“25”, “50”, “100”: cells treated with IGF-I at the concentration of 25, 50, and 100ng/ml for 48 
hours, respectively; “IGF-I”: cells treated with IGF-I at the certain concentration of 50ng/ml 
for 48 hours). After 48 hours of treatment, cells were harvested to investigate the changes in 
protein abundance and localisation using WB and cellular fractionation analysis, accordingly. 
All blots demonstrate typical results from three experiments each performed at least in 
triplicate (n=3). 
 (A): The blot shows the abundance of 14-3-3 β in RT4 and T24 cells in response to an 
increased dosage of IGF-I treatment. Samples from whole lysates were loaded equally at 60µg 
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for protein detection, and GAPDH was assessed as reference protein. Proteins from MCF7 (a 
human breast adenocarcinoma cell line) cell lysates were used as positive controls for β-
catenin. (B) & (C): The graphs show the mean of fold change of the optical density 
measurements of 14-3-3 β in RT4 and T24 cells, respectively, in response to increased dosage 
of IGF-I (from 0 to 100ng/ml for 48 hours) from three experiments each performed at least in 
triplicate; and error bars demonstrate the standard error of the mean of experiments (n=3). 
(D) & (E): The blots present the localisation of 14-3-3 β in the presence or absence of IGF-I 
treatment in RT4 and T24 cells, respectively, using cellular fractionation. Lamin and Tubulin 
exist only in nuclei and cytoplasm, respectively, and they are an indicator of the efficiency of 
protein separation. “T”: total cell lysates; “C”: cytoplasmic extract; “N”: nuclear extract. (F) & 
(G): The graphs present the densitometry fold change of cytoplasmic 14-3-3 β normalised to 
total 14-3-3 β in the total cell lysates in RT4 and T24 cells, respectively, in response to 
treatment with and without the presence of IGF-I (at 50ng/ml for 48 hours), with error bars 
representing the standard error of the mean of experiments (n=3). 
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5.5 Discussion 
Accumulating evidence indicates a relationship between IGF-activity and the 
promotion of EMT in bladder cancer: in this study two bladder cancer cell lines 
the RT4 (with an epithelial-like phenotype) and T24 (with a mesenchymal-like 
phenotype) were used to investigate this suggested role of IGF-I. 
Promoting effects of IGF-I on cell events, such as cell proliferation and invasion, 
have been reported in many cancer types such as breast (Sarkissyan, 
Sarkissyan et al. 2014). As summarised in Table 28, the results of my study 
showed that exogenous IGF-I induced a significant increase of cell 
proliferation in T24 cells, but it did not affect RT4 cells, whilst the increase 
induced by IGF-I observed in RT4 cells which was shown in the TTI assay was 
due to the high sensitivity of this technique in measuring DNA synthesis. 
Similarly, the ability of T24 cells to migrate was enhanced by the treatment of 
IGF-I with RT4 cells showing no stimulation of migration. IGF-I promoted cell 
invasion in both RT4 and T24 cell lines. Regarding colony formation in soft 
agar, in response to the treatment of IGF-I, both RT4 and T24 cells exhibited 
larger colonies but increased colony forming efficiency was only found in T24 
cells. These data suggest the association between higher IGF activity and 
increased risk of progression of bladder cancer. 
With the promoting effects of IGF-I on bladder cancer development identified, 
the signalling pathway(s) through which it may act was investigated. Two 
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signalling pathways, including IGF-IR/PI3K/Akt and IGF-IR/MAPK/ERK, were 
examined (Hermanto, Zong et al. 2000, Liu, Li et al. 2011, Zhu, Qi et al. 2011). 
A study of bladder cancer biopsies showed up-regulated IGF-IR in bladder 
cancer compared with non-malignant bladder (Rochester, Patel et al. 2007), 
and IGF-IR knockdown via microRNA-145 was suggested to inhibit bladder 
cancer progression (Zhu, Xu et al. 2014). However, the correlations between 
IGF-IR level and tumour grade in bladder cancer remains unclear. In my study, 
the basal levels of the insulin-like growth factor receptor 1 (IGF-IR) and the 
insulin receptor (IR) were found to be much higher in the epithelial-like RT4 
cell line than that in the mesenchymal-like T24 cells, Short-exposure-to-IGF-I 
treatment (from 5 to 30 minutes) showed a more rapid phosphorylation of the 
IGF-IR in RT4 cells (from 5 minutes) than that in T24 cells (with no obvious 
phosphorylation of IGF-IR observed until 30 minutes), which suggests the 
abundance of the IGF-IR plays an important role in facilitating the quick 
response to IGF-I in cells (Pandini, Vigneri et al. 1999). 
Rapid stimulation of phopho-Akt (p-Akt) activation from 5 to 30 minutes was 
observed in both RT4 and T24 cells in response to IGF-I. In contrast, no 
stimulation of phospho-MAPK (p-MAPK) activation was observed in either 
RT4 or T24 cells, implying that the IGF-IR/PI3K/Akt might be the dominant 
signalling pathway in bladder cancer. As I observed that p-Akt was activated 
by IGF-I earlier than any detected change in the IGF-IR in T24 cells, it suggests 
the activation of IGF-IR was transient or the sensitivity in its detection by 
Western blotting poor, or that other tyrosine kinase receptors, such as the IR, 
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may also be playing a role in the aggressive bladder cancer cells; this would be 
worth further investigation. 
To confirm that IGF-I exerts its effects through the IGF-IR/PI3K/Akt axis in 
bladder cancer, AG1024 and LY294002, a specific inhibitor of IGF-IR and PI3K, 
respectively, were used to block the signalling pathway and the following 
effects on cell proliferation, invasion, migration and colony formation were 
examined with results briefly summarised in Table 28. 
Inhibiting the IGF-IR using AG1024 induced a significant decrease in cell 
growth as well as an increase in cell death in T24 cells, with no significant 
changes observed in RT4 cells. Both the invasive and colony forming ability 
was impaired when the IGF-IR was inhibited in RT4 and T24 cells. Moreover, 
the migratory ability was impeded in T24 cells following the inhibition of the 
IGF-IR. Similarly, inhibiting PI3K using LY294002 significantly decreased cell 
colony formation in both RT4 and T24 cells with the migratory ability of T24 
cells reduced. 
Therefore, the IGF-IR/PI3K/Akt axis is considered to be the dominant 
signalling pathway involved in the promotion of bladder cancer progression 
induced by exogenously added IGF-I. The results with T24 cells showing a 
stronger response to IGF-I treatment with less basal IGF-IR expression suggest 
that the examination of endogenous levels of IGF-I in bladder cancer cells is 
required. 
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IGF-I also influenced EMT in bladder cancer (Table 28) with the results briefly 
summarised in Table 29. It induced changes in the levels of EMT markers in 
bladder cancer with the down-regulation of E-cadherin, an epithelial marker, 
in RT4 cells and up-regulation of N-cadherin, a mesenchymal marker, in T24 
cells, indicating its links to EMT during the progress of cancer aggressiveness 
(Morali, Delmas et al. 2001, Ahmad, Morton et al. 2011). Up-regulation of the 
levels of ZEB-1, an EMT-inducing transcription factor that has been reported 
in the development of many types of cancer, including breast (Walsh and 
Damjanovski 2011), was also observed in T24 cells. β-catenin is absent in the 
nuclear component of RT4 cells and is present in small amounts in the nuclear 
component of T24 cells. IGF-1 stimulated translocation of β-catenin into the 
nucleus in both cell lines which could lead to its binding to transcription 
factors (TCF) and, therefore, promote the expression of target oncogenes 
involved in Wnt signalling pathway (Ahmad, Morton et al. 2011). Nuclear β-
catenin is considered as a metastasis inducer in colon cancer by conferring 
resistance to the FOXO3a-mediated apoptosis which was reversed by XAV-939, 
an inhibitor of Wnt-β-catenin signalling (Tenbaum, Ordonez-Moran et al. 
2012). The decrease in FOXO3a was reported in urothelial carcinoma tumour 
samples with higher aggressiveness (Shiota, Song et al. 2010). However, 
increased levels of FOXO3a were observed in both RT4 and T24 cells with 
decreased expression in the nuclear extracts following IGF-I treatment, which 
suggests IGF-I induced cancer progression through inhibiting the binding of β-
catenin and FOXO3a in cell nuclei. FOXA1 is also reported to be low in high-
grade bladder cancer (DeGraff, Clark et al. 2012) which was confirmed in this 
study with reduced levels of FOXA1 found in mesenchymal-like T24 cells. In 
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response to IGF-I treatment, T24 cells showed a further reduction in FOXA1 
levels. However, in RT4 cells a significant increase in the level of this protein 
was observed in whole lysates with a trace of, but not a significant induction 
of expression in the cytoplasmic cell extracts. It has been reported that 
knockdown of FOXA1 in RT4 cells led to decreased E-cadherin and increased 
cell proliferation (DeGraff, Clark et al. 2012), and as a cell line propagated from 
a well-differentiated tumour, RT4 cells demonstrated higher FOXA1 
expression (DeGraff, Clark et al. 2012). Therefore, it would be interesting to 
further investigate the role FOXA1 in IGF activity in bladder cancer. It has also 
been reported that insulin/IGF induced activation of Akt results in 
phosphorylation of FOXO proteins leading to their binding to 14-3-3 proteins 
which then retains the FOXO proteins in the cytoplasm and thus promotes cell 
survival by reducing the nuclear actions of FOXO proteins (Jin, George Fantus 
et al. 2008). It was observed that 14-3-3 β was expressed at high levels in both 
RT4 and T24 cells with localisation mainly in the cytoplasm, and IGF-I-induced 
an enhancement in the levels of this protein compared to the control; 
consistent with a supportive role for 14-3-3 β in EMT of bladder cancer 
through the binding of FOXO3a . 
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Table 28: a summary of the effects of IGF-I, AG1024 and LY294002 on cell 


















RT4 NE √ (+) NE √ (+) √ (+) 




RT4 NE √ (-) / √ (-) / 




RT4 / √ (-) / / / 
T24 / √ (-) √ (-) / / 
“√ (+)”: promoting effect; “√ (-)”: inhibiting effect; “NE”: no effect. “/”: not performed in this 
study. 
 







β-catenin ZEB-1 FOXO3a FOXA1 14-3-3 β 




































“√ (+)”: increased in total protein levels; “√ (-)”: decreased in total protein levels; “NE”: no 
effect on total protein levels; “NS*”: not significant. 
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In summary, exogenously added IGF-I exerts promoting effects on bladder 
cancer development by enhancing the proliferative, invasive, migratory and 
colony forming abilities of bladder cancer cells, and these effects are more 
potent in mesenchymal-like T24 cells than that in epithelial-like RT4 cells. The 
IGF-IR/PI3K/Akt is the dominant signalling pathway by which the above 
effects of IGF-I are mediated, and inhibitors targeting components in this 
signalling pathway shed light on potential therapeutic drugs for bladder 
cancer treatment. A relationship between IGF-I and regulation of EMT 
molecules implies a promoting role for IGF-I in bladder cancer progression. 
Page | 269  
 
Chapter 6 - Final Discussion 
  
Chapter 6 - Final Discussion 
Page | 270  
 
6.1 Summary of Main results  
In humans, bladder cancer is the most common malignancy of the urinary tract. 
With its high incidence and recurrence, poor prognoses after progression, as 
well as great costs to both patients and the society, bladder cancer has become 
a major clinical issue that requires more understanding in order to impact 
treatment strategies to improve outcome. 
Epithelial-to-mesenchymal transition (EMT) facilitates metastatic progression 
of many cancer types including bladder (McConkey, Choi et al. 2009), and 
accumulating evidence indicates an association of EMT with IGF-activity in 
many cancers such as colorectal (Yao, Su et al. 2016). Therefore, this study 
aimed to investigate whether the IGF-axis influenced EMT in bladder cancer 
progression. 
As a member of the IGF system, IGFBP-2 is the second most abundant IGFBP 
in human serum with contradictory results about its role in cancer, being 
reported as a promoter (Perks, Vernon et al. 2007, Uzoh, Holly et al. 2011, 
Foulstone, Zeng et al. 2013, Gao, Sun et al. 2016) but also an inhibitor (Hoflich, 
Lahm et al. 1998, Frommer, Reichenmiller et al. 2006).  
To investigate the role of IGFBP-2 in bladder cancer development, we 
manipulated its levels in specific bladder cancer cell lines and examined any 
phenotypic changes that occurred. 
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Knocking down IGFBP-2 using specific siRNA was performed in IGFBP-2-
abundant epithelial-like RT4 cells. With the reduction in IGFBP-2 expression, 
a significant increase in cell proliferation and promotion of cell invasion, as 
well as colony formation, was observed, along with a decrease in the levels of 
E-cadherin (an epithelial marker) along with β-catenin translocation to the 
nucleus. Exogenous IGFBP-2 was added to IGFBP-2-null mesenchymal-like 
T24 and TCCSUP cells, and this led to a significant decrease in cell growth, 
invasion, migration, colony formation as well as the expression of N-cadherin 
(a mesenchymal marker). These data suggested that IGFBP-2 was playing a 
critical inhibitory role in bladder cancer exerting anti-proliferative, -invasive, 
-migratory, -colony-forming as well as -EMT effects in cancer progression. 
Chemo-sensitivity to cisplatin in bladder cancer was also investigated using 
epithelial-like RT4 and mesenchymal-like T24 cells representing cancer types 
with less and more aggressiveness, respectively. With the same manipulations 
of the levels of IGFBP-2 using siRNA transfection or exogenous addition, the 
results demonstrated that higher levels of IGFBP-2 were associated with 
enhanced sensitivity to cisplatin suggesting IGFBP-2 may be used as a marker 
of chemo-sensitivity to cisplatin in bladder cancer. However, in contrast the 
inhibition of IGFBP-2 using gene silencing was reported to enhance cell 
sensitivity to cisplatin in a cisplatin-resistant bladder cancer subline (BIU87-
CisR) (Zhu H 2015). Therefore, further studies on additional cell lines are 
required. 
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How the levels of IGFBP-2 are regulated and in which way(s) IGFBP-2 acts as 
a tumour suppressor in bladder cancer, either an IGF-dependent or -
independent, were then assessed. 
Based on studies of epigenetic changes in cancer (Han, Wolff et al. 2012, 
Tahara, Shibata et al. 2014), aberrant hypermethylation of the gene promoter 
of IGFBP-2 was considered to contribute to the loss of IGFBP-2 in advanced 
bladder cancer. This conclusion was supported by the data of my study: the re-
expression of IGFBP-2 in IGFBP-2-null T24 cell line following treatment with 
AZA, a commonly used demethylating agent, and the detection of relevant 
changes in the methylation status of the promoter region of IGFBP-2 gene in 
T24 cells using Combined Bisulphite Restriction Assay (COBRA). Moreover, in 
T24 cells, dosing with AZA led to similar phenotypic changes that were 
observed on addition of exogenous IGFBP-2, including a reduction in the levels 
of N-cadherin, a mesenchymal marker, along with significantly decreased cell 
proliferation, colony formation and increased cell death. 
Differences in cell responses to AZA treatment were found between TCCSSUP 
and T24 cells, and this likely reflects the heterogeneity among cell lines with 
similar phenotypes, whilst another study demonstrated differences in the 
sensitivity of T24 and TCCSUP cell lines in response to cisplatin (Falso, 
Buchholz et al. 2012). These data suggest further studies on additional cell 
lines and other epigenetic changes, such as histone modification, are required. 
To understand the working mechanism of IGFBP-2 in bladder cancer, we used 
a number of strategies: we used NBI-31772, an inhibitor of IGF/IGFBP 
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interactions, along with exogenously added human recombinant IGF-I as well 
as manipulation of IGFBP-2 levels in RT4 and T24 cells by siRNA transfection 
and adding exogenous IGFBP-2, respectively. These data indicated that IGFBP-
2 acted in both IGF-dependent and -independent manner in bladder cancers 
despite the cancer phenotype (Frommer, Reichenmiller et al. 2006, Wheatcroft 
and Kearney 2009, Uzoh, Holly et al. 2011). The intrinsic effects of IGFBP-2 via 
binding to integrin receptors have been reported in many cancers such as 
prostate (Uzoh, Holly et al. 2011), and should be further investigated in 
bladder cancer. 
Having established that the exogenous addition of IGF-I promoted cell 
proliferation and migration of T24 cells in this study, and the conclusion that 
IGFBP-2 exerted some of its effects partly through an interaction with IGFs in 
both cell lines, we next compared the effects of exogenously added IGF-I on 
bladder cancer cell phenotypes using  epithelial-like RT4 and mesenchymal-
like T24 cell lines. 
Following the addition of IGF-I, enhanced proliferation, invasion, migration as 
well as colony formation were observed. And these effects were more potent 
in T24 (of a mesenchymal phenotype) than in epithelial-like RT4 cells. 
Moreover, the regulation of EMT molecules by IGF-I, such as nuclear 
translocation of β-catenin which can lead to more aggressive cancer, was also 
observed, suggesting that IGF-I plays a role in bladder cancer progression 
(Walsh and Damjanovski 2011, Liao, Wang et al. 2014, Sarkissyan, Sarkissyan 
et al. 2014). 
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Further investigation into how exogenous IGF-I exerts these effects 
demonstrated rapid stimulation of phospho-Akt (p-Akt) in both RT4 and T24 
cells in comparison with no activation of phospho-MAPK (p-MAPK) in either 
RT4 or T24 cell lines. And inhibition of PI3K using LY294002, a specific PI3K 
inhibitor, blocked these effects induced by IGF-I. 
This indicated that the IGF-IR/PI3K/Akt might be the dominant signalling 
pathway in mediating IGF-I actions, and that specific inhibitors targeting its 
components may provide potential particular therapeutic drugs for bladder 
cancer treatment (Bergqvist, Holgersson et al. 2017, Xu, Wang et al. 2017). 
6.2 Future work 
Considering the heterogeneity that exists in tumours, including those of the 
bladder, studies on a more expansive panel of bladder cancer cell lines would 
be required to fully understand the mechanism of progression. In addition, I 
have already obtained ethics approval to access a cohort of bladder tumours, 
and in future work a pilot translational tissue study would be performed. We 
could assess the levels of the key molecules we have identified as playing a role 
in bladder cancer progression, such as IGFBP-2, the IGF-IR, p-Akt and markers 
of EMT, such as nuclear β-catenin that has been shown to confer resistance to 
FOXO3a-mediated apoptosis induced by PI3K and Akt inhibitors in colon 
cancer (Tenbaum, Ordonez-Moran et al. 2012). Thus further studies to 
examine the associations between these molecules would be valuable to 
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confirm the findings of my in vitro studies and to determine their association 
with any clinicopathological features of bladder cancer progression.  
My study examined the impact of blocking the IGF-IR  and of adding in 
exogenous IGF-I; these were informative experiments, and future work 
measuring levels of endogenously produced IGFs and other IGFBPs would 
complete the picture. 
To better understand the relationship between IGFBP-2 and cell 
chemosensitivity to cisplatin in bladder cancer, well-developed stable 
clinically relevant cisplatin-resistant cell lines and doses of cisplatin 
administered at a pulsed low-level treatment strategy would be needed to 
mimic the clinic setting.  
6.2.1 A co-culture model at the development stage 
Poor prognoses are related to advanced bladder cancers when disease 
includes muscle invasion. I have also been developing a co-culture model to 
investigate bladder cancer invasion behaviour by growing BdSMC (see 2.1.2), 
a primary human bladder smooth muscle cell line in combination with the 
aggressive mesenchymal-like IGFBP-2-null T24 cells. Using this co-culture 
model, I have also been assessing if cross-talk exists between the T24 and 
epithelial-like IGFBP-2-abundant RT4 cells. 
A preliminary migration assay was performed (as described in 2.9) to 
investigate the migration of T24 cells in the presence of RT4 or BdSMC cells. 
As shown in Figure 80, the migration of T24 cells was inhibited in the presence 
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of RT4 cells, and this inhibition was more marked when T24 cells were 
cultured in the presence of BdSMC cells. 
 
Figure 80: co-culture of T24, RT4 and BdSMC cells 
Cells were seeded at a certain density (T24: 0.028x106, RT4: 0.0525 x106; BdSMC: 0.0315 x106 
cells) into each chamber in GM and allowed to grow for approximately 24 hours to reach about 
80% confluence. Cell reached 90-95% confluence during an additional 24 hours in SFM. The 
inserts were then removed leaving an observed gap, and gap closure was recorded for up to 
30 hours. Images of cell gaps were taken at different times with relative labels. “0hr”: the start 
point after the removal of inserts; “7hrs”, “29hrs”: 7 and 29 hours after the removal of inserts. 
All images demonstrate the results from one experiment performed in duplicate (n=1). All 
images shown are at x10 magnification. 
 
Optimisation of this co-culture model, such as cell seeding density, is required 
in the first instance. Then, as we found that components of the IGF axis played 
a critical role in bladder cancer progression including cell migration and 
invasion, future work would use this model to investigate whether 
manipulating components of the IGF axis, such as IGFBP-2, affects the 
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behaviour of bladder cancer cells in the presence of normal bladder muscle 
cells. 
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